THE MOVEMENT DISORDER SOCIETY'S

7th International Congress of Parkinson's Disease and Movement Disorders

final program

November 10-14, 2002
What if you could give your Parkinson’s patients an extra 6 hours of “on” time a day – while decreasing their levodopa-induced dyskinesia?

Imagine what they would do.

### Absolute Change in Patient Daily “On” Time at 12 Months*

<table>
<thead>
<tr>
<th>Stimulation Type</th>
<th>Average Improvement</th>
<th>Percent Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>STN (n=40*)</td>
<td>6.1 Hours*</td>
<td>30%</td>
</tr>
<tr>
<td>GPi (n=24*)</td>
<td>6.7 Hours*</td>
<td>29%</td>
</tr>
</tbody>
</table>

* Includes only patient data that were fully verified against medical records. Percentages have been rounded to the nearest whole percent. Data on file at Medtronic, Inc.

---

**Indications:** Bilateral stimulation of the internal globus pallidus (GPI) or the subthalamic nucleus (STN) using Medtronic**<sup>®</sup> **Activa<sup>®</sup> Parkinson's Control Therapy is indicated for adjunctive therapy in reducing some of the symptoms of advanced, levodopa-responsive Parkinson’s disease that are not adequately controlled with medication.

**Contraindications:** Contraindications include patients who will be exposed to MRI using a full body radio-frequency (RF) coil or a head transmit coil that extends over the chest area, patients for whom test stimulation is unsuccessful, or patients who are unable to properly operate the neurostimulator. Also, diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy) is contraindicated because diathermy’s energy can be transferred through the implanted system (or any of the separate implanted components), which can cause tissue damage and can result in severe injury or death. Diathermy can damage parts of the neurostimulation system.

**Warnings/Precautions/Adverse Events:** There is a potential risk of tissue damage using stimulation parameter settings of high amplitudes and wide pulse widths. Extreme care should be used with lead implantation in patients with a heightened risk of intracranial hemorrhage. Do not place the lead-extension connector in the soft tissues of the neck. Placement in this location has been associated with an increased incidence of lead fracture. Theft detectors and security screening devices may cause stimulation to switch ON or OFF, and may cause some patients to experience a momentary increase in perceived stimulation. Although some MRI procedures can be performed safely with an implanted Activa System, clinicians should carefully weigh the decision to use MRI in patients with an implanted Activa System. MRI can cause induced voltages in the neurostimulator and/or lead possibly causing uncomfortable, jolting or shocking levels of stimulation. MRI image quality may be reduced for patients who require the neurostimulator to control tremor, because the tremor may return when the neurostimulator is turned off. Severe burns could result if the neurostimulator case is ruptured or perforated. The Activa System may be affected by or adversely affect medical equipment such as cardiac pacemakers or defibrillators, external defibrillators, ultrasonic equipment, electrocautery or radiation therapy. Safety and effectiveness has not been established for patients with neurological disease other than Parkinson’s disease, previous surgical ablation procedures, dementia, coagulopathies or moderate to severe depression; or for patients who are pregnant, under 18 years or over 75 years of age. Adverse events related to the therapy, device or procedure can include: stimulation not effective, cognitive disorders, pain, dyskinesia, dystonia, speech disorders including dysarthria, infection, paresthesia, intracranial hemorrhage, electromagnetic interference, cardiovascular events, visual disturbances, sensory disturbances, device migration, paresis/asthenia, abnormal gait, incoordination, headaches, lead repositioning, thinking abnormal, device explant, hemiplegia, lead fracture, seizures, respiratory events and shocking or jolting stimulation.

Rx only

© Medtronic, Inc. 2002  All Rights Reserved  Printed in USA  UC200301356EN

---

**To learn more about Activa<sup>®</sup> Therapy and receive a complimentary “Abstracts-on-Disk” CD from this year’s congress, visit Medtronic booth #306.
Dear Colleagues,

On behalf of The Movement Disorder Society, we are pleased to welcome you to Miami for the 7th International Congress of Parkinson’s Disease and Movement Disorders.

To offer forums for exchange and debate of the most recent research results as well as practical issues in diagnosis and treatment of Parkinson’s Disease and other movement Disorders is one of the key missions of The Movement Disorder Society. As in past years, the 7th International Congress is a unique opportunity to network and learn from colleagues. The International Congress Organizing Committee has created a groundbreaking scientific program including outstanding plenary and parallel sessions, topic-focused wine and cheese seminars, video dinners, and innovative abstract poster sessions.

On Sunday, November 10, the Congress will begin with Kickoff Seminars, funded through unrestricted educational grants from our industry supporters. To provide a complete educational experience throughout the week, the 7th International Congress offers eight Plenary Sessions, six Parallel Sessions, as well as three Lectureships. Wine and Cheese Seminars and Video Dinners take place in the evening and offer a smaller more interactive atmosphere.

This year, we have a record-breaking 1,182 abstracts to be presented as posters. To ensure all Congress delegates the opportunity to view the latest developments in movement disorders, time is set aside exclusively for poster viewing. In addition to poster presentations, please take time to visit the Exhibit Hall, as companies and organizations from around the world join us in sharing their contributions to the field of movement disorders.

Aside from the professional aspects of the Congress, Miami is a beautiful city with numerous activities to enjoy. In addition to the MDS Welcome Cocktail Reception on the Great Lawn and the Banquet at the Miami Seaquarium, there are many opportunities to tour the Miami Beach area and all the culture it has to offer.

We thank you for joining us at this exceptional event, and we are pleased and honored to have you with us.

Sincerely,

Werner Poewe C. Warren Olanow
President President-Elect

---

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organization</td>
<td>2</td>
</tr>
<tr>
<td>MDS Committees</td>
<td>8</td>
</tr>
<tr>
<td>Congress Registration and Venue</td>
<td>10</td>
</tr>
<tr>
<td>Congress Information</td>
<td>10</td>
</tr>
<tr>
<td>1. Continuing Education</td>
<td></td>
</tr>
<tr>
<td>2. MDS Committee Meetings</td>
<td></td>
</tr>
<tr>
<td>3. MDS History Exhibit</td>
<td></td>
</tr>
<tr>
<td>Faculty</td>
<td>16</td>
</tr>
<tr>
<td>Map of Miami</td>
<td>34</td>
</tr>
<tr>
<td>Abstract Submission Guidelines</td>
<td>35</td>
</tr>
</tbody>
</table>

All photos provided by the Greater Miami Convention & Visitors Bureau, www.TropicoolMiami.com
Acknowledgments

The International Congress Organizing Committee of The Movement Disorder Society’s 7th International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge and thank the following companies for their generous support:

Platinum Level:

ALLERGAN  
élan  
gsk GlaxoSmithKline  
NOVARTIS  
ORION PHARMA  
PHARMACIA  
TEVA NEUROSCIENCE  
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Silver Level:

SCHWARZ PHARMA

Bronze Level:

Aventis  
NPF The National Parkinson Foundation, Inc.  
Medtronic

3
Patients with Parkinson’s disease are...

EQUIPPED FOR LIVING

The only dopamine agonist with 5-year clinical data

REQUIP maintains ADLs with continued therapy with or without added L-dopa

- No statistically significant difference in mean change in ADL scores from baseline to end of study with REQUIP, with or without added L-dopa, compared with L-dopa alone.1,2

- One third of patients on REQUIP completing the study (29/85) were maintained on REQUIP alone.1

REQUIP provides a lower risk of dyskinesia compared with L-dopa

- Patients on REQUIP, with or without adjunct L-dopa, were almost 4 times less likely to develop dyskinesia than patients on L-dopa alone (P<0.0001).1

REQUIP has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Hallucinations may occur at any time during treatment. REQUIP may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.

Please see Brief Summary of complete Prescribing Information on adjacent page.

References:

STAY WITH REQUIP® ropinirole HCl

Help patients shape a functional future
Patients with Parkinson’s disease are...

EQUIPPED FOR LIVING

The only dopamine agonist with 5-year clinical data

REQUIP controls PD symptoms in initial monotherapy (5-year study)

- No statistically significant difference in mean change in ADL scores from baseline to end of study in patients on monotherapy with REQUIP compared with patients on L-dopa

- One third of patients on REQUIP completing the study (29/85) were maintained on REQUIP alone

Lower risk of dyskinesia in patients on monotherapy with REQUIP compared with L-dopa

- Overall incidence of dyskinesia in patients on monotherapy with REQUIP was 5%, compared to 36% of patients on L-dopa

REQUIP has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Hallucinations may occur at any time during treatment. REQUIP may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesias.

Please see Brief Summary of complete Prescribing Information on adjacent page.

START WITH

REQUIP ropinirole HCl

Help patients shape a functional future
The Movement Disorder Society (MDS) is an international not-for-profit organization representing and serving clinicians, other health professionals, researchers, and policy makers in movement disorders. The spectrum of clinical disorders represented by the Society includes but is not limited to:

- Parkinson’s disease
- Blepharospasm
- Dysphonia
- Dystonic disorders
- Tremor
- Gait disorders
- Ataxia
- Tics and Tourette syndrome
- Tardive dyskinesia
- Myoclonus
- Spasticity
- Huntington’s disease

The Movement Disorder Society’s Mission

- To bring clinicians the latest developments and practical advice for the diagnosis and treatment of all movement disorders and related neurological matters
- To offer an international forum for sharing new developments in basic and clinical research in movement disorders
- To publish the pre-eminent clinical and research journal devoted to movement disorders, using print, online and video formats
- To create professional liaisons with other regional and subspecialty organizations for unifying the many disciplines represented in the field of movement disorders

MDS Officers (2001-2002)

- President: Werner Poewe, Austria
- President-Elect: C. Warren Olanow, USA
- Secretary: Niall P. Quinn, UK
- Secretary-Elect: Andres M. Lozano, Canada
- Treasurer: Robert E. Burke, USA
- Treasurer-Elect: Wolfgang H. Oertel, Germany
- Past President: Mark Hallett, USA

International Executive Committee (2001-2002)

- Francisco Cardoso, Brazil
- Cynthia L. Comella, USA
- Ann M. Graybiel, USA
- Eldad Melamed, Israel
- Yoshikuni Mizuno, Japan
- John G. Nutt, USA
- José A. Obeso, Spain
- Olivier Rascol, France
- Caroline M. Tanner, USA
- Philip D. Thompson, Australia

International Congress Organizing Committee Chair

- Chair: William C. Koller, USA

Members

- Alfredo Berardelli, Italy
- David J. Brooks, UK
- Robert E. Burke, USA
- Lueder Decheme, Austria
- Stanley Fahn, Mark Hallett, USA
- Eldad Melamed, Israel
- Niall P. Quinn, UK
- Olivier Rascol, France
- Miguel S. Rueda, Colombia
- Eduardo Tolosa, Spain

Past Presidents

- 1998-2000: Mark Hallett, USA
- 1996-1998: Eduardo Tolosa, Spain
- 1994-1996: Joseph Jankovic, USA
- 1988-1991: Stanley Fahn, USA
MDSC Committees, 2001-2002

Archives

Chair: Robert E. Burke, USA

Awards

Chair: Anthony Schapira, UK

Members:
Oscar S. Gershanik, Argentina
José A. Obeso, Spain
Serge Przedborski, USA
Heinz Reichmann, Germany
Matthew B. Stern, USA
Caroline M. Tanner, USA

Bylaws

Chair: Demetrius Maraganore, USA

Members:
Kailash P. Bhatia, UK
Elan Louis, USA
David Riley, USA
Evzen Ruzicka, Czech Republic

Education

Chair: Cynthia L. Comella, USA
Co-Chair: Fabrizio Stocchi, Italy

Members:
Stewart Factor, USA
Joaquim Ferreira, Portugal
Robert Iansek, Australia
Kelly Lyons, USA
Yoshikuni Mizuno, Japan
Kapil D. Sethi, USA

Financial Affairs

Chair: Robert E. Burke (Treasurer), USA

Members:
Mark Hallett (Past President), USA
William C. Koller (Past Treasurer) USA
Wolfgang H. Oertel (Treasurer-Elect), Germany
C. Warren Olanow (President-Elect), USA
Werner Poewe (President), Austria

Industrial Relations

Chair: Olivier Rascol, France

Members:
David J. Brooks, UK
Joseph Jankovic, USA
Karl D. Kieburtz, USA
William C. Koller, USA
Wolfgang H. Oertel, Germany
C. Warren Olanow, USA

Journal Oversight

Chair: Mark Hallett, USA

Members:
Rivka Inzelberg, Israel
William C. Koller, USA
Hiroshi Shibasaki, Japan

Liaison

Chair: Christopher G. Goetz, USA

Members:
Regina Katzenschläger, UK
Klaus Leonhard Leenders, The Netherlands
Masahiro Nomoto, Japan
Ivan Rektor, Czech Republic

Membership

Chair: Günther Deuschl, Germany

Members:
Carlo Colosimo, Italy
Roger J. Eble, USA
Nir Giladi, Israel
Horta Wagner, Brazil
Ruyji Kaji, Japan
Elan Louis, USA
Gregor K. Wenning, Austria

Scientific Issues

Chair: David J. Brooks, UK

Members:
Thomas Gasser, Germany
Etienne Hirsch, France
Paul Krack, France
Irene Litvan, USA
Fabrizio Stocchi, Italy

Strategy and Planning

Chair: Eduardo Tolosa (Past-Past President), Spain

Members:
Mark Hallett (Past President), USA
C. Warren Olanow (President-Elect), USA
Werner Poewe (President), Austria
## Congress Registration & Venue

### Venue

**Fontainebleau Hilton Resort & Towers**  
4441 Collins Avenue  
Miami Beach, Florida 33140  
USA  
Phone: +1 305-538-2000  
Fax: +1 305-674-4607

The Fontainebleau Hilton Resort & Towers, located in the South Beach district of Miami, Florida is the headquarters for all scientific sessions, posters and exhibits.

### Dates

Sunday, November 10, 2002 through Thursday, November 14, 2002

### Congress Hotels

**Best Western Beach Resort**  
4333 Collins Avenue  
Miami Beach, Florida 33140  
USA  
Phone: +1 305-532-3311  
Fax: +1 305-531-5296

The Best Western is located one-half block south of the Fontainebleau Hilton. It can be easily accessed via Miami Beach's oceanfront boardwalk. The Best Western features an outdoor swimming pool, beach access, and a restaurant and lounge. Check-in time is 3:00 pm.

**Days Inn Oceanside**  
4299 Collins Avenue  
Miami Beach, Florida 33140  
USA  
Phone: +1 305-673-1513  
Fax: +1 305-538-0727

The Days Inn is located one block south of the Fontainebleau Hilton, easily accessed via Miami Beach's oceanfront boardwalk. The Days Inn offers an outdoor swimming pool, beach access, and restaurant. Check-in time is 3:00 pm.

**Four Points Sheraton**  
4343 Collins Avenue  
Miami Beach, Florida 33140  
Phone: +1 305-538-1938  
Fax: +1 305-538-2025

The Four Points Sheraton is located one-half block south of the Fontainebleau Hilton, easily accessed via Miami Beach's oceanfront boardwalk. The Four Points Sheraton offers an outdoor swimming pool, beach access, and restaurant. Check-in time is 3:00 pm.

### Registration Desk

To verify participation, all Congress delegates will be required to provide a signature on the Congress sign-in sheet, upon registration.

Name badges, tickets and registration bags can be collected at the Registration Desk located in the Grand Gallerie, adjacent to the main lobby of the Fontainebleau Hilton, during the following hours:

- **Saturday, November 9**: 3:00 pm – 8:30 pm  
- **Sunday, November 10**: 6:30 am – 7:30 pm  
- **Monday, November 11**: 6:30 am – 7:30 pm  
- **Tuesday, November 12**: 6:30 am – 7:30 pm  
- **Wednesday, November 13**: 6:30 am – 6:00 pm  
- **Thursday, November 14**: 6:30 am – 12:00 pm

### Continuing Medical Education Registration

To verify participation, all Congress delegates will be required to provide a signature on the Congress sign-in sheet. Delegates interested in receiving Continuing Medical Education (CME) for attending the Congress may check the appropriate box indicating interest in CME.

**Please note**: Delegates requesting CME must sign in at the Congress registration area in the Grand Gallerie, each day to verify participation. Each physician should claim only those hours of credit actually spent in the educational activity.

### Badges

All Congress attendees will receive a name badge with their registration materials. Badges should be worn at all times as they will be used to control access to all Congress sessions and activities. Individuals will be identified as follows:

- **Red** = Delegate  
- **Yellow** = Exhibitor  
- **Orange** = Exhibitor Delegate  
- **Green** = Guest  
- **Purple** = Press  
- **Blue** = Staff

### Special Accessibility Needs

Delegates requiring special arrangements in order to fully participate in the Congress should contact the MDS Secretariat.
## Congress Information

### Abstracts-On-Disk™

All abstracts published in the supplement to the MDS Journal will also be available on the Abstracts-On-Disk™ funded through an unrestricted educational grant from Medtronic. To obtain a copy, visit the Medtronic Exhibit Booth (306) and exchange the voucher located in your registration bag.

### Abstract Volume

All abstracts accepted for poster presentation have been published in an abstract supplement to the MDS Journal, Movement Disorders. The supplement is funded through an unrestricted educational grant from Teva Neuroscience and Teva Pharmaceuticals. Each delegate will receive one copy with their registration materials. MDS members will receive an additional copy with their November journal issue.

### Business Center

For your convenience, the Fontainebleau Hilton has a Business Center that is located on Level IV in the Versailles Building. The Business Center offers business and office supplies, facsimiles, copy machines, and computer workstations. Hours for the Business Center are 8:00 am – 5:00 pm, Monday through Friday. With a 24-hour notice, the Business Center will remain open after hours.

### Child Care Center

For your convenience, the Fontainebleau Hilton offers child care service at Kids Cove, located on the lower level of the Chateau Building. Available seven days a week, from 9:00 am – 5:00 pm, Kids Cove is fully supervised. Please contact the Fontainebleau Hilton for further information.

### Continuing Education

#### Target Audience

The target audience of the 7th International Congress of Parkinson’s Disease and Movement Disorders includes clinicians, researchers, post-doctoral fellows and medical school students with an interest in the current research and approaches for the treatment of movement disorders.

#### Statement of Educational Objectives

Upon completion of this activity, attendees should be able to:

1. Describe the pathophysiology and neurobiology of Parkinson’s disease and other movement disorders;
2. Discuss the surgical treatment options available for Parkinson’s disease and other movement disorders;
3. Discuss the pharmacological treatment options available for Parkinson’s disease and other movement disorders.

**CME Credit**

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and The Movement Disorder Society. The NIH/FAES is accredited by the ACCME to provide continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 34.5 hours in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

**CPD Approval**

The Congress has been approved for Continuing Professional Development (CPD) by the Royal College of Physicians of London. This activity has been awarded 51 CPD credits for full attendance. Participants should claim only those hours of credit actually spent in the activity.

### Congress Evaluations

Please take time to complete the evaluation forms provided for each session you attend. Your input and comments are essential in planning future educational sessions for MDS Congresses. When completed, evaluations may be returned to MDS Staff or dropped in the evaluation collection boxes located in the registration area.

### Exhibition

Please allow adequate time in your daily schedule to visit the Exhibit Hall, located in the East Ballroom. The exhibition is an integral component to your Congress experience, offering you the opportunity to speak with representatives of companies that provide services and market products directly related to movement disorders. Delegates may enter the Exhibit Hall at the entrance between the Jade Promenade and Fontainebleau Gallerie, or through the West Ballroom during the following hours:

- Monday, November 11: 8:00 am – 5:00 pm
- Tuesday, November 12: 8:00 am – 5:00 pm
- Wednesday, November 13: 8:00 am – 5:00 pm

### Internet Café

Internet access will be available to meeting attendees in the Grand Gallerie, near the Registration Desk. Please limit your Internet use to 15 minutes so that other attendees can also access the service.

---

*Airboat touring the Everglades*
MDS Committee Meetings

Saturday, November 9, 2002

**Awards Committee**
6:00 pm – 7:30 pm
Location: Imperial I, Level IV

**Bylaws Committee**
6:00 pm – 7:30 pm
Location: Imperial II, Level IV

**Industrial Relations Committee**
6:00 pm – 7:30 pm
Location: Imperial III, Level IV

**Liaison Committee**
6:00 pm – 7:30 pm
Location: Imperial IV, Level IV

**Scientific Issues**
6:00 pm – 7:30 pm
Location: Pasteur, Level IV

**Task Force on Epidemiology**
6:00 pm – 7:30 pm
Location: Imperial V, Level IV

Sunday, November 10, 2002

**Education Committee**
6:00 am – 8:00 am
Location: Imperial II, Level IV

**Journal Oversight Committee**
6:30 am – 8:00 am
Location: Imperial III, Level IV

**Membership Committee**
6:00 am – 8:00 am
Location: Imperial IV, Level IV

**Task Force for the Development of Rating Scales for Parkinson’s Disease**
6:00 am – 8:00 am
Location: Imperial V, Level IV

Tuesday, November 12, 2002

**Strategy and Planning Committee**
7:30 pm – 9:30 pm
Location: To be determined

MDS Exhibit & Information Booth

The Movement Disorder Society (MDS) is an international society of professionals committed to research and patient care in the fields of Parkinson’s disease and other disorders of movement and motor control.

MDS supports and promotes a wide range of educational programming and other initiatives to advance scientific understanding and standards of care as they pertain to movement disorders. For this, MDS provides forums such as a high ranking journal, scientific symposia and international congresses.

Attendees are invited to take advantage of MDS member benefits by applying to the Society. Learn more about MDS initiatives and speak with a representative at the MDS Exhibit and Information Booth located in the Grand Gallerie across from Registration during the following hours:

- Saturday, November 9 3:00 pm – 8:30 pm
- Sunday, November 10 8:30 am – 7:30 pm
- Monday, November 11 6:30 am – 5:00 pm
- Tuesday, November 12 6:30 am – 5:00 pm
- Wednesday, November 13 6:30 am – 5:00 pm

MDS History Exhibit

Throughout the Congress there will be an exhibit focusing on the historical background of Movement Disorders. The exhibit will trace the early development of Movement Disorders as a discipline, as well as the development of MDS as a preeminent International Society.

Original books, manuscripts, letters, photographs, medical artifacts and instruments related to the development of movement disorders as a discipline will be displayed in glass cases. The MDS membership has been the primary source of the original artifacts; other loans come from libraries and private collections. Archival films documenting early clinical demonstrations of movement disorders and celebrated neurologists examining movement disorder patients will be shown as well.

The MDS History Exhibit will be displayed in the Fontainebleau Gallerie of the Fontainebleau Hilton. The hours are as follows:

- Saturday, November 9 3:00 pm – 8:30 pm
- Sunday, November 10 7:00 am – 5:30 pm
- Monday, November 11 7:00 am – 5:00 pm
- Tuesday, November 12 7:00 am – 5:00 pm
- Wednesday, November 13 7:00 am – 5:00 pm

Optional Tour

Tours have been arranged by: PGI
Jennifer George, Operations Manager
1320 South Dixie Highway
Suite 241
Miami, FL 33146, USA
Fax: +1-305-740-9432

Tickets for the Everglades Adventure tour are to be collected at the Concierge Desk in the Grand Gallerie of the Fontainebleau Hilton during regular on-site registration hours. Additional tickets for this tour may be purchased at the Concierge Desk and will be handled on a first-come, first-served basis.

Transportation for the Everglades Adventure will depart from the Fontainebleau Hilton main driveway. Please be present at 8:45 am (15 minutes prior to departure).
**Congress Information**

**Optional Tour - Continued**

**Monday, November 11, 2002**  
**Everglades Adventure**  
9:00 am – 1:00 pm  
Experience South Florida’s outdoors with a trip to the Everglades. This vast wilderness area is home to an abundance of wildlife and plants unique to North America.

Cost: $55.00 USD per person

Please note: Tours that have not met the minimum participation have been cancelled by PGI. All pre-registered individuals have been notified and will be issued reimbursement for the cancelled tours.

Individual tours may be arranged through the Concierge Desk at the Fontainebleau Hilton.

**Press Room**  
Conference Room 2, Level IV, Versailles Building

Members of the working media may register without charge for the 7th International Congress in the Press Room. Press must register, provide credentials and wear their press badge for admittance to MDS sessions. Press Conferences related to previously selected newsworthy abstracts, along with additional scientific session highlights will be conducted throughout the Congress. Interview space, computers, telephones and fax services are available for the convenience of media representatives covering the meeting.

Please note: the Press Room will be moving on Thursday, November 14, to Imperial I, located on Level IV of the Versailles Building.

Press Room hours are as follows:

- **Sunday, November 10**: 8:00 am – 5:00 pm
- **Monday, November 11**: 8:00 am – 5:00 pm
- **Tuesday, November 12**: 8:00 am – 5:00 pm
- **Wednesday, November 13**: 8:00 am – 5:00 pm
- **Thursday, November 14**: 8:00 am – 12:00 pm

**Scientific Program**

**Kick off Seminars**  
Kick off seminars have been organized through unrestricted educational grants from Congress industry supporters and are open to all Congress registrants.

**Plenary and Parallel Sessions**  
Plenary and Parallel Sessions will feature scientific updates presented by international leaders in the field of movement disorders. These general sessions are open to all Congress registrants.

**Wine & Cheese Seminars**  
Late afternoon Wine & Cheese seminars are designed to be informal and interactive. As the title suggests, wine and cheese will be served during the seminars. To encourage discussion, attendance is limited to 50-75 participants per seminar. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Fee: $50 USD / $35 USD for junior participants and allied health

**Video Dinner Sessions**  
Video Dinner Sessions have become a popular segment of the MDS Congress as participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session. Participants may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Fee: $75 USD / $50 USD for junior participants and allied health

**Abstract Poster Sessions**  
All accepted abstracts will be presented during poster sessions located in the West Ballroom and Jade Promenade. Poster sessions and times are as follows:

- **Poster Session 1, 1-168**  
  Monday, November 11, 7:00 am – 8:30 am

- **Poster Session 2, 169-338**  
  Monday, November 11, 12:30 pm – 2:00 pm

- **Poster Session 3, 339-520**  
  Tuesday, November 12, 7:00 am – 8:30 am

- **Poster Session 4, 521-694**  
  Tuesday, November 12, 12:00 pm – 1:30 pm

- **Poster Session 5, 695-850**  
  Wednesday, November 13, 7:00 am – 8:30 am

- **Poster Session 6, 851-1020**  
  Wednesday, November 13, 12:00 pm – 1:30 pm

- **Poster Session 7, 1021-1182**  
  Thursday, November 14, 7:00 am – 8:30 am

Please see pages 36-73 for a complete listing of abstract titles, topics and authors.
Congress Information

Social Events

Sunday, November 10, 2002
Welcome Reception
7:15 pm – 9:00 pm
All Congress attendees are invited to meet friends and colleagues during the traditional Congress Welcome Reception on Sunday evening, November 14th, on the Great Lawn of the Fontainebleau Hilton. Following the Opening Ceremony, guests will be guided to this beautiful outdoor area with local Miami music, where cocktails and hors d’oeuvres will be served.

Wednesday, November 13, 2002
Banquet at the Miami Seaquarium
Co-Sponsored by the National Parkinson Foundation and the Movement Disorder Society
Partially funded through an unrestricted educational grant from GlaxoSmithKline
6:30 pm – 11:00 pm
The Miami Seaquarium, located adjacent to beautiful Biscayne Bay, will be open exclusively for the MDS Congress banquet on Wednesday evening, November 13th. Guests can stroll through a lush, tropical jungle surrounding mangrove islands and tide pools which are home to native fish, birds, and sea turtles. The park contains dozens of aquariums with more than 100 species of marine life, including Atlantic and Caribbean reef fish and endangered Florida manatees.

The evening’s itinerary will include cocktails and hors d’oeuvres followed by flipper dolphin and killer whale shows. Dinner will be served at 8:45 pm accompanied by relaxing music.

Informal dress is recommended, including comfortable, rubber-soled shoes.

Transportation to and from the Miami Seaquarium will be provided. Shuttle buses will depart the Fontainebleau Hilton’s main driveway beginning at 6:30 pm. Shuttle service will depart the Seaquarium, returning to the Fontainebleau in 20-30 minute intervals, beginning at 9:15 pm and thereafter until 11:00 pm.

Tickets purchased in advance will be enclosed with your registration materials. Additional tickets will be sold in the Grand Gallerie of the Fontainebleau Hilton.

Fee: $85 USD ($50 for children, ages 14 and under)

Speaker Ready Room
Conference Room 1, Level IV, Versailles Building
All speakers must check in at the Speaker Ready Room with presentation materials, 24-hours prior to their scheduled presentation. Equipment is available for faculty to review their presentations. Audio visual personnel will be available for assistance.

Please note the Speaker Ready Room will be moving on Thursday, November 14, to Imperial II, located on level IV of the Versailles building. The Speaker Ready Room hours are as follows:

Saturday, November 9 12:00 pm – 8:00 pm
Sunday, November 10 6:30 am – 7:30 pm
Monday, November 11 6:30 am – 7:30 pm
Tuesday, November 12 6:30 am – 7:30 pm
Wednesday, November 13 6:30 am – 6:00 pm
Thursday, November 14 6:30 am – 10:30 am

Transportation
Taxi cabs are easily accessed in the main drive of the Fontainebleau Hilton. A hotel super shuttle is available for travel to and from Miami International Airport (MIA).
<table>
<thead>
<tr>
<th>Time</th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Kickoff Seminar 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Kickoff Seminar 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Kickoff Seminar 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td>Parallel Kickoff Seminars 4 and 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>Parallel Kickoff Seminars 6 and 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td>MDS Business Meeting</td>
<td></td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td>Wine &amp; Cheese Seminars</td>
<td></td>
</tr>
<tr>
<td>7:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Congress Banquet at the Miami Seaquarium</td>
</tr>
<tr>
<td>8:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Elan Ad
Scientific Program

Kickoff Seminar 1  8:00 am - 10:00 am
Location: Fontainebleau Ballroom A/ B, Level II

Novel approaches to the treatment of Parkinson’s disease: From early disease to late stage fluctuations
Funded through an unrestricted educational grant from Teva Pharmaceuticals and Teva Neuroscience

Co-Chair: Olivier Rascol, France
Co-Chair: Eldad Melamed, Israel

Neuroprotective effects of a novel MAO-B inhibitor: Preclinical studies with rasagiline
Moussa Youdim, Israel

Results of the TEMPO trial - Efficacy and safety of rasagiline as monotherapy 12-month data
Ira Shoulson, USA

Fluctuations in Parkinson’s disease - Mechanisms, treatment approaches and unmet needs
Stanley Fahn, USA

Etilevodopa: The molecule, the rationale, preliminary studies which proved the concept
Eldad Melamed, Israel

Pivotal studies with etilevodopa
Werner Poewe, Austria

Kickoff Seminar 2  10:15 am - 11:15 am
Location: Fontainebleau Ballroom C/ D, Level II

Non-oral drug delivery in Parkinson’s disease
Funded through an unrestricted educational grant from Schwarz Pharma AG

Co-Chair: Wolfgang H. Oertel, Germany
Co-Chair: Niall P. Quinn, United Kingdom

Non-oral drug delivery in Parkinson’s disease
Olivier Rascol, France

Rotigotine CDS, the Parkinson’s patch: Concept and results
Peter A. LeWitt, USA

Continuous dopaminergic stimulation: A promising and valuable clinical concept
Thomas N. Chase, USA

Kickoff Seminar 3  12:30 pm - 2:00 pm
Location: Fontainebleau Ballroom A/ B, Level II

COMT Inhibition: Enhancing Levodopa therapy in Parkinson’s disease
Funded through an unrestricted educational grant from Novartis and Orion Pharma

Co-Chair: Abraham Lieberman, USA
Co-Chair: A. Jon Stoessl, Canada

Kickoff Seminar 4  2:15 pm - 3:45 pm
Location: Fontainebleau Ballroom A/ B, Level II

Botulinum neurotoxins: Where are we now?
Funded through an unrestricted educational grant from Allergan

Co-Chair: Alfredo Berardelli, Italy
Co-Chair: Mark Hallett, USA

Understanding the therapeutic window
Roger K. Aoki, USA

Understanding the duration of effect
Oliver W. Dolly, UK

Properties of botulinum toxins in clinical practice
Dirk W. Dressler, Germany

Kickoff Seminar 5  2:15 pm - 3:45 pm
Location: Fontainebleau Ballroom C/ D, Level II

Dopamine agonists: State of the art in Parkinson’s disease treatment
Funded through an unrestricted educational grant from Pharmacia

Co-Chair: Paolo Barone, Italy
Co-Chair: Yoshikuni Mizuno, Japan

Neuroprotection and neurorescue in Parkinson’s disease
Anthony H. V. Schapira, UK

Long term neuroimaging data: The bridge from bench to clinic
Kenneth Marek, USA

Long term benefits of initial treatment with dopamine agonists
Joseph Jankovic, USA

Strategies for 24-hour management of Parkinson’s disease
K. Ray Chaudhuri, UK
Sunday, November 10

Kickoff Seminar 6  
4:00 pm - 5:30 pm  
Location: Fontainebleau Ballroom C/D, Level II  

**Distinguishing features of botulinum toxins**  
*Funded through an unrestricted educational grant from Élan*

- Co-Chair: William C. Koller, USA  
- Co-Chair: Mark Lew, USA  

**Characteristics of botulinum toxins**  
Paulette S. Setler, USA

**Understanding the differences between botulinum toxins**  
Joseph Arezzo, USA

**Important factors influencing the immunogenicity of botulinum toxins**  
Jeffrey Critchfield, USA

**Clinical efficacy of botulinum toxins**  
Francesca Mancini, Italy  
Mark Lew, USA

Kickoff Seminar 7  
4:00 pm - 5:30 pm  
Location: Fontainebleau Ballroom A/B, Level II  

**Dopamine agonists: Realizing the promise**  
*Funded through an unrestricted educational grant from GlaxoSmithKline*

- Co-Chair: Werner Poewe, Austria  
- Co-Chair: Fabrizio Stocchi, Italy

**The pharmacological rationale for the use of dopamine agonists in Parkinson's disease**  
C. Warren Olanow, USA

**Key clinical goals in modern Parkinson's disease therapy - The contribution of dopamine agonists**  
Matthew B. Stern, USA

**Assessing the impact of ropinirole on disease progression - The REAL-PET study**  
David J. Brooks, UK

Opening Ceremony  
6:30 pm - 7:15 pm  
Location: Fontainebleau Ballroom, Level II

**Welcome, Opening Remarks**  
Werner Poewe, MD, President, MDS

**Perspectives on research efforts treatment and management for Parkinson's disease**  
Ms. Janet Reno

**Education and research Initiatives in Parkinson's disease**  
Nathan Slewett, Chairman of the Board, National Parkinson's Foundation  
Co-Chair, of the newly formed, The Parkinson's Foundation

**Acknowledgement of MDS Honorary Membership**  
Werner Poewe, MD, Oleh Hornykiewicz, MD (Austria) will be honored, in recognition of his role in discovering Dopamine deficiency in PD and in introducing L-Dopa replacement therapy.

Stanley Fahn, MD (USA) will be honored in recognition of his role as founder of MDS and international leader in the field of movement disorders.

Gerald Stern, MD (UK) will be honored in recognition of his pioneering work in clinical pharmacology of Parkinson’s disease.

**Close**

Welcome Reception  
7:15 pm - 9:00 pm

All congress attendees are invited to meet friends and colleagues during the traditional Congress Welcome Reception on Sunday evening, November 14th, on the Great Lawn of the Fontainebleau Hilton. Following the Opening Ceremony, guests will be guided to this beautiful outdoor area with local Miami music, where cocktails and hors d’oeuvres will be served.
### Monday, November 11

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Location</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plenary Session 3</strong></td>
<td>2:00 pm - 3:30 pm</td>
<td>Fontainebleau Ballroom, Level II</td>
<td>Medical therapies in Parkinson’s disease: Evidence-based medicine</td>
</tr>
<tr>
<td><strong>Stanley Fahn Lecture</strong></td>
<td>8:30 am - 9:00 am</td>
<td>Fontainebleau Ballroom, Level II</td>
<td>Evidence-based treatment of Parkinson’s disease – Possibilities and limitations</td>
</tr>
<tr>
<td><strong>Parkinson’s Disease: New insights from functional imaging</strong></td>
<td></td>
<td>Fontainebleau Ballroom, Level II</td>
<td>Evidence-based treatment of Parkinson’s disease – Possibilities and limitations (Cristina Sampaio, Portugal)</td>
</tr>
<tr>
<td><strong>Plenary Session 1</strong></td>
<td>9:00 am - 10:30 am</td>
<td>Fontainebleau Ballroom, Level II</td>
<td>Alpha-synucleinopathies</td>
</tr>
<tr>
<td><strong>Alpha-synucleinopathies</strong></td>
<td></td>
<td></td>
<td>Chair: Michel Goedert, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Co-Chair: Dennis Dickson, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Relevance of alpha-synuclein for Lewy body diseases and multiple system atrophy (Michel Goedert, UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genetic analysis of alpha-synucleinopathies in Drosophila (Mel Feany, USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transgenic mouse models of alpha-synucleinopathies (Eliezer Masliah, USA)</td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td>10:30 am - 11:00 am</td>
<td>Exhibit Hall, East Ballroom, Level II</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session 2</strong></td>
<td>11:00 am - 12:30 pm</td>
<td>Fontainebleau Ballroom, Level II</td>
<td>Genetics of parkinsonism</td>
</tr>
<tr>
<td><strong>Genetics of parkinsonism</strong></td>
<td></td>
<td></td>
<td>Chair: Yoshikuni Mizuno, Japan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Co-Chair: Thomas Gasser, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Overview: Clinico-genetic correlation and genetic contributions to sporadic Parkinson’s disease (Nicholas Wood, UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Parkin and neuronal death (Ted M. Dawson, USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical features of recessive Parkinson’s disease (Vincenzo Bonifati, Italy)</td>
</tr>
<tr>
<td><strong>Poster Session 2</strong></td>
<td>12:30 pm - 2:00 pm</td>
<td>West Ballroom and Jade Promenade, Level II</td>
<td>Topics: Parkinson’s disease</td>
</tr>
<tr>
<td><strong>Poster Session 1</strong></td>
<td>7:00 am - 8:30 am</td>
<td>West Ballroom and Jade Promenade, Level II</td>
<td>Topics: Basic science, genetics, neuropharmacology, Parkinson’s disease</td>
</tr>
</tbody>
</table>

### Wine & Cheese Seminars

- **Wine & Cheese Seminar 1** | 4:00 pm - 5:30 pm | Pasteur, Level IV | Autonomic nervous system dysfunction in neurodegenerative disease (Pietro Cortelli, Italy; Horacio Kaufmann, Germany) |
- **Wine & Cheese Seminar 2** | 4:00 pm - 5:30 pm | Imperial III, Level IV | Advances in stiff person syndrome (Philip D. Thompson, Australia; Hans Michael Meinck, Germany) |
- **Wine & Cheese Seminar 3** | 4:00 pm - 5:30 pm | Champagne, Level I | Treatment options in tremor disorders (Roger J. Elble, USA; Peter George Bain, UK) |

### Break

- **3:30 pm - 4:00 pm**
  - **Location**: Exhibit Hall, East Ballroom, Level II
## Monday, November 11

<table>
<thead>
<tr>
<th>Wine &amp; Cheese Seminar 4</th>
<th>4:00 pm - 5:30 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Management of levodopa-induced hallucinations/behavioral disturbance</strong></td>
<td></td>
</tr>
<tr>
<td>E.Ch. Wolters, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Joseph H. Friedman, USA</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 5</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Patient selection/monitoring for surgery in Parkinson’s disease</strong></td>
<td></td>
</tr>
<tr>
<td>Jerrold Lee Vitek, USA</td>
<td></td>
</tr>
<tr>
<td>Marcelo Merello, Argentina</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 6</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Update on Huntington’s disease</strong></td>
<td></td>
</tr>
<tr>
<td>Justo De Yebenes, Spain</td>
<td></td>
</tr>
<tr>
<td>Gillian P. Bates, UK</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 7</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>How to evaluate clinical trials in movement disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Mario Zappa, Italy</td>
<td></td>
</tr>
<tr>
<td>Joaquim Ferreira, Portugal</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 8</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Restless leg syndrome and sleep problems in Parkinson’s disease</strong></td>
<td></td>
</tr>
<tr>
<td>Cynthia L. Comella, USA</td>
<td></td>
</tr>
<tr>
<td>Birgit Hogl, Austria</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 9</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Diagnosis and management of motor complications</strong></td>
<td></td>
</tr>
<tr>
<td>Marie Vidailhet, France</td>
<td></td>
</tr>
<tr>
<td>Jan Petter Larsen, Norway</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 10</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Parkinsonism - PSP, MSA, CBGD: Clinical update</strong></td>
<td></td>
</tr>
<tr>
<td>Gregor K. Wenning, Austria</td>
<td></td>
</tr>
<tr>
<td>Irene Litvan, USA</td>
<td></td>
</tr>
<tr>
<td>Wine &amp; Cheese Seminar 21</td>
<td>4:00 pm - 5:30 pm</td>
</tr>
<tr>
<td><strong>Gene therapy for Parkinson’s disease</strong></td>
<td></td>
</tr>
<tr>
<td>María G. Castro, USA</td>
<td></td>
</tr>
<tr>
<td>Jeffrey H. Kordower, USA</td>
<td></td>
</tr>
</tbody>
</table>

### Video Dinner Sessions

**Video Dinner Sessions** have become a popular segment of the MDS Congress as participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session and may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

#### Video Dinner

**Location:** Burgundy, Level I  
**Time:** 7:00 pm - 10:00 pm

**Tremor**

Günter Deuschl, Germany  
William C. Koller, USA

#### Video Dinner 2

**Location:** LeMans, Level I  
**Time:** 7:00 pm - 10:00 pm

**Dystonia**

Alberto Albanese, Italy  
Joseph Jankovic, USA

#### Video Dinner 3

**Location:** Bordeaux, Level I  
**Time:** 7:00 pm - 10:00 pm

**Myoclonus**

José A. Obeso, Spain  
Peter Brown, UK

#### Video Dinner 4

**Location:** Brittany, Level I  
**Time:** 7:00 pm - 10:00 pm

**Atypical Parkinsonism**

Niall P. Quinn, UK  
Jean Hubble, USA

#### Video Dinner 5

**Location:** Champagne, Level I  
**Time:** 7:00 pm - 10:00 pm

**Unusual movement disorders**

Rajesh Pahwa, USA  
Oscar S. Gershanik, Argentina

---

**Video Dinner Sessions**

Video Dinner sessions have become a popular segment of the MDS Congress as participants will be encouraged to discuss clinical aspects of the featured movement disorder throughout the session and may bring their own videos to share with the audience. Attendance is limited to 50-75 participants per session. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

**Video Dinner**

**Location:** Burgundy, Level I  
**Time:** 7:00 pm - 10:00 pm

**Tremor**

Günter Deuschl, Germany  
William C. Koller, USA

**Video Dinner 2**

**Location:** LeMans, Level I  
**Time:** 7:00 pm - 10:00 pm

**Dystonia**

Alberto Albanese, Italy  
Joseph Jankovic, USA

**Video Dinner 3**

**Location:** Bordeaux, Level I  
**Time:** 7:00 pm - 10:00 pm

**Myoclonus**

José A. Obeso, Spain  
Peter Brown, UK

**Video Dinner 4**

**Location:** Brittany, Level I  
**Time:** 7:00 pm - 10:00 pm

**Atypical Parkinsonism**

Niall P. Quinn, UK  
Jean Hubble, USA

**Video Dinner 5**

**Location:** Champagne, Level I  
**Time:** 7:00 pm - 10:00 pm

**Unusual movement disorders**

Rajesh Pahwa, USA  
Oscar S. Gershanik, Argentina
### Tuesday, November 12

#### Plenary Session 3
- Time: 7:00 am - 8:30 am
- Location: West Ballroom and Jade Promenade, Level II
- **Topics:** Parkinson's disease

#### Plenary Session 4
- Time: 8:30 am - 10:00 am
- Location: Fontainebleau Ballroom, Level II
- **Topics:** Tauopathies
  - Chair: Zbigniew K. Wszolek, USA
  - Co-Chair: Timothy Lynch, Ireland
  - **Familial tauopathies – Clinical considerations**
    - Zbigniew K. Wszolek, USA
  - **Neuropsychological and behavioral aspects of tauopathies**
    - David Neary, UK
  - **Molecular genetic dissection of tauopathies**
    - Peter Heutink, The Netherlands
  - **Pathology of tauopathies**
    - Bernardino Ghetti, USA

#### Coffee Break
- Time: 10:00 am - 10:30 am
- Location: Exhibit Hall, East Ballroom, Level II

#### Plenary Session 5
- Time: 10:30 am - Noon pm
- Location: Fontainebleau Ballroom, Level II
- **Clinical and basic aspects of dystonia**
  - Chair: Stanley Fahn, USA
  - Co-Chair: Giovanni Abbruzzese, Italy
  - **Clinical and genetic heterogeneity of dystonia**
    - Susan B. Bressman, USA
  - **The genetics and its biochemical implications in myoclonus-dystonia**
    - Thomas Gasser, Germany
  - **Deep brain stimulation in the treatment of dystonia**
    - Philippe Coubes, France

#### Poster Session 4
- Time: Noon - 1:30 pm
- Location: West Ballroom and Jade Promenade, Level II
- **Topics:** Neuroimaging, surgical therapy, transplantation

#### Plenary Session 6
- Time: 2:00 pm - 3:30 pm
- Location: Fontainebleau Ballroom, Level II
- **Neuroimaging update**
  - Chair: David J. Brooks, UK
  - Co-Chair: Klaus Leonhard Leenders, The Netherlands
  - **Understanding complications of Parkinson’s disease**
    - A. Jon Stoessl, Canada
  - **Huntington’s disease**
    - Klaus Leonhard Leenders, The Netherlands
  - **Dystonia**
    - David Eidelberg, USA

#### Video Dinner Sessions
- Video Dinner 6
  - Time: 7:00 pm - 10:00 pm
  - Location: Burgundy, Level I
  - **Drug-induced movement disorders**
    - Philippe Damier, France
    - Amos D. Korczyn, Israel

- Video Dinner 7
  - Time: 7:00 pm - 10:00 pm
  - Location: Brittany, Level I
  - **Paroxysmal movement disorders**
    - Kailash P. Bhatia, UK
    - Kapil D. Sethi, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 pm - 10:00 pm</td>
<td><strong>Video Dinner 8</strong>&lt;br&gt;Location: Le Mans, Level I&lt;br&gt;<strong>Psychogenic movement disorders</strong>&lt;br&gt;Anthony E. Lang, Canada&lt;br&gt;John G. L. Morris, Australia</td>
</tr>
<tr>
<td>7:00 pm - 10:00 pm</td>
<td><strong>Video Dinner 9</strong>&lt;br&gt;Location: Champagne, Level I&lt;br&gt;<strong>Gait disorders</strong>&lt;br&gt;John G. Nutt, USA&lt;br&gt;Nir Giladi, Israel</td>
</tr>
<tr>
<td>7:00 pm - 10:00 pm</td>
<td><strong>Video Dinner 10</strong>&lt;br&gt;Location: Bordeaux, Level I&lt;br&gt;<strong>Tourette's syndrome</strong>&lt;br&gt;Francisco Cardoso, Brazil&lt;br&gt;Andrew J. Lees, UK</td>
</tr>
<tr>
<td>7:00 am - 8:30 am</td>
<td><strong>Poster Session 5</strong>&lt;br&gt;Location: West Ballroom and Jade Promenade, Level II&lt;br&gt;<strong>Topics</strong>: Non-motor aspects of movement disorders, clinical, parkinsonism</td>
</tr>
<tr>
<td>8:30 am - 10:00 am</td>
<td><strong>Parallel Session 7A</strong>&lt;br&gt;Location: Fontainebleau Ballroom A/B, Level II&lt;br&gt;<strong>Trinucleotide repeat diseases</strong>&lt;br&gt;Chair: Anne B. Young, USA&lt;br&gt;Co-Chair: Thomas Klockgether, Germany</td>
</tr>
<tr>
<td>8:30 am - 10:00 am</td>
<td><strong>Parallel Session 7B</strong>&lt;br&gt;Location: Fontainebleau Ballroom C/D, Level II&lt;br&gt;<strong>Mental changes in Parkinson's disease</strong>&lt;br&gt;Chair: Bruno Dubois, France&lt;br&gt;Co-Chair: Ramon Leiguarda, Argentina</td>
</tr>
<tr>
<td>10:00 am - 10:30 am</td>
<td><strong>Coffee Break</strong>&lt;br&gt;Location: Exhibit Hall, East Ballroom, Level II</td>
</tr>
<tr>
<td>10:30 am - Noon</td>
<td><strong>Parallel Session 8A</strong>&lt;br&gt;Location: Fontainebleau Ballroom A/B, Level II&lt;br&gt;<strong>Neurophysiology of movement disorders</strong>&lt;br&gt;Chair: Alfredo Berardelli, Italy&lt;br&gt;Co-Chair: Reiner Benecke, Germany</td>
</tr>
</tbody>
</table>

| Topics: Non-motor aspects of movement disorders, clinical, parkinsonism |
| Trinucleotide repeat diseases |
| Mental changes in Parkinson's disease |
| The non-motor functions of the basal ganglia from anatomy to behavior |
| Friedreich's ataxia |
| Spinocerebellar ataxias |
| Huntington's disease |
| Is Parkinson's disease with dementia and DLB the same disease?  
  Yes: Andrew J. Lees, UK  
  No: Charles Duyskaerts, France |
| Does deep brain stimulation affect cognition/behavior?  
  Yes: Jean Saint-Cyr, Canada  
  No: Pierre Pollak, France |
| Neurophysiology of movement disorders |
| The role of non-corticospinal system  
  John C. Rothwell, UK |
| Changes in the excitability of cortical motor areas  
  Alfredo Berardelli, Italy |
| Rhythmic activity in basal ganglia and in motor cortex  
  Peter Brown, UK |
| Cerebellar control of movement  
  Mark Hallett, USA |
Wednesday, November 13

Parallel Session 8B  
10:30 am - Noon  
Location: Fontainebleau Ballroom C/D, Level II  
Public health issues and epidemiology in Parkinson's disease  
Chair: Eduardo Tolosa, Spain  
Co-Chair: Ali Rajput, Canada  
Risk factors for Parkinson's disease: An epidemiological approach  
Caroline M. Tanner, USA  
Impact of co-morbidities on Parkinson's disease  
Mark Guttman, Canada  
Quality of life determinants in Parkinson's disease  
Anette Schrag, UK

Poster Session 6  
Noon - 1:30 pm  
Location: West Ballroom and Jade Promenade, Level II  
Posters 851-1020  
Topics: Clinical electrophysiology, dystonia

Junior Awards Lectures  
1:30 pm - 2:00 pm  
Location: Fontainebleau Ballroom C/D, Level II  
Basic science award  
Is the rhythm of physiologic tremor involved in cortical motor planning?  
Jan H. Raethjen, Kiel, Germany  
Clinical science award  
Staged lesions through implanted deep brain stimulating electrodes: A new surgical procedure for treating tremor or dyskinesia  
Sylvia Raoul, Nantes, France

Parallel Session 9A  
2:00 pm - 3:30 pm  
Location: Fontainebleau Ballroom A/B, Level II  
Sleep disorders in movement disorders  
Chair: Wayne A. Hening, USA  
Co-Chair: Claudia M. Trenkwalder, Germany  
The spectrum of motor disorders of sleep  
Pasquale Montagna, Italy  
Restless legs syndrome and periodic limb movements: The most common motor sleep disturbances  
Claudia M. Trenkwalder, Germany  
REM sleep behavior disorder: A condition of sleep state motor dysregulation linked to Lewy body diseases  
Cynthia L. Comella, USA  
Daytime sleepiness in Parkinson's disease: A problem of multiple etiologies?  
David Rye, USA

Parallel Session 9B  
2:00 pm - 3:30 pm  
Location: Fontainebleau Ballroom C/D, Level II  
Update on mechanisms of neurodegeneration  
Chair: Robert E. Burke, USA  
Co-Chair: Eldad Melamed, Israel  
An update on mechanisms of MPTP toxicity  
Serge Przedborski, USA  
Rotenone-induced dopamine neuron death in a rodent model  
John Timothy Greenamyre, USA  
Mechanisms of programmed cell death in dopamine neurons  
Jorg B. Schulz, Germany

Break  
3:30 pm - 4:00 pm  
Location: Exhibit Hall, East Ballroom, Level II

Wine & Cheese Seminars  
Late afternoon Wine & Cheese seminars are designed to be informal and interactive. To encourage discussion, attendance is limited to 50-75 participants per seminar. Please check in at the Registration Desk for availability. Tickets for available sessions will be sold on-site on a first-come, first-served basis.

Wine & Cheese Seminar 11  
4:00 pm - 5:30 pm  
Location: Voltaire, Level IV  
Gene therapy for Parkinson's disease  
Maria G. Castro, USA

Wine & Cheese Seminar 12  
4:00 pm - 5:30 pm  
Location: LeMans, Level I  
Ataxias  
S.H. Subramony, USA  
Alessandro Filla, Italy

Wine & Cheese Seminar 13  
4:00 pm - 5:30 pm  
Location: Imperial II, Level IV  
Occupational cramps  
Alberto Priori, Italy  
Steven Frucht, USA

Wine & Cheese Seminar 14  
4:00 pm - 5:30 pm  
Location: Pasteur, Level IV  
Neurodegeneration with iron accumulation; DRPLA  
Susan J. Hayflick, USA  
Shoji K. C. Tsuji, Japan

Wine & Cheese Seminar 15  
4:00 pm - 5:30 pm  
Location: Imperial III, Level IV
Wednesday, November 12

Recent advances of Wilson’s disease; dopa-responsive dystonia
Yoshiaki Furukawa, Canada
Federico Micheli, Argentina

Wine & Cheese Seminar 16
Location: Champagne, Level I
4:00 pm - 5:30 pm
Dementia with Lewy bodies
I.G. McKeith, UK
Glenda M. Halliday, Australia

Wine & Cheese Seminar 17
Location: Brittany, Level I
4:00 pm - 5:30 pm
Systemic diseases that cause movement disorders
Fernando Alarcon, Ecuador
Santiago Gimenez-Roldan, Spain

Wine & Cheese Seminar 18
Location: Burgundy, Level I
4:00 pm - 5:30 pm
Pediatric movement disorders
Harvey S. Singer, USA
Robert A. H. Surtees, UK

Wine & Cheese Seminar 19
Location: Bordeaux, Level I
4:00 pm - 5:30 pm

Thursday, November 14

Poster Session 7
Location: West Ballroom and Jade Promenade, Level II
7:00 am - 8:30 am
Posters 1021-1182
Topics: Ataxia, chorea, drug-induced movement disorders, myoclonus, spasticity, stereotypies, tics, tremor

Plenary Session 10
Location: Fontainebleau Ballroom, Level II
8:30 am - 10:00 am
Clinical trials in movement disorders
Chair: Olivier Rascol, France
Co-Chair: Miguel Rueda S., Colombia
The ELLDOPA study
Stanley Fahn, USA
Effects of coenzyme Q10 in early Parkinson’s disease:
The QE2 study
Cliff Shults, USA
“N=1” trials - A possible solution to assess interventions in movement disorders
Joaquim Ferreira, Portugal
Update on clinical trials in Huntington's disease
Karl D. Kieburtz, USA

Break
10:00 am - 10:30 am
Location: Fontainebleau Gallerie

Plenary Session 11
Location: Fontainebleau Ballroom, Level II
10:30 am - Noon
Surgical treatment of movement disorders
Chair: Andres M. Lozano, Canada
Co-Chair: Alim L. Benabid, France
Targeting Parkinson’s disease: The role of surgery
Alim L. Benabid, France
What neuroimaging in surgery has taught us about movement disorders
Andres M. Lozano, Canada
Transplantation for Parkinson’s disease - Pros, cons and where do we go from here?
C. Warren Olanow, USA
Faculty

Abbruzzese, Giovanni
Genoa, Italy
PL05

Alarcon, Fernando
Quito, Ecuador
WC 17

Albanese, Alberto
Milano, Italy
V02

Aoki, Roger K.
Irvine, CA, USA
KS04

Arezzo, Joseph
Bronx, NY, USA
KS06

Bain, Peter George
Richmond, Surrey, UK
WC 03

Barone, Paolo
Napoli, Italy
KS05

Bates, Gillian P.
London, UK
WC 06

Benabid, Alim L.
Grenoble, France
PL08A

Benecke, Reiner
Rostock, Germany
KS04

Berardelli, Alfredo
Roma, Italy
PL08A

Bhatia, Kailash P.
London, UK
V07

Bonifati, Vincenzo
Rotterdam, The Netherlands
PL02

Bressman, Susan B.
New York, NY, USA
PL05

Brooks, David J.
London, UK
KS07, PL06, Fahn Lectureship

Brown, Peter
London, UK
PL08A, V03

Burke, Robert E.
New York, NY, USA
PL09B

Cardoso, Francisco
Belo Horizonte, Brazil
V10

Castro, Maria G.
Los Angeles, CA, USA
WC 11, WC 21

Cha, Yung-Ho John
Charleston, MA, USA
PL07A

Chase, Thomas N.
Baltimore, MD, USA
KS02

Chaudhuri, K. Ray
London, UK
KS05

Chen, Robert
Toronto, ON, Canada
WC 19

Comella, Cynthia L.
Chicago, IL, USA
PL09A, WC 08

Cortelli, Pietro
Bologna, Italy
WC 01

Coubes, Philippe
Montpellier, France
PL05

Crichton, J. Jeffrey
San Francisco, CA, USA
KS06

Cuma, Antonio
Venafro, Italy
WC 19

Damier, Philippe
Nantes, France
V06

Dawson, Ted M.
Baltimore, MD, USA
PL02

De Yebenes, Justo
Madrid, Spain
WC 06

Deuschl, Günther
Kiel, Germany
V01

Dickson, Dennis
Jacksonville, FL, USA
PL01

Dodel, Richard
Marburg, Germany
PL03

Dolly, Oliver W.
London, UK
KS04

Dressler, Dirk W.
Rostock, Germany
KS04

Dubois, Bruno
Paris, France
PL07B

Duyckaerts, Charles
Paris, France
PL07B

Eidelberg, David
Manhasset, NY, USA
PL06

Elble, Roger J.
Springfield, IL, USA
WC 03

Fahn, Stanley
New York, NY, USA
KS01, PL05, PL10

Feany, Mel
Boston, MA, USA
PL01

Ferreira, Joaquim
Dois Portos, Portugal
PL10, WC 07

Filla, Alessandro
Napoli, Italy
WC 12

Friedman, Joseph H.
Pawtucket, RI, USA
WC 04

Frucht, Steven
New York, NY, USA
WC 13

Fukunaga, Yoshiaiki
Toronto, ON, Canada
WC 15

Gasser, Thomas
Munchen, Germany
PL02, PL05

Gershaniak, Oscar S.
Buenos Aires, Argentina
V05

Ghetti, Bernardino
Indianapolis, IN, USA
PL04

Giladi, Nir
Tel Aviv, Israel
V09

Gimenez-Roldan, Santiago
Madrid, Spain
WC 17

Goerdert, Michel
Cambridge, UK
PL01

Goetz, Christopher G.
Chicago, IL, USA
PL03

Greenamyre, John Timothy
Atlanta, GA, USA
PL09B

Gutman, Mark
Markham, ON, Canada
PL08B

Hallett, Mark
Bethesda, MD, USA
KS04, PL08A

Halliday, Glenda M.
Randwick, Australia
WC 16

Hayflick, Susan J.
Portland, OR, USA
WC 14

Hening, Wayne A.
New York City, NY, USA
PL09A

Heutink, Peter
Rotterdam, Netherlands
PL04

Hogi, Birgit
Innsbruck, Austria
WC 08

Hubble, Jean
East Hanover, NJ, USA
V04

Jankovic, Joseph
Houston, TX, USA
KS05, V02

Jenner, Peter
London, UK
KS03

Kaufmann, Horacio
New York, NY, USA
WC 01

Kieburz, Karl D.
Rochester, NY, USA
PL10

Klockgether, Thomas
Bonn, Germany
PL07A

Koenig, Michel
Strasbourg, France
PL07A

Koller, William C.
New York, NY, USA
KS03, KS06, V01

Korczyn, Amos D.
Ramat-Aviv, Israel
V06

Kordower, Jeffrey H.
Chicago, IL, USA
WC 21

Lang, Anthony
Toronto, ON, Canada
V08

Larsen, Jan Peter
Stavanger, Norway
WC 09
## Faculty

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leenders, Klaus Leonhard</td>
<td>Groningen, Netherlands</td>
<td>PL06</td>
</tr>
<tr>
<td>Lees, Andrew J.</td>
<td>London, UK</td>
<td>PL07B, V10</td>
</tr>
<tr>
<td>Leiguarda, Ramon</td>
<td>Buenos Aires, Argentina</td>
<td>PL07B</td>
</tr>
<tr>
<td>Lew, Mark</td>
<td>Los Angeles, CA, USA</td>
<td>KS06</td>
</tr>
<tr>
<td>LeWitt, Peter A.</td>
<td>Southfield, MI, USA</td>
<td>KS02</td>
</tr>
<tr>
<td>Lieberman, Abraham</td>
<td>Miami, FL, USA</td>
<td>KS03</td>
</tr>
<tr>
<td>Livian, Irene</td>
<td>Bethesda, MD, USA</td>
<td>WC10</td>
</tr>
<tr>
<td>Lozano, Andres M.</td>
<td>Toronto, ON, Canada</td>
<td>PL11</td>
</tr>
<tr>
<td>Ludlow, Chrisy L.</td>
<td>Bethesda, MD, USA</td>
<td>WC20</td>
</tr>
<tr>
<td>Lynch, Timothy</td>
<td>Dublin, Ireland</td>
<td>PL04</td>
</tr>
<tr>
<td>Mancini, Francesca</td>
<td>Pavia, Italy</td>
<td>KS06</td>
</tr>
<tr>
<td>Marek, Kenneth</td>
<td>New Haven, CT, USA</td>
<td>KS05</td>
</tr>
<tr>
<td>Masiah, Eliezer</td>
<td>La Jolla, CA, USA</td>
<td>PL01</td>
</tr>
<tr>
<td>McKeith, I.G.</td>
<td>Newcastle Upon Tyne, UK</td>
<td>WC16</td>
</tr>
<tr>
<td>Meinck, Hans Michael</td>
<td>Heidelberg, Germany</td>
<td>WC02</td>
</tr>
<tr>
<td>Melamed, Edad</td>
<td>Petah Tiqva, Israel</td>
<td>KS01, PL09B</td>
</tr>
<tr>
<td>Merello, Marcelo</td>
<td>Buenos Aires, Argentina</td>
<td>WC05</td>
</tr>
<tr>
<td>Micheli, Federico</td>
<td>Buenos Aires, Argentina</td>
<td>WC15</td>
</tr>
<tr>
<td>Mizuno, Yoshikuni</td>
<td>Tokyo, Japan</td>
<td>KS05, PL02</td>
</tr>
<tr>
<td>Montagna, Pasquale</td>
<td>Bologna, Italy</td>
<td>PL09A</td>
</tr>
<tr>
<td>Morris, John G.L.</td>
<td>Sydney, Australia</td>
<td>V08</td>
</tr>
<tr>
<td>Neary, David</td>
<td>Manchester, UK</td>
<td>PL04</td>
</tr>
<tr>
<td>Nutt, John G.</td>
<td>Portland, OR, USA</td>
<td>V09</td>
</tr>
<tr>
<td>Oseso, Jose A.</td>
<td>Pamplona, Spain</td>
<td>KS03, V03</td>
</tr>
<tr>
<td>Oertel, Wolfgang H.</td>
<td>Marburg, Hessen, Germany</td>
<td>KS02</td>
</tr>
<tr>
<td>Olano, C. Warren</td>
<td>New York, NY, USA</td>
<td>KS03, KS07, PL07</td>
</tr>
<tr>
<td>Pawha, Rajesh</td>
<td>Kansas City, KS, USA</td>
<td>V05</td>
</tr>
<tr>
<td>Poewe, Wemer</td>
<td>Innsbruck, Austria</td>
<td>KS01, KS07, PL03</td>
</tr>
<tr>
<td>Pollak, Pierre</td>
<td>Grenoble, France</td>
<td>PL07B</td>
</tr>
<tr>
<td>Priori, Alberto</td>
<td>Milano, Italy</td>
<td>WC13</td>
</tr>
<tr>
<td>Przedborski, Serge</td>
<td>New York, NY, USA</td>
<td>PL09B</td>
</tr>
<tr>
<td>Quinn, Niall P.</td>
<td>London, UK</td>
<td>KS02, V04</td>
</tr>
<tr>
<td>Rajput, Ali</td>
<td>Saskatoon, SK, Canada</td>
<td>PL08B</td>
</tr>
<tr>
<td>Ramig, Lorraine</td>
<td>Denver, CO, USA</td>
<td>WC20</td>
</tr>
<tr>
<td>Rascol, Olivier</td>
<td>Toulouse, France</td>
<td>KS01, KS02, PL10</td>
</tr>
<tr>
<td>Rothwell, John C.</td>
<td>London, UK</td>
<td>PL08A</td>
</tr>
<tr>
<td>Rueda S., Miguel</td>
<td>Bogota, Colombia</td>
<td>PL10</td>
</tr>
<tr>
<td>Rye, David</td>
<td>Atlanta, GA, USA</td>
<td>PL09A</td>
</tr>
<tr>
<td>Saint-Cyr, Jean</td>
<td>Toronto, ON, Canada</td>
<td>PL07B</td>
</tr>
<tr>
<td>Sampaio, Cristina</td>
<td>Lisboa, Portugal</td>
<td>PL03</td>
</tr>
<tr>
<td>Schapira, Anthony H.V.</td>
<td>London, UK</td>
<td>KS05</td>
</tr>
<tr>
<td>Schrag, Anette</td>
<td>London, UK</td>
<td>PL08B</td>
</tr>
<tr>
<td>Schulz, Jorg B.</td>
<td>Tuebingen, Germany</td>
<td>PL09B</td>
</tr>
<tr>
<td>Sethi, Kapil D.</td>
<td>Augusta, GA, USA</td>
<td>V07</td>
</tr>
<tr>
<td>Setler, Paulette</td>
<td>Burlington, CA, USA</td>
<td>KS06</td>
</tr>
<tr>
<td>Shoulson, Ira</td>
<td>Rochester, NY, USA</td>
<td>KS01</td>
</tr>
<tr>
<td>Shults, Cliff</td>
<td>San Diego, CA, USA</td>
<td>PL10</td>
</tr>
<tr>
<td>Singer, Harvey S.</td>
<td>Baltimore, MD, USA</td>
<td>WC18</td>
</tr>
<tr>
<td>Stem, Matthew B.</td>
<td>Philadelphia, PA, USA</td>
<td>KS07</td>
</tr>
<tr>
<td>Stocchi, Fabrizio</td>
<td>Roma, Italy</td>
<td>KS07</td>
</tr>
<tr>
<td>Stoessler, A. Jon</td>
<td>Vancouver, BC, Canada</td>
<td>KS03, PL06</td>
</tr>
<tr>
<td>Strick, Peter L.</td>
<td>Pittsburg, PA, USA</td>
<td>PL07B</td>
</tr>
<tr>
<td>Subramony, S.H.</td>
<td>Jackson, MS, USA</td>
<td>WC12</td>
</tr>
<tr>
<td>Surtees, Robert A. H.</td>
<td>London, UK</td>
<td>WC18</td>
</tr>
<tr>
<td>Tanner, Caroline M.</td>
<td>Sunnyvale, CA, USA</td>
<td>PL08B</td>
</tr>
<tr>
<td>Thompson, Philip D.</td>
<td>Adelaide, Australia</td>
<td>WC02</td>
</tr>
<tr>
<td>Tolosa, Eduardo</td>
<td>Barcelona, Spain</td>
<td>PL08B</td>
</tr>
<tr>
<td>Trenkwaldner, Claudia M.</td>
<td>Goettingen, Germany</td>
<td>PL09A</td>
</tr>
<tr>
<td>Tsuji, Shoji K.C.</td>
<td>Niigata, Japan</td>
<td>WC14</td>
</tr>
<tr>
<td>Vidalhiet, Marie</td>
<td>Paris, France</td>
<td>WC09</td>
</tr>
<tr>
<td>Vitek, Jemold Lee</td>
<td>Marletta, GA, USA</td>
<td>WC05</td>
</tr>
<tr>
<td>Watts, Ray L.</td>
<td>Atlanta, GA, USA</td>
<td>KS03</td>
</tr>
<tr>
<td>Wenning, Gregor K.</td>
<td>Innsbruck, Austria</td>
<td>WC10</td>
</tr>
<tr>
<td>Wohlers, E.C.</td>
<td>Amsterdam, Netherlands</td>
<td>WC04</td>
</tr>
<tr>
<td>Wood, Nicholas</td>
<td>London, UK</td>
<td>PL02</td>
</tr>
<tr>
<td>Wszolek, Zbigniew K.</td>
<td>Jacksonville, FL, USA</td>
<td>PL04</td>
</tr>
<tr>
<td>Youdim, Moussa</td>
<td>Haifa, Israel</td>
<td>KS01</td>
</tr>
<tr>
<td>Young, Anne B.</td>
<td>Boston, MA, USA</td>
<td>PL07A</td>
</tr>
<tr>
<td>Zappia, Mario</td>
<td>Catanzaro, Italy</td>
<td>WC07</td>
</tr>
</tbody>
</table>

### Key

| KS  | = Kickoff Seminar |
| PL  | = Plenary or Parallel Session |
| V   | = Video Dinner Session |
| WC  | = Wine & Cheese Seminar |

25
General Information and Exhibit Hall Hours

Please allow adequate time in your daily schedule to visit the Exhibit Hall, located in the East Ballroom. The exhibition is an integral component to your Congress experience, representatives of companies providing services or marketing products directly related to movement disorders. Delegates may enter the Exhibit Hall at the entrance between the Jade Promenade and Fontainebleau Gallerie or through the West Ballroom during the following hours:

- Monday, November 11: 8:00 am – 5:00 pm
- Tuesday, November 12: 8:00 am – 5:00 pm
- Wednesday, November 13: 8:00 am – 5:00 pm

Exhibitor Registration

Exhibitors may register at the Exhibitor Registration Desk, located in the Grand Gallerie of the Fontainebleau Hilton during the following hours:

- Saturday, November 9: 3:00 pm – 8:30 pm
- Sunday, November 10: 6:30 am – 7:30 pm
- Monday, November 11: 6:30 am – 7:30 pm
- Tuesday, November 12: 6:30 am – 7:30 pm
- Wednesday, November 13: 6:30 am – 6:00 pm

Exhibitor Badge Policy

Exhibit booth personnel must show an official MDS exhibitor name badge in order to gain access to the Exhibit Hall during installation, show, or dismantlement hours. Badges should be worn at all times as security guards will monitor Exhibit Hall entrances for proper identification. Exhibitors will be identified as follows:

- **Exhibitor Badge (Yellow)** - Allows admittance to the Exhibit Hall area only.
- **Exhibitor Delegate Badge (Orange)** - Allows the delegate to enter the Exhibit Hall as an exhibitor and attend scientific sessions including poster presentations (access to Wine and Cheese Seminars and Video Dinners at an additional cost).

Endorsement Disclaimer

Products and services displayed in the Exhibit Hall or advertised in the program occur by contractual business arrangements between the MDS and participating companies and organizations. These arrangements do not constitute nor imply an endorsement by the MDS of these products and services.

Exhibitor Information

- **Chinese Medical Association**
  - 42 Dongsi Xidajie
  - Beijing, China, 100710
  - E-mail: xvicpd@chinamed.com.cn
  - Website: www.chinamed.com.cn/xvicpd
  - **Booth Number:** 14
  - The XV International Congress of Parkinson’s Disease will be held May 30 - June 3, 2003, in Beijing, China. At the Congress, the latest information in combating Parkinson’s disease will be shared, as well as the application of the traditional Chinese medicine in the treatment of Parkinson’s disease.

- **Allergan**
  - 2525 Dupont Drive
  - Irvine, CA, 92612-1599, USA
  - Website: www.allergan.com
  - **Booth Number:** 200
  - Allergan is the manufacturer of BOTOX®, Botulinum Toxin Type-A, Purified Neurotoxin Complex. There are presently a number of BOTOX® clinical trials underway for a wide variety of uses. Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide.

- **Amarin Pharmaceuticals, Inc.**
  - 2 Belvedere Place
  - Suite #330
  - Mill Valley, CA 94941, USA
  - Website: www.amarinpharma.com
  - **Booth Number:** 412
  - Amarin Pharmaceuticals is a fully integrated specialty pharmaceutical company, focused on the development and marketing of novel neurological and pain disorder treatments that target unmet medical needs. Amarin Pharmaceuticals currently markets Permax® (pergolide mesylate), a dopamine agonist for the treatment of Parkinson’s Disease.

- **American Parkinson Disease Association, Inc.**
  - 1250 Hylan Boulevard
  - Suite 4B
  - Staten Island, NY 10305, USA
  - E-mail: info@apdaparkinson.org
  - Website: www.apdaparkinson.org
  - **Booth Number:** 9
  - The American Parkinson Disease Association, Inc. (APDA) provides educational, referral and support programs for medical professionals, patients, their families and the public through regional symposia, educational literature and video tapes. APDA has 64 Chapters and more than 800 support groups; funds 54 Information & Referral Centers and sponsors research on Parkinson’s disease by funding Advanced Centers for Parkinson’s Research, fellowships and research grants.
The American Society for Experimental NeuroTherapeutics (ASENT) brings together leaders in government, academia and industry engaged in the field of neurotherapeutics to advance the knowledge of these scientists in advances in experimental neurotherapeutics. ASENT's 5th Annual Meeting will be held from March 13-15, 2003 at the Capital Hilton in Washington, DC.

The major goal of the Bachmann-Strauss Dystonia & Parkinson Foundation is to find a cure for Dystonia and Parkinson diseases. We strive to achieve this goal by raising awareness of Dystonia and Parkinson’s disease in the general public and the medical community, raising funds to support research, and sponsoring educational symposia for patients and families.

The Benign Essential Blepharospasm Research Foundation, Inc. founded in 1981, is the only organization dedicated solely to finding the cause and cure for Blepharospasm, Meige and related disorders. BEBRF, a volunteer directed, nonprofit organization, has support groups nationwide, promotes awareness and research, distributes educational material to patients and physicians, and serves as a referral clearing house.

Phenytek® 300mg Capsules contain the active ingredient extended phenytoin sodium and has proven equal to Dilantin® Kapseals® in bioequivalence studies. Specially patented technology has allowed scientists to put 300mg of extended phenytoin sodium into one capsule to allow convenient dosing options. Phenytek is also available in 200mg Capsules.

Biotene-Laclede, Inc.

2030 East University Drive
Rancho Dominguez, CA 90220, USA
E-mail: help@laclede.com
Website: www.laclede.com
Booth Number: 118

Biotene & Oralbalance Dry Mouth Products – Over the counter dry mouth care products contain natural antibacterial salivary enzymes that help reduce oral irritations due to dry mouth caused by anti-Parkinson’s medications. Biotene dry mouth toothpaste, alcohol-free mouthwash, sugar-free chewing gum and Oralbalance moisturizing gel saliva substitute.

Cambridge Laboratories

Deltic House
King Fisher Way
Silverlink Business Park
Wallsend, Tyne & Wear NE28 9NX
United Kingdom
E-mail: marketing@camb-labs.com
Website: www.camb-labs.com
Booth Number: 117

Cambridge Laboratories is a specialist pharmaceutical company that develops and markets niche pharmaceutical products to hospitals and consultants worldwide. The company’s lead product is xenazine 25 which is indicated for the treatment of organic hyperkinetic movement disorders and tardive dyskinesia.

Cleveland Medical Devices

11000 Cedar Avenue
Suite 130
Cleveland, OH 44106, USA
E-mail: sales@clevemed.com
Website: www.clevemed.com
Booth Number: 120

Cleveland Medical Devices’ line of lightweight physiological monitors include: two wireless 8-channel programmable devices, the BioRadio® 110 and the Crystal Monitor®, and a wireless 2-channel miniature device, the BioRadio Jr., which by eliminating restricting wires, allows continuous EEG, EMG, EOG, and PSG (polysomnograph) monitoring of patients.

The Dystonia Medical Research Foundation has a 3-fold mission: to advance research into the cause of, and cure for dystonia. To date, 356 grants totaling over $17 million have been awarded. The second goal is to create public and physician awareness of dystonia, and the third goal is to sponsor educational and support programs.
Eastern Medical Publishers
173 NW 81 Way
Coral Springs, FL  33071, USA
Website: www.empbooks.com
Booth Number: 219
Eastern Medical Publishers represents several of the leading publishers in the industry.

Élan
5880 Pacific Center
San Diego, CA  92121, USA
Website: www.elan.com
Booth Number: 110
Élan is focused on the discovery, development, manufacturing, selling and marketing of novel therapeutic products in neurology, pain management and autoimmune diseases. Élan products include MYOBLOC, registered in the United States, and NEUROBLOC, registered in Europe.

European Dystonia Federation
69 East King Street
Helensburgh, Argyll&Bute  G84 7RE
United Kingdom
Website: www.dystonia-europe.org
Booth Number: 10
The aim of the European Dystonia Federation is to support and coordinate the work of its member groups. The group tends to sponsor those activities or events of an international nature organized by its member groups in their own countries. It also works to establish worthwhile relations with other organizations with similar aims, with governmental and other agencies, and with neurological and other specialists of the international medical community.

European Federation of Neurological Societies
Alser Strasse 4
Vienna, 10900
Austria
E-mail: headoffice@efns.org
Website: www.efns.org
Booth Number: 8
The aim of the European Federation of Neurological Societies (EFNS) is to advance the development of the neurological sciences in Europe. Thirty-eight European national neurological associations are registered members of the EFNS. The EFNS welcomes individual members from all over the world.

FHC, Inc. (Frederick Haer Co., Inc.)
9 Main Street
Bowdoinham, Maine  04008
Email: fhcinc@fh-co.com
Website: www.fh-co.com
Booth Number: 318
FHC’s microTargeting® products are used for intraoperative micro- and macro-electrode recording, micro- and macro-stimulation, and data analysis in functional neurosurgery for the treatment of movement disorders. MicroTargeting® devices include FDA cleared and CE marked mono and bipolar microelectrodes, microdrive systems, and the new microTargeting® Platform. The microTargeting® Platform mounts on implanted fiducial markers creating a frameless stereotactic system. Benefits of the microTargeting® Platform include reduced operating room set-up and times, unique dual targeting capabilities, as well as increased patient comfort and mobility.

GlaxoSmithKline
F2129, COC Building
5 Moore Drive
Research Triangle Park
RTP, NC 27709, USA
Website: www.gsk.com
Booth Number: 206
GlaxoSmithKline is a world leading research-based pharmaceutical company dedicated to improving the quality of life of patients. GlaxoSmithKline continues to strive to provide solutions to many of the problems encountered within the complex field of neurological medicine.

IM Systems
1055 Taylor Avenue
Suite 300
Baltimore, MD  21286, USA
E-mail: mail@imsystems.net
Website: www.imsystems.net
Booth Number: 115
IM Systems’ miniature DigiTrac monitor records the frequency and amplitude of movements, and provides PC download for graphical plots and FFT analysis. The monitor also measures a patient’s real-time tremor in the clinical setting. This wrist-worn unit is completely ambulatory and ideally suited for use in both the clinical and home environments.
### Exhibitor Directory

#### Image-Guided Neurologics

2290 W. Eau Gallie Boulevard  
Melbourne, FL 32937, USA  
Website: www.igneurologics.com  
**Booth Number:** 218

Image-Guided Neurologics (IGN) is a leading innovator in the development of precision access, navigation, and delivery products for the less invasive treatment of neurological disease. Focused on expanding the applications for frameless stereotaxy, IGN is guiding the way to a new era where neurosurgeons will have real-time guidance and navigation capabilities right in the operating room – where accurate, less-invasive technologies will enable patients to recover faster and more fully than ever before.

#### In-Step Mobility Products, Inc.

In-Step Mobility Products, Inc.  
8040 N. Ridgeway Avenue  
Skokie, Illinois 60076  
E-mail: jmiller@ustep.com  
Website: www.ustep.com  
**Booth Number:** 220

**PRODUCT FEATURING:** U-Step Walking Stabilizer with Laser Module  
The U-Step is an advanced rolling walker that addresses the needs of those with neurological conditions. Unique design offers greater stability and control than other walkers. The U-Step is beneficial to those with: Parkinsonism, Multiple Sclerosis, ALS, Stroke, PSP, MSA, etc. The Laser Module can be added to reduce freezing common with Parkinson’s disease and other Movement Disorders. Medicare approved.

#### International Tremor Foundation

7046 West 105th Street  
Overland Park, KS 66212-1803, USA  
E-mail: staff@essentialtremor.org  
Website: www.essentialtremor.org  
**Booth Number:** 1

The International Tremor Foundation provides information, services and support to individuals and families affected by essential tremor. The organization supports research to determine the causes, treatment and cures for essential tremor.

#### John Wiley & Sons, Inc.

111 River Street  
Hoboken, NJ 07030, USA  
Website: www.wiley.com  
**Booth Number:** 116

Founded in 1807, John Wiley & Sons, Inc. is an independent, global publisher of print and electronic products. Wiley specializes in scientific and technical books, journals, textbooks and educational materials for colleges and universities, as well as professional and consumer books and subscription services. Wiley’s Internet Site can be accessed at http://www.wiley.com.

#### Lippincott Williams Wilkins

21525 Laguna Drive  
Boca Raton, FL 33433, USA  
Website: www.lww.com  
**Booth Number:** 121

LWW is a premier medical publisher in movement disorders and all other areas of neurology. This year, we are pleased to announce the NEW fourth edition on the popular title, “Parkinson’s Disease and Movement Disorders,” edited by Joseph Jankovic and Eduardo Tolosa. Also newly available in the Advances in Neurology series is the proceedings from the XIVth World Congress on Parkinson’s Disease.

#### MEDSYS Technologies

7777 Bonhomme Avenue  
Suite 1700  
Clayton, MO 63105, USA  
Website: www.medsystechnologies.com  
**Booth Number:** 221

MEDSYS Technologies provides innovative technology solutions for neurology and movement disorders. Products include: MARS, a clinical records database system made specifically for neurology; and PiqûrePerfect, a state of the art system for tracking the delivery of neurotoxin treatment.

#### Medtronic Neurological

710 Medtronic Parkway NE  
LN 370  
Minneapolis, MN 55432-5604, USA  
Website: www.medtronic.com  
**Booth Number:** 306

Medtronic Neurological’s Activa Therapy is a reversible and adjustable treatment for some of the most disabling symptoms of Parkinson’s disease and essential tremor. It uses an implanted neurostimulation system, akin to a pacemaker, to relieve symptoms when medication alone fails to provide adequate benefit or consistently causes intolerable side effects.
Exhibitor Directory

Muhammad Ali Parkinson Research Center
500 W. Thomas Road
Suite 720
Phoenix, AZ 85013, USA
E-mail: maprc@chw.edu
Website: www.aliproject.com
Booth Number: 11
The Muhammad Ali Parkinson Research Center at Barrow Neurological Institute has developed a clinical database called the Ali Project. Using information technology, the Ali Project links Parkinson’s centers around the country in order to gather, store, and share information about Parkinson’s disease. The Ali Project also provides an educational e-learning tool for Parkinson’s patients that covers the topics of speech, swallowing, and deep-brain stimulation. The Ali Project hopes that collecting core data about Parkinson’s disease will aid researchers in treating and potentially curing the disease.

Myoclonus Research Foundation
200 Old Palisade Road
Suite 17D
Fort Lee, NJ 07024, USA
E-mail: research@myoclonus.com
Website: www.myoclonus.com
Booth Number: 2
The Myoclonus Research Foundation is a public foundation supporting research in Myoclonus, investigating its basic mechanisms and developing new therapies. This research may also help provide clues to other types of movement and neurological disorders such as Epilepsy, Parkinson’s disease and Alzheimer’s disease.

National Parkinson Foundation, Inc.
Bob Hope Parkinson Research Center
1501 NW 9th Avenue
Bob Hope Road
Miami, Florida 33136-1494
E-mail: mailbox@parkinson.org
Website: www.parkinson.org
Booth Number: 320
The National Parkinson Foundation’s mission is to find the cause and cure for Parkinson’s disease and related neurodegenerative disorders through research; to educate general medical practitioners to detect the early warning signs of Parkinson’s disease; to educate patients, their caregivers and the general public; to provide diagnostic and therapeutic services; to improve the quality of life for both patients and their caregivers.

Nicolet Biomedical
5225 Verona Road
Building 2
Madison, WI 53711, USA
E-mail: info@nicoletbiomedical.com
Website: www.viasyshealthcare.com
Booth Number: 215
Nicolet Biomedical features the MicroGuide, a multi-channel, microelectrode recording (MER) device used for functional neurosurgery procedures for optimal target localization in the treatment of movement disorders, mainly Parkinson’s disease, during deep brain stimulator (DBS) implantation, pallidotomy, thalamotomy, and other similar neurosurgical procedures.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936, USA
Website: www.novartis.com
Booth Number: 100
Novartis Pharmaceuticals Corporation is dedicated to discovering, developing, manufacturing, and marketing prescription drugs that help meet unmet medical needs and provide better options to treat your patients. The Novartis Neuroscience Business Unit is committed to using new skills to improve health and well being through innovative products and services in the treatment of neurodegenerative and neuropsychiatric diseases. Please visit our exhibit area where, in conjunction with Orion Pharma, professional sales representatives will be able to discuss Comtan® (entacapone), answer questions and supply scientific information.

Orion Pharma
P.O. Box 65
Espoo, 02101
Finland
Website: www.orionpharma.com
Booth Number: 100
Orion Pharma is the pharmaceutical division of the Orion Group, one of the leading companies in the healthcare sector in the Nordic area of Europe. Orion Pharma’s continued expansion and success is built upon the research and development of its own new innovative drugs in four core therapy areas: CNS therapies, Cardiology and Critical Care, Hormonal therapies, and Respiratory therapies. Orion’s leading product in the CNS therapy area is the Parkinson’s disease drug Comtess® (entacapone). Entacapone, a COMT enzyme inhibitor, is Orion Pharma’s patented molecule discovery, which Orion Pharma developed through multinational clinical trials. Entacapone is available globally as Comtess® and Xouta®. Please visit our exhibition area.
### Parkinson Foundation of the National Capital Area

7913 Westpark Drive  
Suite 101  
McLean, VA  22102, USA  
E-mail: info@parkinsonfoundation.org  
Website: www.parkinsonfoundation.org  

**Booth Number: 15**  
The Parkinson Foundation of the National Capital Area (PFNCA), a nonprofit organization serving the Washington, DC, Metropolitan Area, provides services and support for people with Parkinson's disease to improve quality of life and supports research into the cause and cure for Parkinson's disease.

### Safe Dose Pharmacy

8770 Guion Road  
Suite G  
Indianapolis, IN  46268, USA  
E-mail: info@safedose.com  
Website: www.safedose.com  

**Booth Number: 314**  
Pharmacy providing medication management solutions.

### Schwarz Pharma AG

Alfred-Nobel-Strasse 10  
Monheim, 40789  
Germany  
Website: www.schwarzpharma.com  

**Booth Number: 212**  
Rotigotine CDS, the Parkinson Patch, is the unique formulation designed to test the hypothesis that constant dopaminergic stimulation is beneficial in the treatment of Parkinson's disease. It is applied as a patch once-a-day and replaced by a new patch the next day. Phase III studies in both early and late-stage PD patients are underway.

### SDS/ MSA Support Group

2004 Howard Lane  
Austin, TX  78728, USA  
E-mail: don.summers@shy-drager.com  
Website: www.shy-drager.com  

**Booth Number: 13**  
The mission of the Shy Drager Syndrome/Multiple System Atrophy Support Group (SDS/MSA) is to gather information from each group of people involved (Patients, Caregivers, Family Members, and Physicians) and disseminate that information to all. The SDS/MSA Support Group is an information center and a “Helping Hand” for affected people. Through various programs, including regional patient/caregiver support group meetings, support of local groups, the toll free help line, newsletters and web site, the

---

### Parkinson Study Group/ Huntington Study Group

1351 Mount Hope Avenue  
Suite 220  
Rochester, NY  14620, USA  
Website: www.parkinson-study-group.org, www.huntington-study-group.org  

**Booth Number: 12**  
The Parkinson Study Group (PSG) and the Huntington Study Group (HSG) are democratically governed, non-profit, academic consortiums of physicians and other health care providers experienced in the care of Parkinson/Huntington patients and dedicated to the clinical research of Parkinson’s/Huntington’s disease. The PSG currently has 84 research sites in North America. The HSG has 60 research sites in North America, Europe and Australia. For information on the clinical trials associated with these study groups go to their websites which are located at www.Parkinson-Study-Group.org and www.Huntington-Study-Group.org.

### Pharmacia Corporation

100 Route 206 North  
MS-041  
Peapack, NJ  07977, USA  
Website: www.pharmacia.com  

**Booth Numbers: 300 & 400**  
Pharmacia Corporation is a global, innovation-driven pharmaceutical and health care company. Our products, services and employees demonstrate the company’s commitment to improve wellness and quality of life for people around the world. Stop by our international booth to discuss Cabaser (cabergoline tablets). We look forward to your questions and comments.

### Radionics

Department of Marketing  
22 Terry Avenue  
Burlington, MA  01803, USA  
E-mail: info@radionics.com  
Website: www.radionics.com  

**Booth Number: 113**  
The NeuroPlan System provides the ability to fully support deep brain stimulator implantation. With the AccuDrive and REK, implantation is supported through one system. With this simplified approach the surgeon is able to place a deep brain stimulator with accuracy and confidence.
Exhibitor Directory

**Restless Legs Syndrome Foundation**

819 Second Street SW  
Rochester, MN  55902, USA  
E-mail: rlsfoundation@rls.org  
Website: www.rls.org  
**Booth Number: 312**

The Restless Legs Syndrome Foundation is a nonprofit organization dedicated to increasing universal awareness, developing effective treatments, and finding a definitive cure for Restless Legs Syndrome (RLS). The organization provides information about RLS, develops local support groups, publishes a quarterly newsletter, and funds research for the study of RLS. SDS/MSA’s Support Group can reach many people in need. The support group also works closely with physicians who are newly involved with the disease and/or treating the patients as well as those who are involved in the essential research to discover a cause, modes of treatment, and hopefully a cure. Information about the disease and tips on explaining it to the patient will be provided through several modes, including the website, links to the American Autonomic Society, access to a referral base of experienced physicians, and educational meetings. By sharing information, resources, and support the SDS/MSA Support Group will create a “Circle of Hope” for those affected by SDS/MSA.

**SHS North America**

P.O. Box 117  
Gaithersburg, MD  20884, USA  
E-mail: guestbook@shsna.com  
Website: www.shsna.com  
**Booth Number: 111**

SHS North America, International Leader in Clinical Nutrition, invites you to visit our booth to learn more about new medical foods for the nutritional management of intractable epilepsy and tardive dyskinesia. Our representatives will be happy to inform you about the latest clinical trials conducted in this field.

**Society for Progressive Supranuclear Palsy, Inc.**

1838 Greene Tree Road  
Suite 515  
Baltimore, MD  21208-6391, USA  
E-mail: spsp@pseudp.org  
Website: www.psp.org  
**Booth Number: 6**

The Society for Progressive Supranuclear Palsy (PSP) exists to promote and fund research in finding the cause and cure of PSP, a terminal neurological disease. The society is a nonprofit organization 501(c)3 that provides information, education, support and advocacy for persons diagnosed with PSP, families, physicians and allied health professionals.

**W.B. Saunders/ Mosby**

10810 SW 14th Court  
Davie, FL  33324, USA  
Website: www.us.elsevierhealth.com  
**Booth Number: 119**  
Medical publisher

**WE MOVE**

204 W. 84th Street  
3rd Floor  
New York, NY  10024, USA  
E-mail: wemove@wemove.org  
Website: www.wemove.org  
**Booth Number: 213**

WE MOVE provides movement disorder information and educational materials to physicians, patients, the media and the public. Visit WE MOVE to learn about its comprehensive website www.wemove.org; CME courses and teaching slide sets; E-MOVE-the research news service; rating scales; grant information and more.
Floor Plan & Meeting Space

Versailles Building, Level I / Versailles Building, Level IV

Versailles Building, Level I
Brittany
Burgundy
Bordeaux
Champagne
Le Mans
Monaco

Versailles Building, Level II
East Ballroom
Fontainebleau Ballroom
Fontainebleau Gallerie
Grand Gallerie
Jade Promenade
West Ballroom

Versailles Building, Level IV
Club Atlantic
Conference Room 1
Conference Room 2
Conference Room 3
Conference Room 4
Conference Room 5
Conference Room 6
Conference Room 7
Imperial I
Imperial II
Imperial III
Imperial IV
Imperial V
Lafayette
Pasteur
Voltaire
Map of Miami
Poster Session 1 - Monday, November 11
7:00 am - 8:30 am

Poster numbers 1-168
Basic Science, Genetics, Neuropharmacology, Parkinson’s Disease

P1 A “single toxin-double lesion” rat model of striatognal degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis
I. Ghorayeb, P.O. Fernagut, L. Hervier, B. Labattu, B. Bioulac, F. Tison

P2 A clinico-pathological analysis of subjects with synucleinopathy
L. Parkkinnen, H. Sohinen, J. Autere, I. Alafuozoff

P3 A combined simultaneous MPTP + 3 nitropropionic acid (3-NP) systemic mouse model of striatognal degeneration
P.O. Fernagut, E.N. Diguet, B. Bioulac, F. Tison

P4 Activity-dependent plasticity in the basal ganglia
B.E. Fisher, C. Meshul, K. Nixon, G.M. Petzinger, M.W. Jakowec

P5 Beginning-of-dose and rebound worsening in MPTP-treated common mammosets treated with L-dopa
M. Kuoppamaki, G. Al-Barghouthy, M. Jackson, L. Smith, B.-Y. Zeng, N. Quinn

P6 Bone marrow stromal cell as potential cellular therapy for treatment of Parkinson’s Disease
K. Yang, X. Yuan, J. Sun, Y. Long, E.C. Lai

P7 Cartography of the limbic territory of the subthalamic nucleus of monkeys: A potential target for Deep Brain Stimulation
C. Karachi, J. Yelnik, C. Jan, K. MacCaim, L. Tremblay, C. Francois

P8 Case report of motor evoked potentials from the subthalamic nucleus (STN) DBS electrodes
E.B. Montgomery, Jr., K.B. Baker, W. Bingaman, A. Rezai, H.O. Loders

P9 Comparing region specific mRNA expression profiles in Progressive Supranuclear Palsy
P. Rizzu, V. Bonifati, R. Ravid, A.H. Rajput, P. Heutink

P10 D3 receptors contribute to the neuroprotective properties of D3/D2 agonists against MPP-induced neurotoxicity but not DA-induced toxicity in SH-SYSY cells
J.N. Joyce, S.P. Presgraves, S. Bowege, M.J. Millan

P11 Dissection of tau isoform composition of tauopathy lesions using novel isoform-specific monoclonal antibodies
R. de Silva, T. Lashley, G. Ghiba, D. Hanger, T. Revesz, A. Lees

P12 Does extraneuronal melanin maintain neurodegeneration in Parkinson Disease?
H. Wilms, P. Rosenstiel, J. Sievers, G. Deuschl, L. Zecca, R. Lucius

P13 Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic MPTP + 3-nitropropionic acid primate model of striatognal degeneration
I. Ghorayeb, P.O. Fernagut, N. Stefanova, G.K. Wenning, B. Bioulac, F. Tison

P14 Effects of levodopa and amphetamine on the neuronal activity of the subthalamic nucleus (STN) in rats with moderate and severe Parkinsonism: relevance of the degree of dopaminergic denervation
J.A. Ruíz Ortega, S. Gomez Uquijo, L. Ugedo, G. Linasaoro

P15 Feasibility of ex vivo gene therapy for neurologic disorders using the new retroviral vector GCDNas packed in the vesicular stomatitis virus G protein
K. Obi, A. Suzuki, T. Urabe, M. Onodera, H. Mochizuki, Y. Mizuno

P16 Functional characterization of novel target genes in neurodegeneration
B. Bingham, S. Naureckiene, S. Kotnis, L. Ma, R. Shen, L.W. Chang

P17 Glutamatergic and dopaminergic neuroplasticity in the basal ganglia of the MPTP-lesioned mouse
M.W. Jakowec, C. Meshul, T. McNeill, K. Nixon, G.M. Petzinger

P18 Increased Alzheimer pathology in Parkinson’s Disease is associated with chronic antimuscarinic drug treatment
E.K. Perry, D.J. Bum, L. Kiford, A.J. Lees, R.H. Perry

P19 Is there neurogenesis in the substantia nigra of adult mice?

P20 LEC rat model of Wilson Disease does not show nigrostriatal degeneration at age 20 weeks
TB. Ahn, B.S. Jeon

P21 Magnesium sulphate potentiates the antiparkinsonian levodopa effect and has antidyskinetic effect in MPTP-lesioned monkeys
C. Chassaïn, A. Eschalièr, F. Dufif

P22 Methamphetamine induces neuronal inclusions reminiscent of Lewy bodies
F. Fornai, M. Gesi, P. Lenzé, M. Ferrucci, G. Lazzeri, S. Ruggieri

P23 Minocycline attenuates bilirubin-induced neurotoxicity in both cultured cerebellar granule neurons and the Gunn Rat
S. Lin, Z. Ma, R.C. Dodel, W.H. Oertel, M.R. Farlow, Y. Du

P24 Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons

P25 Motor temporal patterns and stereotypes but not rotational behavior can better explain motor response complications in Parkinson’s Disease
M.A. Delfinó, A.V. Stefano, J.E. Ferrari, I.R. Taravini, G.M. Murer, O.S. Gershank

P26 MPP+ and 6-OHDA neurotoxicity to dopaminergic neurons is ameliorated by NSAIDs
P. Werner, E. Canasno, A. Di Rocco, M.D. Yahr

P27 MPTP systemic toxicity in the non-human primate (Saimiri sciureus)

P28 Neurochemical markers and microarrays in postmortem Tourette Syndrome putamen and brain area 9

P29 Neuronal death induced by proteasomal inhibition involves cytochrome-c and caspase-9, but not bcl-2

P30 Neuroplasticity of the MPTP-lesioned non-human primate in behavioral recovery
Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

P31 Neuroprotection against 6-OHDA toxicity elicited by intranigral infusion of IL-1β in vivo in the rat
J. Saura, M. Parex, J. Sobe, E. Tolosa, M.J. Marti

P32 Parkin knockdown induces the apoptotic cell death in human neuroblastoma cells
Y. Machida, Y. Tanaka, T. Chiba, N. Hattori, K. Tanaka, Y. Mizuno

P33 Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated ingestion: a comparative study in the rat
M. Forsberg, M. Lehtonen, M. Heikkinen, J. Savolainen, T. Jarvinen, P.T. Mannisto

P34 Preserved learning ability of a visuo-motor task in Parkinson’s Disease patients
R. Inzelberg, N. Feirstein, P. Nisipeanu, R.L. Carasso, S. Hocherman

P35 Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide
W. Le, S.Z. Imam, W. Xie, S. Ali, J. Jankovic

P36 Role of Heat Shock Proteins in proteasomal inhibition-induced inclusion formation and death of cultured cortical neurons
H.J. Rideout, A. Perger, O. Jabado, S. Papantonis, L. Stefanis

P37 Subthalamic neuronal resting activities in humans with and without Parkinson’s Disease

P38 Subthalamial nucleus (SN) neuronal activity in meaningful and non-meaningful speech
P. Watson, E.B. Montgomery, Jr., K.B. Baker, A. Rezai, N. Boulis, J. Henderson

P39 The Antiparkinsonian agent, piribedil, possesses a distinctive profile of dopamine D2/D3 agonist and a1-adenoeceptor antagonist properties: a multivariate comparison to other Antiparkinsonian agents at recombiant, human monoaominerics receptors
M.J. Millan, D. Cussac, L. Maiofiss, V. Audinot, N. Bodjarian, A. Newman-Tancredi

P40 The developmental time course of glial cell line-derived neurotrophic factor (GDNF) and GDNF receptor α-1 mRNA (GFRα-1) expression in the striatum and substantia nigra
J. Cho, N.G. Kholidilov, R.E. Burke

P41 The effect of chronic lisuride treatment on behavioral sensitization and gene expression in dopamine denervated striatum
G. Sahin, E.S. Topcuoglu, T. Dalkara, B. Ellob

P42 The novel AMPA receptor potentiator, LY40187, is neuroprotective in experimental models of Parkinson’s Disease

P43 The novel AMPA receptor potentiator, LY404187, is neurotrophic in a nigral 6-hydroxydopamine model of Parkinson’s Disease

P44 TorsinA immunoreactivity in inclusion bodies in neurodegenerative disorders
R.H. Walker, P. Good, P. Shashidaran

P45 Tracing the neuronal progenitor cells (NPCs) derived from the subventricular zone (SVZ) in the adult mice: migration, differentiation and apoptosis
M. Yamada, M. Onodera, H. Mochizuki, Y. Mizuno

P46 A family with E3D40 mutations in the Parkin gene: evidence for autosomal recessive inheritance of young onset benign Parkinsonism rather than autosomal dominant inheritance

P47 A screen of GTP cyclohydrolase I in Parkinson’s Disease patients
A. Singleton, C. Evey, K. Gwinn-Hardy, A. Singleton

P48 A Yorkshire kindred with young onset atypical PSP and central hypoventilation due to a novel homozygous S352L tau mutation
D.J. Nicholl, M.A. Greenstone, P. Rizzu, C.E. Clarke, D. Crooks, P. Heutink

P49 Apolipoprotein e4 and e2 alleles associated with higher risk and earlier onset of psychosis in patients with Parkinson’s Disease
N. Giardi, B. Feldman, J. Chapman, A.D. Korczyn

P50 Association between genetic polymorphism of angiotensin converting enzyme gene and Parkinson’s Disease
J.J. Lin, K.Y. Yueh, D.C. Chang

P51 Association of the C677T and A1298C polymorphisms in the MTHFR gene with Essential Tremor risk in Turkey
A. Sazi, E. Ergul, K. Bayulkem

P52 Autosomal recessive juvenile Parkinsonism: heterozygosity and disease
O. Tunkel, S. Hassin-Baer, Y. Shinnar, H. Matsumine, N. Hattori, Y. Mizuno

P53 Case-control study of the synuclein, alpha interacting protein (SNCAIP) and Parkinson’s Disease
D.M. Maraganore, M.J. Farer, T.G. Lesnick, M. de Andrade, J.A. Hardy, W.A. Rocca

P54 CASPR2 is interrupted in a family with Gilles de la Tourette Syndrome
A.J. Verkerk, C.A. Mathews, M. Joosse, B. Eussen, P. Heutink, B.A. Oostra

P55 Characterization of the molecular defect and genotype-phenotype analysis in Wilson Disease patients from Yugoslavia
G. Loudianos, P. Solinas, M. Lovicu, M. Svetel, A. Cao, V.S. Kostic

P56 Clinical and genetic evaluation of two large kindreds with Restless Legs Syndrome from South Tyrol (Northern Italy)
S. Mania, C. Klein, B. Cujkovic, N. Kock, P.L. Kramer, P.P. Pramstaller

P57 Clinical and genetic heterogeneity of 11 Italian families with autosomal recessive spastic paraplegia
G. De Michele, C. Criscuolo, M. Orio, M. Carella, P. d’Adamo, A. Peretti, L. Santoro, A. De Rosa, V. Scaramo, A. Filla

P58 Complex segregation analysis of Restless Legs Syndrome from South Tyrol (Northern Italy)
S. Mania, C. Klein, B. Cujkovic, N. Kock, P.L. Kramer, P.P. Pramstaller

P59 Early onset Parkinson’s Disease and the Parkin gene
A.J. Verkerk, C.A. Mathews, M. Joosse, B. Eussen, P. Heutink, B.A. Oostra

P60 Ethnic differences of clinical and genetic characteristics of inherited forms of Parkinson’s Disease in Russia, Uzbekistan and Zambia
M. Atadzhanov, P. Mwaba

P61 Exon 1 nurr1 gene mutations are rare in familial PD
D.G. Healy, P. Steinman, M.G. Sweeney, L.H. Eunson, N.W. Wood
Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

P62 Gene sequencing in Brazilian patients with neurological form of Wilson's Disease

P63 Genetic analysis of the Parkinsonism dementia complex of Guam
H.R. Morris, R. Crook, N. Wood, J. Hardy, J. Steele, J. Perez-Tur

P64 Genetic structure of autosomal dominant ataxias in different Savonic populations
S.N. Ilaroshkin, S.A. Klyushnikov, N. Dragasevic, I.A. Ivanova-Smolenskaya, V. Kostic, E.D. Markova

P65 HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease
M. Onofoj, A. Thomas, G. D'Andreamatteo, D. Iacono, A.L. Luciano

P66 Monoamine Oxidase B polymorphism, cigarette smoking and risk of Parkinsons Disease
E.K. Tan, A. Chai, Y. Zhao, M.C. Wong

P67 Mutation analysis of the epsilon-sarcoglycan gene in families with myoclonus-dystonia suggests genomic imprinting
P.M. de Carvalho Aguila, V. Borges, H.B. Ferraz, K. Sethi, D. Raymond, S.B. Bressman

P68 Mutational screening of epsilon-sarcoglycan in European patients with Myoclonus-Dystonia Syndrome
F. Asmus, A. Zmrisch, S. Tezenas du Montcel, N. Wood, A. Bric, T. Gasser

P69 PACP, a novel gene for Parkin function
A. West, P.J. Lockhart, S. Lincoln, K. Wilkes, M. Farrer

P70 Parkin gene mutations in young onset Parkinson's Disease
E.K. Tan, H. Shen, Y. Zhao, W.P. Hu, R. Pavanin, M.C. Wong

P71 Parkin mutations in young-onset or recessive form of Parkinson's Disease
N.N. Hatton, H.H. Yoshino, Y.Y. Immich, Y.Y. Mizuno

P72 Phenotypes of Juvenile Parkinsonism in Russian patients with mutations in the Parkin gene
E.D. Markova, T.B. Zagorovskaya, S.N. Ilaroshkin, I.A. Ivanova-Smolenskaya, P.A. Sominsky, A. Bric

P73 Refinement of PARK7 critical region on chromosome 1p36
V. Bonifati, P. Rizzu, N. Vanacore, F. Squitieri, G. Meco, P. Heutink

P74 Screening of the epsilon-sarcoglycan gene in ten families with myoclonus-dystonia
N. Kock, B. Mueller, K. Kabakci, L.J. Ozceli, V. Kostic, C. Klein

P75 Suggestive linkage to Chromosome 1p in a family with autosomal dominant Parkinson's Disease
A.M. Bertoli Avella, J.L. Giroud Benitez, V. Bonifati, C.M. van Duijn, L. Heredero Baute, P. Heutink

P76 Survival duration of Parkinson's Disease patients carrying the G209A alpha-synuclein mutation living in Greece
S. Papapetriou, J. Ellui, A. Athanassiadou, C. Paschalidis

P77 Tau gene linkage disequilibrium analysis implicates region for risk variants in PD and PSP
L. Skipper, K. Wilkes, M. Baker, M. Hutton, J. Aasy, M. Farrer

P78 The Nurr1 7048 G 7049 intronic insertion is not associated with Parkinson's Disease
D.G. Healy, J. Slie, M.G. Sweeney, N. Khan, L.H. Eunson, N.W. Wood

P79 Two different phenotypes of the same Parkin mutation in a large pedigree
N. Hatton, R. Inzelberg, P. Nispeanu, S. Blumen, R.L. Carasso, Y. Mizuno

P80 A 2-year multicenter, placebo-controlled, double-blind parallel-group study of the effect of iruzole on Parkinson Disease progression
O. Rascou, W. Olanow, D. Brooks, G. Koch, P. Tuffinet, R. Bejilt

P81 A double-blind placebo-controlled crossover trial of iruzole in Multiple System Atrophy

P82 A model of experimental Parkinsonism induced by free-radical oxidation of dopamine
G. Shilau, S. Belugin, O. Shadyo, E. Titovetz

P83 A multi-center, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's Disease experiencing end-of-dose deterioration
J.H. Im, B. Jeon, M.S. Lee, W.Y. Lee, J.W. Kim, M.C. Lee

P84 A role for opioid receptor antagonism in the treatment of levodopa-induced motor complications in Parkinson's Disease?
S. Fox, M. Silverdale, M. Kellett, M. Steiger, N. Fletcher, M. Hill

P85 A systematic analysis of dose related local anhydric effects of botulinum toxin B injections as measured by sudometry
M. Winterhoff, F.J. Erbgh, F. Birklein

P86 Age-related tolerability of tetrabenazine
C.B. Hunter, A. Wang, K.D. Vuong, J. Jankovic

P87 Anti-dyskinetic actions of AMPA receptor antagonists in the MPP+-lesioned marmoset model of Parkinson's Disease
M.A. Silverdale, S.L. Nicholson, A.R. Crossman, J.M. Brothie

P88 Behavior and the basal ganglia: gambling and compulsive shopping in Parkinson's Disease
H. Shabtai, N. Giladi, A.D. Korczyn

P89 Clozapine treatment for Parkinson's psychosis. Five years follow-up
C. Klein, Y. Gordon, T. Prohorov, L. Pollak, J.M. Rabey

P90 Comparison of the pharmacokinetics of Sinemet (R) and Grifoparkin (R)(generic carbidopa/levodopa 25/250): a single dose, randomized study
M. Onofoj, A. Thomas, G. D'Andreamatteo, D. Iacono, A.L. Luciano

P91 Comparison of the pharmacokinetics of Sinemet (R) and Grifoparkin (R)(generic carbidopa/levodopa 25/250): a single dose, randomized study
M. Onofoj, A. Thomas, G. D'Andreamatteo, D. Iacono, A.L. Luciano

P92 Continuous trandermal iontophoretic delivery of apomorphine in Parkinson's Disease experiencing end-of-dose deterioration
J.H. Im, B. Jeon, M.S. Lee, W.Y. Lee, J.W. Kim, M.C. Lee

P93 Differences in toxicity of two different Catechol-O-Methyltransferase inhibitors to human neuroblastoma cells
V. Bonifati, P. Rizzu, N. Vanacore, F. Squitieri, G. Meco, P. Heutink

P94 Cost-effectiveness analysis (CEA) of Pramipexole (P) in patients with Parkinson's Disease (PD)
M. Onofoj, A. Thomas, G. D'Andreamatteo, D. Iacono, A.L. Luciano

P95 Dopamine D3 receptor acting compounds dramatically improved l-dopa-induced dyskinesia in the MPP+-treated monkey
E. Bezard, T. Boraud, S. Ferry, P. Sokoloff, C.E. Gross
Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

P96 Dopamine receptor binding profiles of clinically used dopamine agonists
M. Gerlach, K.L. Double, P. Riederer

P97 Double-blind, randomised, parallel comparative Dysport vs Bototox study in primary palmar hyperhidrosis
M. Simonetta-Moreau, J.-M. Senard


P99 Effects of MDMA administration in the MPTP-lesioned non-human primate model of Parkinson's disease
P. Ravenscroft, C. Imbert, C.E. Gross, E. Bezard

P100 Entacapone improves the bioavailability of levodopa and smoothens the plasma fluctuations of levodopa as an adjunct to CR levodopa (Sinemet CR 25-100) after repeat dosing

P101 Entacapone increases the bioavailability of controlled-release L-DOPA and prolongs ON time in patients with Parkinson's disease (PD)
L. Barbata, G. Nordera, A. Bolner T. Caraceni, F. Stocchi

P102 Gabapentin versus ropinirole in the treatment of restless legs syndrome
S. Happe, C. Kauter, G. Kloesch, B. Saluet, J. Zilthofer

P103 Levodopa effect on experimental pain in Parkinson's disease: a clinical and neuroimaging pilot study
C. Brefel-Courbon, P. Payoux, I. Quelven, T. Claire, M. Gallay, J.L. Montastruc

P104 Long-term safety and efficacy of cabergoline in the treatment of restless legs syndrome: first results from a 6 months clinical trial
H. Benes, C.R. Heinrich, M. Ueberall, the German Cabergoline Safety Study Group

P105 Madopar HBS in treatment of Parkinson's disease in patients with cardiovascular disorders
M.I. Vendrova, V.L. Golubev, R.A. Sadekov, A.M. Vein

P106 New onset diabetes among Parkinsonian patients on long-term clozapine use
H.H. Fernandez, J.H. Friedman, S.A. Factor, E.S. Molho, J.D. Coskun, M.C. Lamsa

P107 pergolide pharmacokinetics in patients with Parkinson disease
C. Thalmas, O. Rascov, O. Blin, J. Kulisevsky, I. Rajman, C. Brefel-Courbon

P108 Piribedil in adjunct to levodopa in Parkinson disease patients: a nine months follow up
G. Salazar, C. Cardiel, P. Rheder, J.C. Jimez

P109 Piribedil is able to reverse stress-induced anhedonia in the chronic mild stress model
M. Papp, P. Grucza, C. Bonhomme, N. Bodjaran

P110 Predictive value of levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off (EODWO)
K. Reiniikainen, M. Leinonen, J. Isojarvi, S. Kaakka

P111 Predicting the need for levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off (EODWO)
K. Reiniikainen, M. Leinonen, J. Isojarvi, S. Kaakka
Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

P130 The PPARgamma agonist pioglitazone inhibits neuronal cell loss and glial activation in the substantia nigra of MPTP treated mice

P131 The decline of dopaminergic neurons in Parkinson's Disease is non-linear: a serial position emission tomography study with 18-Fluorodopa
R. Hikita, K. Scheweitzer, M. Ghaemi, S. Weisenbach, K. Herholz, W.-D. Heiss

P132 Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin

P133 Behavioral consequences of bicuculline injection in the subthalamic nucleus and the zona incerta in rat
C. Périer, L. Tremblay, J. Fèger, E.C. Hirsch

P134 Do levodopa and/or ropinirole induce an internalization of D1 and/or D2 dopamine receptors?
M.-P. Muriel, G. Orieux, E.C. Hirsch

P135 Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons or dose of Parkinsonian toxin MPTP in mice

P136 Role of INF-α receptors in mice intoxicated with the Parkinsonian toxin MPTP

P137 Caspase-11 plays an important role in the dopaminergic cell death induced by acute MPTP treatment not but chronic treatment
T. Furuya, H. Rochraki, M. Yamada, M. Miura, J. Yuan, Y. Mizuno

P138 Inhibition of mitochondrial apoptotic cascade can block MPTP toxicity as anti-apoptotic therapy in Parkinson’s Disease
H. Rochraki, H. Hayakawa, M. Yamada, M. Migita, Y. Mizuno

P139 Metabolic activity of the cortical neurons projecting to the subthalamic nucleus in a rat model of Parkinson’s Disease
G. Orieux, C. François, J. Féger, E.C. Hirsch

P140 Zonisamide increases dopamine synthesis by inducing TH mRNA
M. Murata, E. Horuchi, Y. Takahashi, I. Kanazawa

P141 Lewy bodies and neuronal degeneration in preclinical stage of Parkinson's Disease
A. Krygowska-Waś, D. Adamek, A. Szczudlik, J. Kaluza

P142 Measurement of the function and density of dopamine transporter in peripheral lymphocytes of Parkinson's Disease
Z. Weng, J. Zhang, S. Chen, Z. Liu, J. Fei

P143 Accelerated formation of α-synuclein aggregates in differentiated SH-SYSY neuroblastoma cells
T. Hasegawa, M. Matsuzaki, A. Kikuchi, K. Furukawa, A. Takeya, Y. Itoyama

P144 Asymmetrical IBZM binding in patients with Parkinson’s Disease is due to a preexisting physiological striatal asymmetry in IBZM binding
C.C. Verstappen, W.W. Oyen, M.M. Horstink

P145 Transplantation of differentiated murine embryonic stem cells in a 6-OHDA rat model for Parkinson's Disease
P.C. Baier, J. Schindehette, K. Thynane, W. Paulus, P. Gruss, C. Tenkwalder

P146 Entacapone combined with L-DOPA enhances Anti-Parkinsonian activity and avoids dyskinesia in the MPTP-treated primate model of Parkinson’s Disease (PD)
P. Jenner, G. Al-Barghouthy, L. Smith, M. Kuoppamaki, M. Jackson, S. Rose

P147 The effects of IFNα on glial cells overexpressing a-synuclein
N. Stefanova, L. Klismaschewski, G.K. Wenning, M. Reindl

P148 Plastic-adherent cells from human bone marrow differentiate into neural cells: implication for Parkinson’s Disease
Y.S. Levy, S. Bulvik, V. Holdengreber, Y. Barhum, E. Melamed, D. Offen

P149 Viral delivery of GAD antisense genes to basal ganglia output neurons promotes behavioral recovery in a rat Parkinson model
D.W. Anderson, P. Cordelier, D.S. Stayer, J. Schneidner

P150 The frontal lobe synaptic pathology in Parkinson’s Disease. A Golgi and electron microscope study
M.A. Amaoutoglou, A.C. Amaoutoglou, E.N. Amaoutoglou, V. Košta, S. Joly-Baloyannis

P151 Oxidative stress induced by 6-hydroxydopamine increases ubiquitin-conjugates and protein degradation: Implications for the pathogenesis of Parkinson’s Disease
H. Elkon, E. Melamed, D. Offen

P152 6-hydroxydopamine affects proteasome activity in the PC12 cell line
H. Elkon, E. Melamed, D. Offen

P153 Annocin, the major acetogenin of Annona muricata (Annonaceae) induces neurodegeneration and astrogliosis in rats

P154 CD4 memory increase and programmed cell death decrease in peripheral blood of Parkinson’s Disease patients
L. Speciale, M. Saresella, E. Calabrese, C. Mariani, N. Canal, P. Ferrante

P155 A new scoring system for detection of Parkinsonian symptoms in the chronic MPTP intoxication model in the minipig
E. Vaudano, M. Pierri, M. Berendt, T. Sager

P156 Dopamine D₃, but not D₂, receptor activation is responsible for the Anti-Parkinsonian actions of ropinirole in the MPP⁺-lesioned mamoset model of Parkinson’s Disease
M. Silverdale, H.P. Michael, A.R. Crossman, M.J. Millan, R. Catherine, B.M. Jonathan

P157 Quantitative gene expression studies in animal models of Parkinson’s Disease
A.D. Medhurst, S.L. Colombo, D. Vitley, C. Reavill

P158 Overexpression of wild type and mutant alpha synuclein in a neuroblastoma cell line
L.V.P. Kollipara, K. Messner, J.M. Cooper, A.H. Schapira

P159 Alpha-synuclein is aggregated by the lipid peroxidation product 4-Hydroxynonenal (HNE)
M. Wang, Y. Chikaoka, K. Shiba, N. Hattori, Y. Mizuno

P160 Antiβ-secretase reverses L-DOPA induced dyskinesia in MPTP treated common marmosets
P. Jenner, L. Smith, M. Jackson, M. Kuoppamaki, G. Al-Barghouthy, C. Bonhomme
Poster Sessions

Poster Session 1 - Monday, November 11, 7:00 am - 8:30 am

P161 Bilateral subthalatomy and levodopa-induced motor complications in a rodent model of Parkinsonism
C. Marin, A. Jiménez, M. Bonastre, J. Bové, E. Tolosa

P162 An infection with filterable forms of Nocardia Asteroides in the midbrain nigral lesion in Parkinson’s Disease
S. Kohbata, R. Hayashi, T. Tamura

P163 Ecstasy (3,4-Methylenedioxyamphetamine) inhibits dyskinesia expression and normalises locomotor activity in Parkinsonian primates
M.M. Iravani, M.J. Jackson, G. Al-Barghouthy, M. Kuoppamaki, P. Jenner

P164 Mitochondrial complex I and complex IV activities in lymphocytes from patients with Parkinson gene mutations
O. Dalmizrak, M. Muftuoglu, F.B. Atac, I.H. Oğus, N. Ozer, B. Elibol

P165 Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model possibly through inhibition of p38 MAP kinase and its related kinases

P166 In vivo expression and subcellular localization of Parkin in patients with autosomal recessive Parkinson’s Disease
S.-I. Kubo, N. Hattori, Y. Chikaoka, O. Komure, B. Elibol, Y. Mizuno

P167 Nuclear factor-kB and p53 mediate AMPA excitotoxicity to dopaminergic neurons “in vitro”

P168 Identification of up-regulated genes in the MPTP model of Parkinson’s Disease

Poster Session 2 - Monday, November 11
12:30 pm - 2:00 pm

Poster numbers 169-338
Parkinson’s Disease

P169 Drug adherence in Parkinson’s Disease
N.A. Leopold, M. Polansky, M. Hurka

P170 SLV318, a novel agonist for the dopamine D, and D, receptor: in vitro and in vivo neurochemical characterization
M.B. Hesselink, M. van der Neut, T. Adolfs, R. Feenstra, S. Long, G. van Scharenburg

P171 A comparative assessment of surgical and conservative treatment of Parkinsonism
V.M. Tiourmikov, V.V. Peresedov, A.S. Kadykov, L.P. Metyolkina, A.V. Shishov

P172 Mutation screening and association analysis of the Parkin gene in Parkinson’s Disease patients from South West China
R. Peng, Y. Gou, Q. Yuan, T. Li, H. Latsoudis, D.A. Collier

P173 Spectral EMG characteristics correlates with clinical improvement on dopamine agonist treatment in patients with early stage of Parkinson’s Disease
O.Y. Khutorskaya, I.G. Smolentseva, O.S. Levin, N.V. Fedorova

P174 Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s Disease
G. Linazasoro

P175 Synaptic effects of dopamine agonist therapy in fluctuating Parkinsonian patients

P176 A biochemical marker for central dopaminergic cell loss
K.L. Double, D. Rowe, G. Haliday, the DEDCel Research Group, P. Riederer, M. Gerlach

P177 High pramipexole dosage in the management of fluctuating Parkinsonian patients
F. Viselli, A. Monge, L. Barbato, F. Stocchi, G. Nordera

P178 CEPI-1347 - a new neuroprotective agent
J.S. Christofersen, P. Robertson, E.T. Hellriegel, M.I. Watling

P179 Drug utilization in Parkinson’s Disease: a pharmaco-epidemiological study in a cohort of ambulatory patients attending a Parkinson’s Disease center
S. Sacco, S. Cristina, D. Michielotto, C. Pacchetti, E. Martignoni, O. Leoni, R. Zangaglia, M. Cosentino, S. Leccini, G. Nappi, G. Frigo

P180 Efficacy and tolerability of pramipexole in routine treatment of advanced Parkinson’s Disease (PD) patients in outpatient departments
J. Benetin, D. Richter

P181 Changes of reaction and movements times after STN DBS and clinical improvement in IPD
M.-S. Lee, S.-H. Oh, W.-C. Kim, J.-G. Lee

P182 Quetiapine: no QTC interval prolongation in psychotic Parkinson patients?
N. Kuehn, M.H. Stroth Johann, D. Emmans
P215 Subthalamic nucleus lesioning inhibits expression and phospho-tyrosination of c-Jun and increases enzymatic activity in nigral neurons in the rat's 6-OHDA model of Parkinson's Disease
C. Winter, K. Hosmann, W. Meissner, D. Hamack, R. Morgenstern, A. Kupsch

P216 The advantage of combining two dopamine agonists in the management of Parkinson's Disease
L. Vaccia, A. Berardelli, M. Onofri, M. Manfredi, S. Ruggieri, F. Stocchi

P217 A2A receptor antagonist prevents the development of dopamine agonist-induced motor complications in primate and rodent models of Parkinson's Disease
F. Bibbiani, J. D. Oh, J. P. Petzer, N. Castagnoli, Jr., J. F. Chen, M. A. Schwarzilda

P218 Intraintestinal infusion of levodopa methyl ester in patients with advanced Parkinson's Disease: A clinical and pharmacokinetic study
F. Stocchi, L. Vaccia, S. Ruggieri, W. C. Olanow

P219 Practicability of treatment with entacapone (Comtess) in the very elderly
K. Hahn, D. Bremen, G. Ebersbach

P220 Entacapone (Comtess) in outpatients with Parkinson's Disease
A. Kupsch, T. Rottenberg, D. Bremen

P221 Improvement of sleep and cognitive performance by entacapone in Parkinson's Disease
B. Holinka, J. Malak, H. Ruff, N. Seppmann, C. Calabrèse, W. Gehlen

P222 The effect of entacapone on motor performance in non-fluctuating patients with Parkinson's Disease analyzed with computerized movement analysis
M. Mrowka, B.约翰, D. Bremen, P. Odin

P223 Symptom duration is a key risk factor for development of L-DOPA-induced dyskinesias in Parkinsonian monkeys
J. S. Schneider, H. Gonczi, E. Decamp

P224 Exposure to pesticides and Parkinson's Disease: a community-based case-control study among a population characterized by a high prevalence of exposure
J. S. Vidal, A. Elbas, J. Clavel, B. Delemotte, A. Alperovitch, C. Tsoulo

P225 Assessing the integrity of the dopamine system in Parkinson's Disease: the intrapatient relation between pharmacokinetic-pharmacodynamic modeling and [123I]FP-CIT SPECT
M. Contin, P. Martinelli, R. Riva, M. Dondi, S. Fanti, A. Baruzzi

P226 Waiting for 'on' - a major problem in patients with Parkinson's Disease and 'on-off' motor fluctuations
D. Merins, R. Dijkstra, E. Melamed

P227 Video registration of freezing and festination in Parkinson's Disease in the home situation
A. M. Nieuwboer, R. Dom, W. De Weerdt, D. Van Gool

P228 Manual transport in Parkinson's Disease
B. Hejdukova, N. Hosseini, B. Johnels, G. Steg, T. Olsson

P229 Speech dysfluency characteristics in patients with Parkinson's Disease
Y. Manor, S. Patel, M. Menachemi, H. Shabtai, R. Ezri-Vinacour, N. Galidi

P230 Longterm drug-withdrawal and SIN DBS reverse levodopa-induced dyskinesia
H. Russmann, J. Ghika, P. Combrement, J. G. Villemure, J. Bogousslavsky, F. J. Vingerhoets
Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

P247 A comparative analysis of patient care in Parkinson’s Disease patients in Europe, European Cooperative Network for research, diagnosis, and the therapy of Parkinson’s disease (EuroPa)
S. V. Campenhausen, K. Berger, R. Wick, W.H. Oertel, R. Dodel, Members of EuroPa

P248 Gait improvement after chronic bilateral subthalamic neurostimulation: a quantitative study
M.G. Cervolo, M. Cappechi, C. Catalano, G. Ghetti, P. Pace, L. Provinciali

P249 The efficacy and safety of Entacapone in patients with Parkinson’s disease in true practice conditions
G. Linazasoro, L. Galan

P250 The effectiveness of olanzapine for treatment of hallucinations and psychosis in Parkinson’s disease
M. Kapsis, P. Prifti, J. Kuja

P251 Treatment of drooling in Parkinson’s disease and Motorneuron Disease with Botulinumtoxin-A
T. Totttenberg, A. Lipp, D. Byer, G. Arnold, A. Kupsch

P252 Deep brain stimulation in late stage Parkinson’s disease: a retrospective cost analysis in Germany
W. Meissner, D. Schreiter, J. Volkman, G. Deuschl, J. Vesper, F. Klostermann

P253 The effect of yohimbine on falls in patients with Parkinson’s disease and Parkinsonian syndromes
N. Lev, E. Melamed, R. Djalldeti

P254 The impact of levodopa on axial impairments of the patients with Parkinson’s disease: a motion analysis study during gait before and after levodopa therapy

P255 Improved trunk control during stance and gait tasks with deep brain stimulation for Parkinson’s disease

P256 Subjective appraisal of daytime sleepiness in patients with Parkinson’s disease using ergot or nonergot dopamine agonists

P257 Can homocysteine affect superoxide dismutase activity in Parkinson’s disease?
S. Bostan, J. pitsouliou, Z. Katsarou, G. Kyriazis, T. Fragia, G. Kosseoglou, A. Kapsis

P258 Initial management of Parkinson’s disease

P259 Efficacy and safety of Entacapone in patients with Parkinson’s disease: a pilot study
S.R. Schwid, the Parkinson Study Group

P260 Long term anti-Parkinsonian effects of bilateral deep brain stimulation (DBS) in advanced Parkinson’s disease (PD): a 3 years multicenter study
M.C. Rodriguez-Oroz, on behalf of the Group of APDPMSS (Advanced Parkinson’s Disease Postmarketing Surveillance)

P261 Chronic pallidal deep brain stimulation in advanced Parkinson’s disease: effects on off-period dystonia, cramps and sensory symptoms
T.J. Locher, J.M. Burgunder, S. Weber, R. Sommerhalder, J. Krauss

P262 Increased noradrenergic tone with reboxetine treatment in Parkinson’s disease (PD) and Progressive Sporaneous Palsy (PSP): effects on motor and depressive symptoms
A. Antonini, G. Pezzoli

P263 Rasagiline improves quality of life in patients with early Parkinson’s disease
S.R. Schwid, the Parkinson Study Group

P264 A survival study of Parkinson’s disease patients switched to liquid carbidopa/levodopa
K.A. Janko, C. Goetz, G. Stebbings

P265 The effect of unilateral pallidotomy on motor disability, and levodopa induced dyskinesia in Parkinsonian marmosets
M.M. Iravani, S. Codai, M.J. Jackson, G. Al-Bargouthy, P. Jenner

P266 Freezing of gait in Parkinson’s disease: potential benefit from Botox injection
M. Wieler, A. Jones, W. Martin

P267 Acute subthalamic administration of LY293558, an AMPA glutamate antagonist, attenuates striatal TH depletion in rats with a partial lesion of the nigrostriatal pathway
M. Bonaütre, C. Marin, A. Jiménez, E. Tolosa

P268 Long term anti-Parkinsonian effects of bilateral deep brain stimulation (DBS) in advanced Parkinson’s disease (PD): a 3 years multicenter study
M.C. Rodriguez-Oroz, on behalf of the Group of APDPMSS (Advanced Parkinson’s Disease Postmarketing Surveillance)

P269 Should we operate Parkinsonian under anaesthesia?
D. Matlete, S. Navarro, M.L. Welte, S. Roche, Y. Agid, P. Comu

P270 Does the dopaminergic status influence the non-motor performance of Parkinsonian patients in pre-surgical evaluation?
P. Ollivier, T. Wiljas, J.P. Azalay

P271 Controlled trial of speech therapy and intra-parotid botulinum toxin for the treatment of salivary drooling in Parkinson’s disease
J.D. O’Sullivan, K. Turner, L. Marks, A.J. Lees

P272 Behavioral disorders, Parkinson’s disease and subthalamic stimulation: a prospective study
V. Mesnage, L. Mallet, J.L. Houeto, M. Gargiulo, C. Behar, M.L. Welte

P273 Deep brain stimulation to improve balance in Parkinson’s disease

P274 Bilateral dorsal subthalamotomy in Parkinson’s disease (PD): initial response and evolution after 2 years

P275 Paradoxical response to levodopa and apomorphine in the Parkinson’s disease
M.A. García-Soldévia, L. Puertas, B. Barcenilla, Y. Sayed, E. Garcia-Albea, F.J. Jimenez, J. Jimenez

P276 The Lee Silverman Method in Parkinson’s disease: groups of phonotherapy
A.E. Dias, L.L. Manaur, E.R. Barbosa

P277 Acoustic analysis of prosody in Parkinson’s disease (PD): effect of L-dopa
L.L. Azevedo, F. Cardoso, C. Reis

P278 The effects of bilateral subthalamic nucleus stimulation on motor speech function in a patient with severe dysarthria and Parkinson’s disease
D.G. Theodoros, A.M. Farrell, E.C. Ward, P. Silburn, B. Hall

P279 Efficacy and tolerability of amantadine: a retrospective review of old and new indications at a tertiary referral center
C. Singer, G. Uzcategui, K. Lyons, A. Facca, W. Koller
P280 Cardiovascular evaluation in Parkinson Disease patients treated with selegiline
N.N. Vanacore, A.A. Giovani, S.S. Di Rezze, V.V. Bonifati, C.C. Mastrocola, G.G. Meco

P281 Bilateral stimulation of the subthalamic nucleus improves the late phase of a grasping to lift task in Parkinsonian patients
F. Kopper, R. Wenzelburger, J. Herzog, H.M. Mehdom, G. Deuschl, P. Krack

P282 The evolution of the acute response to levodopa in Parkinson’s Disease: 6 months placebo controlled study
N. Fedorova, Z. Jamiolk, A. Tkalcs, E. Ružička, S. Deligniere, H. Kwiecinski

P283 The electrophysiological consequences of subthalamic frequency stimulation in normal and unilateral 6-hydroxydopamine-lesioned rats
C.H.C. Thi, T.T. Bordaud, C.C. Gross, B.B. Bioulac, A.A. Benazzouz

P284 Striatal expression of Fos-related transcription factors in human Parkinson’s Disease: relation to L-DOPA-induced dyskinesia

P285 Effects of pharmacological and electrical manipulation of the subthalamic nucleus on the behavior and the expression of c-fos protein in the rat
A.A. Benabid, C. Gross, A. Benazzouz

P286 Botulinum toxin type a as a complementary treatment in Parkinson’s Disease
M. Porta, M. Camerlingo, G. Maggioni, A. Peretti, E. Delli’Anna, C. Ferrante

P287 The effects of electrical stimulation of the subthalamic nucleus and substantia nigra pars reticulata during high frequency stimulation in normal and unilateral Parkinson’s Disease patients
F. Kopper, R. Wenzelburger, J. Herzog, H.M. Mehdom, G. Deuschl, P. Krack

P288 Effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on dual task performance in Parkinson’s Disease
T. Schubert, C. Preuschhof, J. Volkman, M. Mehdorn, G. Deuschl

P289 Low-dose apomorphine test in Parkinson’s Disease: Does growth hormone response depend on previous treatment with levodopa?
T. Tings, S. Happe, M. Canelo, W. Wuttke, W. Paulus, E. Trenkwalder

P290 Pharmacokinetic evaluation of Cabergoline treatment in Parkinson’s Disease
T. Hatano, Y.S. Hatano, Y. Okuma, N. Hattori, Y. Mizuno

P291 Chronic intraputaminal infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson’s Disease
N.K. Patel, P. Heywood, G.R. Hutton, D.J. Brooks, C.N. Svendsen, S.S. Gill

P292 Tolerability and safety of buccal JP-1730: A phase I study in healthy male volunteers
J.M. Peltten, R. Huupponen, O. Ahokoski, H. Meriluoto, J.M. Savola, P. Juvärvi

P293 Apomorphine pharmacokinetic-pharmacodynamic correlations following single and repeated subcutaneous injections in patients with Parkinson’s Disease
P.B. Bottini, A. Shaw, M.-Y. Huang, J.H. Sheny

P294 Population pharmacokinetic (PK) modeling and evaluation of the relationship between sumanirole exposure and orthostatic hypotension (OH) in Parkinson’s Disease (PD) patients

P295 Safety and efficacy of piribedil as adjunctive treatment for Parkinson’s Disease
A.M. Cenci, M. Andersson, S.E. Daniel, A.E. Kingsbury, L. Kilford, A.J. Lees

P296 Intraoperative electrophysiological characterization of neurons encountered in electrode trajectories aimed for the subthalamic nucleus (STN) in patients undergoing deep brain stimulation (DBS) for the treatment of Parkinson’s Disease (PD)

P297 The effect of melatonin treatment on sleep and sleepiness in Parkinson’s Disease: 6 months placebo controlled study
N. Fedorova, Z. Jamiolk, A. Tkalcs, E. Ružička, S. Deligniere, H. Kwiecinski

P298 Treatment of dopaminergic dyskinesia in Parkinson’s Disease patients
E. Dzoljic, M. Mijajlovic, I. Kovačević, A. Andjelkovic, M. Pokrajac, V. Kostić

P299 Non-compartmental analysis (NCA) and drug interaction analysis using population pharmacokinetics (PK) of sumanirole in patients with Parkinson’s Disease (PD)

P300 The effect of melatonin treatment on sleep and sleepiness in Parkinson’s Disease patients
E. Dzoljic, M. Mijajlovic, I. Kovačević, A. Andjelkovic, M. Pokrajac, V. Kostić

P301 Reversion of shortening in the duration of levodopa-induced motor response by adenosine A2A antagonists is associated to changes in striatal dynorphin mRNA expression in Hemiparkinsonian rats
J. Bové, J. Serrats, G. Mengod, R. Cortés, E. Tolosa, C. Marin

P302 A tolerability study of intranasal apomorphine powder (5mg), in subjects with Parkinson’s Disease and motor fluctuations, over a seven day period: a phase two study
M. Wickremaratchi, S. Hadjkoutsis, P. Lambert, S. Freear, K. Wareham, R. Weiβer

P303 Multiple development forms of Parkinson’s disease
P. Riedener, P. Foley

P304 Utility of a guide dog to facilitate gait in Parkinson’s Disease patients
A.L. Adkin, W.E. McIlroy, J.M. Miyasaki

P305 Medications reduce errors in antisaccade tasks in Parkinson’s Disease patients
A.E. Cain, S.C. Amador, K.A. Briand, A. Altefai, M.C. Schiess, A.B. Senero

P306 Testosterone replacement for testosterone deficient male patients with Parkinson’s Disease: results of a pilot study
M.S. Okun, B.L. Walter, W.M. McDonald, J.L. Tenover, J. Green, J.L. Jorge

P307 Treatment of hypophonia with collagen vocal fold augmentation in patients with Parkinson’s Disease
A.N. Hill, J. Jankovic, D.P. Vuong, D. Donovan

P308 Testosterone replacement for testosterone deficient male patients with Parkinson’s Disease: results of a pilot study
M.S. Okun, B.L. Walter, W.M. McDonald, J.L. Tenover, J. Green, J.L. Jorge

P309 Changes in quality of life resulting from treatment for persons with early Parkinson’s Disease: sumanirole versus placebo
J. DuChaine, C. Jenkins
Poster Sessions

Poster Session 2 - Monday, November 11, 12:30 pm - 2:00 pm

P310 Efficacy of Aricept in the treatment of Parkinson's Disease dementia syndrome
R. Duchidze, E. Devidze

P311 Nighttime cabergoline substitution for daytime sleepiness induced by dopamine agonists in Parkinson's Disease
P. Del Dotto, G. Gambaccini, S. Agostini, S. Bernardini, U. Bonuccell

P312 Kinematic analysis and segmentation of targeted forearm movements in Parkinson's Disease: quantifying dysfunction and evaluating treatment efficacy

P313 Home monitoring in patients with advanced Parkinson's Disease: a feasibility study. The CHRONIC Consortium
A. Antonini, C. Castiglioni, J. Aniulo', R. Fane', A. Falco, G. Pezzoli

P314 Mirtazapine in levodopa-induced dyskinesias
E. Fabbré, N. Vanacore, L. Pratesi, S. Di Rezze, A. Alessandri, G. Meco

P315 Stereotaxic intrastriatal implantation of retinal pigment epithelial cells attached to gelatin microcarriers: a 12-month, open-label trial in six advanced Parkinson disease (PD) patients

P316 Long-term treatment with the dopamine agonist pramipexole without levodopa: determination of predictive factors for response in patients with early Parkinson's Disease
B. Musch, L.D. Borchert, W. Spalding

P317 Switching on to switching off: the development of a definition and diary to assist people with Parkinson's Disease to identify and monitor wearing-off complications
A. Bowon

P318 [18F]FDOPA PET and clinical features in a PD patient with manganese exposure
B.A. Racette, J. Antenor, V. Kotagal, T. Videen, S. Moerlein, J. Goldman

P319 To evaluate the latency of sublingual atropine and the long-lasting effects of bilateral subthalmic deep brain stimulation (B-STN DBS)
H. Bronte-Stewart, G. Heit, T. Courtney

P320 Improvement of performance in daily life activities in patients with Parkinson's Disease by using declarative memory-guided sequences of instructions. II. A 4-year follow-up study
M.E.P. Piemonte, E. Okamoto, M. Morimoto, G.F. Xavier

P321 The role of the Parkinson's Disease nurse specialist in the multidisciplinary management of fluctuating Parkinson's Disease patients
E. Williams

P322 Effect of chronic SIN deep brain stimulation on the sense of smell in patients with Parkinson's Disease
S. Joergens, C. Dohle, M. Pichatsek, S. Kelm, N. Allert, J. Volkmann

P323 Sumanirole is a promising new agent in the treatment of Parkinson's Disease

P324 The Total Functional Capacity Scale: a useful and rapid assessment tool for monitoring Parkinson's Disease disability
M.A. Stacy, R.A. Hauser, J.E. Samanta, T.A. Zesiewicz, D.L. Sebade, C. Cinino

P325 Tolerability profile of sumanirole in advanced Parkinson's Disease

P326 Assessment of the rate of progression in Parkinson's Disease by [18F]TRODAT-1 SPECT imaging
Y.H. Weng, C.S. Lu, T.C. Yen

P327 An observational survey of the therapeutic value of entacapone in 76 "natural " Parkinson's Disease patients in daily clinical practice in Switzerland
A.M. Hew-Winzeler, I. Zangger, M. Huebschen

P328 Treatment strategies in Parkinson's Disease patients in daily clinical practice - correlation with published treatment recommendations in Switzerland
I. Zangger, A.M. Hew-Winzeler, M. Huebschen

P329 Comparison of two methods of subthalamic nucleus targeting: direct anatomical vs. AC-PC measurements
C.T. Pappas, V.L. Wheelock, K.A. Goyardt

P330 Application of clinical trial simulation to evaluate the ELDOPA trial design
P.L.S. Chan, N.H.G. Holford, J.G. Nutt, Parkinson's Study Group

P331 Disease progression and increased levodopa efficacy with time in Parkinson's Disease

P332 Glutathione does not improve Parkinson's Disease
D.L. Kreitzman, N.V. Nadel, S.H. Isackson

P333 Assessment of long-lasting efficacy of cabergoline (CBG) on Parkinsonian akinesia using actigraphy
S. Katayama, K. Watanabe

P334 The Short Parkinson's Evaluation Scale (SPES) in routine use in a Pramipexole study
P.H. Kraus, P. Martinez Martin, U. Bonicelli, H. Marinus, J.J. van Hulsen, M. Rabey

P335 Motor and non-motor off-periods in Parkinson's Disease: various clinical forms and long-term Apomorphine pump treatment
J.E.G. Vanderheyden

P336 Postural instability in Parkinson's Disease: immediate and persistent effects of bilateral subthalamic deep brain stimulation (B-SIN DBS)
H. Bronte-Stewart, G. Heit, T. Courtney

P337 Gait analysis in de novo and advanced Parkinson's Disease: influence of acute L-dopa administration on spatiotemporal, cinematic and kinetic parameters studied by a 3D computerised system
M. Guidi, C. Catalano, O. Scarpino, P. Pace, G. Ghetti

P338 An item analysis of the Unified Parkinson Disease rating scale (UPDRS) in individuals with early Parkinson's Disease (PD) treated initially with pramipexole or levodopa: a sub-analysis of the 4-year CALM-PD trial
K.M. Biglan, R.G. Holloway, I. Shoulson, the Parkinson's Study Group

45
Poster Session 3 - Tuesday, November 12
7:00 am - 8:30 pm

Poster numbers 339-520
Parkinson’s Disease

P339 Metronome stimulation in Parkinson’s Disease patients with gait freezing
E. Cubo, C.G. Moore, C.G. Goetz

P340 The impact of dopamine dyskinesia on direct health care and non-health care costs associated with patients with Parkinson’s Disease: a prospective European study
M.R. Pechevis, C.E. Clarke, P. Viereggé, M. Ziegler, C.T. Voinet

P341 Turning difficulties associated with Parkinson’s Disease (PD)
E. Stack, A. Ashburn, H. Rassoulian

P342 Validity and reliability of the video-based Standing-start 180° Turn Test (SS-180) in adults with and without Parkinson’s Disease (PD)
E. Stack, A. Ashburn, H. Rassoulian

P343 The Parkinson’s Early Intervention Program (PEIP): theoretical model and evaluation of a self-management program to facilitate improved quality of life for people with Parkinson’s
R.A. Gruber, M.P. Huijbregts

P344 Motor fluctuations and quality of life in Parkinson’s Disease
S. Chapuis, O. Metz, L. Gerbaud, F. Durif

P345 Activities of daily living score in UPDRS is an appropriate indicator of health-related quality of life in Parkinson’s Disease
T. Haapaniemi, K. Sotaniemi, E. Taimela, EcoPD Study Group

P346 Differential diagnosis of Parkinson Disease via visuo-motor testing is confirmed by Quantitative SPECT (Q SPECT) imaging
M. Schwartz, D. Groshar, S. Hocherman

P347 Shaking Palsy or Amyotrophic Lateral Sclerosis: the case of the Count of Lordat by James Parkinson
P. Nispeanu, R. Inzinger

P348 Neuropsychiatric symptoms in Parkinsonian patients: clinical and anatomical correlations
F. Viselli, A. Monge, N. Modugno, M. Paradiso, F. Stocchi, S. Ruggieri

P349 Healthcare utilization and drug therapy in a cohort of Parkinson’s Disease ambulatory patients

P350 Blink rate as a mechanism to monitor motor fluctuations in Parkinson’s Disease
E.A. Fazzini, M.R. Wells

P351 Psychotic symptoms induced by DBS of the STN in a patient with Parkinson Disease: a case report
S.A. Abbas, B. Cook

P352 Autonomic dysregulation in conjunction with freezing of Parkinsonian patients: an ambulatory monitoring study
J. Jörg, S. Jock, W. Boucsein, F. Schaefter

P353 Late-onset autosomal dominant familial Parkinson Disease. Clinico-pathological study of Western Nebraska family (Family D)

P354 Inter- and intra-rater reliability and discriminative ability of five measures of bradykinesia in subjects with and without Parkinson’s Disease
R.A. Gruber, J. Marinus, M. Visser, J.J. van Hilten

P355 Epidemiology of Parkinson’s Disease in Ishimizawa City, Japan
K. Itoh, F. Moriwaka, K. Kuroshima, S. Kikuchi, K. Taishiro

P356 Repetitive trans-cranial magnetic stimulation in Parkinson’s Disease: a prospective study of 33 cases
C.A. Mharti, F. Peki, F. Belahsen, M. Jabali, F. Choyakh, N. Zouari

P357 Clinical tests for postural instability in patients with Parkinson’s Disease
M. Visser, J. Marinus, B.R. Bloem, H. Kjöes, B.M. van den Berg, B.J. van Hilten

P358 Multiple Developmental Forms of Parkinson’s Disease
P. Riederer, P. Foley

P359 A study on dopamine D2 receptor occupancy after multiple oral administration of SLV 308 to healthy male volunteers by means of Positron Emission Tomography using 11C-raclopride
M.H. de Vries, B.J. Hedeman Joosten, M.B. Hesselink, A.A. Winsemius, A. Wall, M. Bergström

P360 Investigation into the significance of 18F-desmethoxfallypride positron emission tomography in the differential diagnosis of Parkinson Syndromes
S. Haegele, F. Rosch, M. Schreckenberger, T. Vogt

P361 Mental disorders in Parkinson’s Disease: treatment with quetiapine
C. Pacchetti, F. Mancini, S. Cristina, R. Zangaglia, E. Martignoni, G. Nappi

P362 Tonic and phasic REM sleep features in Parkinson’s Disease (PD) with and without REM sleep behavior disorder (RBD)
J. F. Gagnon, M.-A. Bedard, L. Fantini, S. Rompré, M. Panisset, J. Montplaisir

P363 High resolution MRI measurement of substantia nigra area in Parkinson’s Disease: a pilot longitudinal study on the impact of chronic treatment with L-Dopa or pergolide

P364 Skin biopsy in patients with Parkinson’s Disease: a novel diagnostic tool for evaluation of autonomic impairment
R. Djdidetti, R. Dabby, M. Schamahurov, T. Treves, E. Melamed, I. Avinoach

P365 The Parkinson’s Disease Sleep Scale (PDSS): a new instrument for assessment of sleep, nocturnal disability and daytime sleepiness in Parkinson’s Disease

P366 Motor cortical disturbances in Parkinson’s Disease: an event-related desynchronization study

P367 Cognitive and regional cerebral blood flow predictive factors of evolution in newly diagnosed Parkinson’s Disease patients
L. Defebvre, K. Dujardin, A. Duhamel, P. Leocuffe, M. Steinling, A. Destee

P368 Sleep-wake cycle and visual hallucinations in Parkinson’s Disease

P369 Standardized training tools for the UPDRS activities of Daily Living scale: clinimetric study of a teaching program
C.G. Goetz, P.A. LeWitt, M. Weidenman, P. Quarg
P370 Cognitive decline and Levo-DOPA responsive Parkinsonism in a longitudinal cohort
S. Gimeno, S. Diez, R. Gantcheva, B. Bonnefoi-Kyriacou, F. Viallet

P371 Measurement properties of two common health status questionnaires in Parkinson's Disease
P. Hagell, D. Whalley, S.P. McKenna, O. Lindvall

P372 Sequence analysis of promoter region of the brain-derived neurotrophic factor gene in Parkinson's Disease
A. Parsian, R. Sinha, B. Racette, J.S. Perlmutter

P373 Elevated taste recognition thresholds in patients with Parkinson's Disease
M. Welker, D. Small, T. Smuni

P374 The poetical Parkinsonian: professor and patient
G.D. Hardacre

P375 Evaluation of timed tests in Parkinson's Disease
P.J. Garcia Ruiz, E. Meseguer, V. Sanchez

P376 Cognitive functions in people with Parkinson's Disease (PwPD) and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy
I. Rektorova, I. Rektor, M. Baes, V. Dostal, E. Eher, Z. Fanf卓ova

P377 Body weight gain in patients with Parkinson's Disease and deep brain stimulation
M. Barichella, A.M. Marczewska, C.B. Marian, A. Landi, A. Vairo, G. Pezzoli

P378 The association of Parkinson's Disease and bone fractures: an assessment of risk
T.W. Downes, R. Genever, P. Medcalf

P379 Visual Hallucination and thalamic inclusions in Parkinson's Disease
T. Fukuda, J. Takahashi, J. Tanaka

P380 Frequency of MTHFR gene polymorphism in Parkinson's Disease
A. Szaci, I. Kara, E. Ergul, G. Kaya, G. Kicil

P381 Body weight changes in patients with Parkinson's Disease received Pramipexole
I.G. Smolentseva, B. Tserensodnom, O.S. Levin, N.V. Fedorova, V.N. Shok

P382 A genome wide linkage disequilibrium screen for Parkinson's Disease
T. Foltynie, S.J. Sawcer, S.J. Lewis, A. Jonasdottir, A. Hicks, R.A. Barker

P383 Validation of the French version of the PDQ-8, a short quality of life (QoL) questionnaire for Parkinson's Disease (PD), and its sensitivity to change by dopamine agonists
F. Tison, J.-L. Thibault, O. Blink, P. Pollack, J.-L. Montastruc, P. Cesaro

P384 Somatosensory and motor evoked potentials in Parkinson's Disease
S. Choi, Y.K. Min, S.R. Lim, J.H. Lee

P385 Cognition and Parkinson Disease
M.C. Garrett, M.R. Fonseca, M.J. Ross, F. Simoes, S. Vieira

P386 Reliability of limits of stability measures in Parkinson's Disease

P387 The influence of depression on executive functions in early Parkinson's Disease
J. Uekermann, I. Daum, S. Peters, B. Wiebel, H. Puzu, T. Mueller

P388 Loss of muscle mass and strength correlates with severity of Parkinson's Disease
E.Y. Uc, R.L. Rodnitzky, W.J. Evans

P389 Putaminal volume in Parkinson's Disease
M. Iijima, Y. Iizuka, T. Maehara, N. Hattori, Y. Mizuno

P390 How neurologists and caregivers agree about disability of patients with Parkinson's Disease (PD)? The case of the UPDRS Section II
P. Martinez-Martín, J. Benito-Leon, F. Alonso, M.J. Catalan, M. Pondal, I. Zamarbide

P391 Health-related quality of life evaluation by proxy in Parkinson's Disease. An approach through the PDQ-8 and the EuroQol-5D
P. Martinez-Martín, J. Benito-Leon, F. Alonso, M.J. Catalan, M. Pondal, I. Zamarbide

P392 Prevalence of Parkinson gene mutations and deletions in idiopathic Parkinson's Disease
R. Sinha, B. Racette, J.S. Perlmutter, A. Parsian

P393 Social costs of Parkinson Disease in Italy
G. Pezzoli, A. Zecchinelli, F. Caprari, P. Pondi, A. Bonetti

P394 Head trauma preceding Parkinson's Disease (PD): a case-control study

P395 Gaucher's disease type 1 and Parkinson's Disease

P396 A clinical comparison of Icelandic familial Parkinson's Disease (PD) patients who contribute to a locus on chromosome 1p32 and those who don't
S. Sveinbjórsmóttí, A. Hicks, T.Jónsson, H. Pétursson, A. Kong, J.R. Gulcher, K. Stefansson

P397 Electromyographic profiles of gait at the onset of freezing in Parkinson's Disease
A.M. Nieuwoerter, R. Dom, W. De Weerdt, K. Desoubovere, S. Vandehelpuw

P398 Social costs of Parkinson Disease in Italy
G. Pezzoli, A. Zecchinelli, F. Caprari, P. Pondi, A. Bonetti

P399 Subclinical pulmonary dysfunctions in Parkinson's Disease
P.K. Pal, T.N. Sathiyaprabha, T. Prasad, K. Thenmarasu

P400 Obsessive-compulsive disorder in idiopathic Parkinson's Disease: Frequency and case report
A.S. Pinto, A.F. Nascimento, A.F. Barbosa, P.R. Menezes, E.C. Miguez

P401 Gait dynamics in subjects with freezing of gait and Parkinson's Disease: Increased variability during usual walking
J.M. Hausdorff, J.D. Schaafsma, J. Balash, A. Bartels, T. Gurevich, N. Giladi

P402 Clinical characterization of freezing of gait and its response to levodopa in Parkinson's Disease
N. Giladi, S.D. Joanna, B. Jacob, G. Tanya, A. Bartels, H.M. Jeffrey

P403 The relation between paroxysmal gait disturbance type 1 (freezing of gait) and akinesia in Parkinson's Disease
N. Giladi, A. Bartels, Y. Balash, J. Schaafsma, T. Gurevich, D. Comanestea

P404 Evaluation by SF 36 of cognitive-behavioural therapy on eight Parkinson's Disease patients and their spouses. Preliminary results
J.P.J. Brandel, A.A. Schneider, M.M. Zegler, P.P. Mougin, H.H. Antaki
Poster Sessions

Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

P406 Performance memorization for Parkinson's Disease: a simple approach to help patients to perform daily life activities
M. E. P. Piemonte, O. Okamoto, M. Morimoto, G. F. Xavier

P407 Lewy body cortical involvement may not always predict dementia in Parkinson's Disease
C. Colosimo, A.J. Hughes, L. Kilford, A.J. Lees

P408 Olfactory function in Parkinson's Disease (PD): Long-term follow-up of de-novo PD patients
A. Muller, H. Reichmann, A. Livermore, T. Hummel

P409 EuroPa - using the advantages of a multinational network to improve clinical research and treatment of Parkinson's Disease (PD) in Europe
R.P. Wick, W. Poewe, C. Sampaio, O. Rascol, R. Dodel, W.H. Oertel

P410 Can cardiac C11-HED-PET help to distinguish between Parkinson's disease and Multiple System Atrophy?
C. Schrader, T. Peschel, H. Kolbe, R. Dengler, W. Knapp, G. Berding

P411 Measuring the rate of progression of early Parkinson's Disease over 5 years period with b-CIT SPECT
W. Pirker, I. Hollec, W. Gerschlager, S. Asenbaum, G. Zettinig, C. Bruecke

P412 Frontal lobe dysfunction in Parkinson's Disease

P413 Lewy body cortical involvement may not always predict incidental Lewy bodies
C. Colosimo, A.J. Hughes, L. Kilford, A.J. Lees

P414 Analysis of direct costs in the treatment of Parkinson's Disease in Europe
M.E.P. Piemonte, E. Okamoto, M. Morimoto, G.F. Xavier

P415 Multivariate analysis of quality of life in Parkinson's Disease
J. Sawek, M. Dereko

P416 Working memory functioning in mild and moderate Parkinson's Disease patients

P417 Are there differences in motor and cognitive disturbances in Parkinson's Disease patients with and without psychosis?
O.S. Levin, T.V. Naimushina, I.G. Smolentseva

P418 Smell identification ability in twins discordant for Parkinson's Disease
S. Keller, T. Kessler, D. Bremen, W. Jost

P419 Quality of life in patients with Parkinson’s Disease
J.W. Kim, S.K. Hong

P420 Using the EuroQol(EQ-SD) to derive patients preferences from the UPDRS
U. Seibert, A. Spottke, A. Schrag, N. Quinn, W.H. Oertel, R. Dodel

P421 Postural adjustment to tilt in patients with Parkinson's Disease in on and off state: preliminary results
N. Abou Azar, C. Van Nechel, D. Zegers de Beyl

P422 Dopamine receptor and hypocretin gene polymorphisms in Parkinson's Disease (PD) patients reporting “sleep attacks”
I. Risling, J.C. Müller Y. Komer, O. Bandmann, K. Stiasny, W.H. Oertel

P423 Late-Onset Movement Disorder caused by filterable forms of Nocardia asteroides in the midbrain of mice
C. Kadoya, S. Kohbata

P424 An investigation into the behavioral and neurochemical bases of morphosyntactic language impairments in Parkinson's Disease
W.L. Amott, P.A. Silbum, H.J. Chenery, B.E. Murdoch

P425 Performance on a computerized reaction time test predicts incidental Lewy bodies

P426 Associations of fatigue in Parkinson’s Disease
M.J. Steiger, R. Davies, J. Brooks, H. Tyne, G.A. Baker

P427 Kinematic analysis of the movements of the hand (tapping test) by Hilbert transformed in patient with Parkinson Disease and controls
P. Chana, H. Gonzalez, A. Gutierrez, N. Barrientos

P428 Validation of a screening questionnaire for Parkinson’s Disease in Singapore

P429 Multivariate analysis of quality of life in Parkinson's Disease
A. Friedman, M. Zich

P430 Quality of life in long-lasting Parkinson’s Disease
R.P. Wick, W. Poewe, C. Sampaio, O. Rascol, D.J. Brooks

P431 Tremor at diagnosis is predictive of slower disease progression in Parkinson's Disease: an 18F dopa PET study
A.L. Whone, C. Brefel-Courbon, R.Y. Moore, O. Rascol, D.J. Brooks

P432 Changes in digestive tract function in Parkinson's Disease (PD) patients receiving Anti-Parkinson agents
M. Hotta, S. Nemoto, Y. Nomura, T. Suzuki, T. Kamo

P433 The posturography study of Parkinson's Disease patients
G.-H. Lee, J.-I. Kim

P434 Validity of family history data on Parkinson's Disease: evidence for a family information bias

P435 The All Project: a web-based database for Parkinson's Disease

P436 Healthcare utilization and economic impact of Parkinson's Disease
A. Spottke, R. Martin, K. Berger, O. Machat, W.H. Oertel, R. Dodel

P437 Predictive factors of falls in elderly subjects and patients with Parkinson's Disease
G. Kemoun, L. Defebvre, E. Watelain, A. Destee, J.-D. Guieu

P438 Executive functions, verbal and visual memory in patients with early and stable Parkinson's Disease - effect of levodopa
S. Singh, S. Sheasadi, M. Behari

P439 Modulation of motor performance by mood in Idiopathic Parkinson's Disease (IPD) patients receiving Anti-Parkinson agents
M. Hotta, S. Nemoto, Y. Nomura, T. Suzuki, T. Kamo

P440 A pilot study of the effects of Parkinson's Disease on golf
J.G. Carpenter, J.R. Rinker II, K.D. Sethi

P441 An evaluation of pull test technique in assessing postural instability in Parkinson's Disease
R.P. Munhoz, J.-Y. Li, P. Piboolnurak, A. Constantino, S. Fahn, A.E. Lang
Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

P445 Nonsteroidal anti-inflammatory drugs and the risk of Parkinson’s Disease
H. Chen, S.M. Zhang, M.A. Heman, M.A. Schwarzschild, W.C. Willet, G.A. Colditz

P446 Early onset of Parkinson’s Disease among subjects professionally exposed to either solvents or metals
L. Buzio, G. De Palma, P. Mozzonzi, A. Negrotti, A. Scaglioni, S. Calzetti

P447 A multicentric observational study on the prevalence of REM sleep behaviour disorder in an Italian population of idiopathic Parkinson’s Disease
C. Scaglione, L. Vignatelli, R. Marchese, A. Negrotti, S. Bernardini, G. Coccagna

P448 Do Parkinsonian patients walk in falling?
M.-L. Welter, M.C. Do, U. Rodriguez Ortiz, O. Messouak, A.-M. Bonnet, Y. Agid

P449 Sebomaria and constipation in early Parkinson’s Disease (PD)
P. Vrentas, G. Tagaris, S. Samell, V. Panayiotopoulou, A. Antelli, G. Moukas

P450 Motor sequence learning in normal control subjects and subjects with Parkinson’s Disease: preliminary results
G. De Palma, P. Mozzoni, E. Scotti, L. Buzio, S. Pizzariotti, A. Scaglioni

P451 Family-based association study of cigarette smoking and Parkinson Disease

P452 Apolipoprotein E gene polymorphism and plasma cholesterol concentrations in Parkinson’s Disease patients
G. Opala, B. Jasinska-Mya, S. Ochudlo, J. Tustanowski, M. Arkuszewski

P453 Immunohistochemical study for ER stress and accumulation of Pael-r in autosomal recessive juvenile Parkinsonism
K. Sato, H. Yoshino, Y. Sasaki, H. Nobutaka, Y. Mizuno

P454 Prospective study of anxiety and risk of Parkinson’s Disease
M.G. Canesi, C. Galli, A. Righini, R. Bentil, M. Rango, M. Gambacorta

P455 Early diagnosis of Parkinson’s Disease at the primary care level by a questionnaire
I. Risling, A. Metz, G. Hoeglinger, V. Ries, E. Baum, W.H. Oertel, A. Heinemann, G. Deuschl, S. Speiker

P456 Important influences of the developing role of the Parkinson’s Disease Nurse Specialist (PDNS)
S.-B. Koh, B.-J. Kim, M.-K. Park, K.-W. Park, D.-H. Lee

P457 Development and validation of a screening tool for epidemiological studies in Parkinson’s Disease in a multi-linguistic society with varying levels of literacy
U.B. Muthane, M. Ragothaman, G. Gururaj, D. Subbukrishna, U.B. Muthane

P458 Assessment of health-related quality of life in Parkinsonian patients:Can a short questionnaire be useful?
Z. Katsarou, S. Bosantipoulou, A. Kafantari, G. Kioseoglou, E. Peitsidou, G. Mentenopoulo

P459 Occurrence of Parkinson’s Disease in an admixed population of European and Indian origin
M. Ragothaman, U.A. Murgod, G. Gururaj, D. Subbukrishna, U.B. Muthane

P460 Mitochondrial DNA polymorphisms in Parkinson’s Disease
M. Weiskopf, H. Chen, I. Kawachi, A. Ascherb

P461 The Competence Network Parkinson in Germany
K. Eggert, S. Spieker, P. Odin, G. Deuschl, T. Gasser, W. Oertel

P462 Coordination of firing rates and patterns in subthalamic neurons of Parkinsonian patients with disease severity
F. Carella, W.D. Hutchison, J. O. Dostrovsky, A.E. Lang, A.M. Lozano

P463 Risk factors for dementia in Parkinson’s Disease
G. Opala, B. Jasinska-Mya, S. Ochudlo, J. Tustanowski

P464 Screening of Social Anxiety in Parkinson’s Disease
D. Uluduz, N. Kocabaosoglu, H. Apaydin, S. Oezemekci, E. Erginoz

P465 Apolipoprotein E gene polymorphism and dementia in Parkinson’s Disease
G. Opala, B. Jasinska-Mya, S. Ochudlo, J. Tustanowski, M. Arkuszewski

P466 Parkinson’s Disease as possible cause of “idiopathic” olfactory dysfunction

P467 Pulmonary function tests in idiopathic Parkinson’s disease
S.-B. Koh, B.-J. Kim, M.-K. Park, K.-W. Park, D.-H. Lee

P468 Acoustic analysis of prosody in Parkinson’s Disease (PD): comparison with normal controls
L.L. Azevedo, F. Cardoso, C. Reis

P469 Family-based association study of familial and sporadic Parkinson’s Disease
H.A. Hanagasi, D. Ayribas, K. Bayral, M. Emre

P470 Important influences of the developing role of the Parkinson’s Disease Nurse Specialist (PDNS)
S. Noble, D. Lewin, L. Osborne

P471 b-CIT SPECT and clinical characteristics in two Parkinson’s Disease patients associated with camptocormia
I. Holec G. Dimberger, W. Pirk, L. Auff, W. Graschlagr

P472 Mortality in patients with Parkinson’s Disease: a Tyrolean cohort study
A. Diem, K. Seppi, E. Ernta, W. Oberaigner, G. Wenning, W. Poewe

P473 The influence of nuclear encoded mitochondrial complex I single nucleotide polymorphisms (SNPs) on the age of onset (A0O) of Parkinson’s Disease (PD)
G.D. Mollick, J.A. Prince, A.J. Brookes, P.A. Silbun

P474 Toxicological studies in Parkinson’s Disease in a multi-linguistic society
U.B. Muthane, M. Ragothaman, G. Gururaj, D. Subbukrishna, U.B. Muthane
Poster Session 3 - Tuesday, November 12, 7:00 am - 8:30 am

P510 Injuries due to falls in Parkinsonian patients
S.A. Parashos, C.L. Wielinski, C. Erickson-Davis, R. Wichmann, M. Walde-Douglas

P511 Relation between movement and single cell discharge in the subthalamic nucleus in Parkinson’s Disease (PD)

P512 The impact of early Parkinson’s Disease on visual search

P513 Genetic variability in tau assessed in Parkinson’s Disease in Ireland
J.A. Wiley, T. Lynch, L. Skipper, F. Matthew

P514 Familial Parkinsonism in an Ohio Amish pedigree
S.L. Lee, A. Crunk, L. McFarland, Y. Bradford, T.L. Davis, J.L. Haines

P515 Proprioceptive regulation of postural control in Parkinson’s Disease (PD)

P516 When researchers in Parkinson’s Disease (PD) say quality of life, what do they measure?

P517 Ratio of large to small rapid alternating movement frequencies (L/S) in the human upper limb: a parameter independent of the joint assessed
J.-M. Gracies, L.J. Guo, D. Crisan, B. Yang, D.J. Weisz, W. Olanow

P518 Pseudo-autosomal dominant inheritance of PARK2: gene dosage analysis, social-geographical-historical backgrounds in two families
T. Kobayashi, H. Matsumine, Y. Imamichi, N. Hattori, S. Tanaka, Y. Mizuno

P519 Activation and apoptosis in lymphocytes of patients with Parkinson’s Disease
A. Callen, M. Mestre, M. Calopa, J. Bas, E. Buendia

P520 Relationship between Aggresomes and Lewy bodies
K.S. McNaught, D.P. Perl, C.W. Olanow

Poster Session 4 - Tuesday, November 12 Noon - 1:30 pm

Poster numbers 521-694
Neuroimaging, Surgical Therapy, Transplantation

P521 b-CIT/SPECT vs clinical examination in Parkinsonian Syndrome: unmasking an early diagnosis
D.L. Jennings, J.P. Seibyl, J. Murphy, K. Marek

P522 A correlation between REM sleep behavior disorder and striatal monoaminergic innervation in Multiple System Atrophy
S. Gilman, R.A. Koepppe, R. Chervin, F. Consens, R. Little, H. An

P523 Activation brain SPECT using the Wisconsin Card Sorting Test in patients with Parkinson’s Disease
B.A. Pickut, P. Jacobs, K.J. Van Laere, J. Vandevivere, R.A. Dierckx, P.P. De Deyn

P524 Adenosine A1 receptor PET in movement disorders

P525 Assessment of CBP-1347 interaction with beta-CIT striatal uptake in Parkinson’s Disease
Parkinson Study Group (Kenneth Marek - presenter)

P526 Basal ganglia hyperintensities on T1-weighted MRI are associated with high blood and cerebrospinal fluid levels of manganese in Chronic Hepatic Encephalopathy
M. Miranda, P. Venegas, J. Valera, M. Kagi, F. Duran

P527 Cardiac MIBG scintigraphy is a sensitive tool for detecting silent Autonomic failure in Parkinson’s Disease
F. Courbon, C. Brefel-Courbon, C. Thalamas, M.J. Alibelli, I. Berry, J.M. Senard

P528 Cardiac uptake of MIBG in patients with essential tremor and tremor-dominant Parkinson’s Disease
M. Yamamoto, T. Tajiy, Y. Kageyama

P529 Cerebral blood flow changes induced by low and high frequency stimulation of the subthalamic nucleus in Parkinson’s Disease: a [15O]-H2O PET study
A. Daghet, A.P. Strafella, A.F. Sadikot

P530 Cerebrovascular disease affects presynaptic dopaminergic imaging: a 123I-FP-CIT SPECT study
H.T. Benamer, D.G. Grosset, J. Patterson, D.D. Hadley

P531 Combined magnetisation transfer imaging and proton magnetic resonance spectroscopy of the lentiform nucleus in idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
T. Eckert, J. Kaufmann, E. Schrader, T. Peschel, H.-J. Heinze, M. Sailer
Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

P535 Comparison of a-dihydroergocryptine and levodopa monotherapy in Parkinson's Disease: assessment of disease progression with dopaminergic transporter SPECT

P536 Corticobasal degeneration and Parkinson's Disease assessed by SPECT and functional discriminant analysis
A. Kreier, L. Defebvre, P. Lecouffe, P. Charpentier, A. Duhamel, M. Steinling, A. Destee

P537 D2 receptor dysregulation in patients with Parkinson gene mutations
C. Scherfler, N.L. Khan, N. Pavese, N.W. Woods, N. Quinn, D.J. Brooks, P. Piccini


P539 Differential effects of VIM thalamus deep brain stimulation upon thalamo-cortical circuitry
B. Haslinger, H. Boecker, C. Buechel, J. Vesper, V.M. Tronnier, A.O. Ceballos-Baumann

P540 Differential patterns of dopamine transporter loss in the basal ganglia of Progressive Supranuclear Palsy and Parkinson's Disease: analysis with [123I]IPT single photon emission computed tomography
J.-H. Im, J. S. Kim, M.C. Lee

P541 Diffusion-weighted MRI discriminates Progressive Supranuclear Palsy from Parkinson's Disease
K. Seppi, M. Schroeke, R. Esterhammer, W. J. Aschke, W. Poewe, G. Wenning

P542 Dissociation of frontal and prefrontal white matter integrity to cognitive and motor behaviors in Parkinson's Disease: a diffusion tensor imaging study
G.T. Stebbins, M.C. Camilo, C.G. Goetz, M.E. Moseley, J.D. Gabrieli

P543 Dopamine transporter imaging and bilateral subthalamic stimulation for Parkinson's Disease: One year follow up
A. Lokkegaard, L.M. Werdelin, L. Regeur, J. Brennum, F.F. Madsen, L. Friberg

P544 Dopaminergic degeneration and perfusional impairment in Lewy Body Dementia (LBD): evidence from a double-tacer SPECT study
R. Ceravolo, D. Voltermani, G. Dell'Agnello, S. Bernardini, G. Manca, C. Berti, G. Mariani, L. Muni, U. Bonuccelli

P545 Ecchogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's Disease

P546 Effects of deep brain stimulation of the SNr and SNc nuclei under resting state and during simple movement tasks: a functional MRI study at 1.5 Tesla

P547 Effects of sensory stimulation on striatal dopamine release in normal subjects: a PET 18F-Dopa and 11C-Raclopride study
S.C. Thobois, V. Leveil, L. Garcia-Lamea, N. Costes, D. Le Bars, E. Broussolle

P548 Effects of subthalamic high-frequency stimulation on dopamine release in Parkinson's Disease: a [11C]raclopride PET study
A.P. Strafella, A.F. Sadikot, M. Panisset, A. Dagher
Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

P564 Proton MR spectroscopy in untreated and treated Wilson's Disease
M. Behari, A.K. Sahani, S. Singh, V. Goyal, R.J. ayasundar, S. Gaikwad

P565 Regional cerebral blood flow profile associated with speech production in normal subjects and Parkinsonian patients
S. Pinto, M. Gentil, N. Costes, A.-L. Benabid, E. Broussolle, P. Pollak

P566 Safety of Magnetic Resonance Imaging in patients with deep brain stimulation

P567 Stratal dopamine release induced by repetitive transcranial magnetic stimulation of the motor cortex: a [11C]raclopride PET study
A.P. Zafarella, T. Paus, M. Fraraccio, A. Dagheer

P568 Stratal dopamine transporter function measured by in vivo [123I]b-CITpinhole SPECT correlates with nigral dopaminergic cell count in the 6-OHDA rat model of Parkinson's Disease
C. Scherfler, E. Donnemiller, M.F. Schokec, C. Decristoforo, W. Poewe, G.K. Wenning

P569 Studies with 99mTc-TRODAT-SPECT in patients with different Parkinson's Syndrome
G. Dibo, M. Argyelan, B. Kanyo, F. Fuloep, L. Vecsei, L. Pavics

P570 Target acquisition in motor sequence learning correlates with caudate dopamine transporter density in early Parkinson's Disease
M. Carbon, F.M. Ghilardi, Y. Ma, A.S. Feigin, T. Chaly, D. Eidelberg

P571 The in vivo detection of iron and ferritins by Transcranial Sonography; a new approach for early diagnosis of Parkinson's Disease
L. Zecca, D. Berg, G. Becker, P. Riederer, M. Muscino, M. Gerlach

P572 White matter microstructural integrity in Parkinsonian hallucinations: a diffusion tensor imaging study
C.G. Goetz, M.E. Moseley, M.C. Camilo, J.D. Gabrieli, G.T. Stebbins

P573 A blinded, randomized comparison of GPi vs. SN stimulation in advanced Parkinson's Disease
J.P. Hammerstad, V. Anderson, J. Favre, P. Hogarth, K. Burchiel

P574 A cardiac pacemaker and thalamic deep brain stimulation (DBS) in the same patient: A case report
J. Lutke Farwick, T.V. Laar, K. Leenders

P575 A novel quality of life instrument for deep brain stimulation in movement disorders

P576 A study of HMPAO TC SPECT before and after sub-thalamic stimulation in advanced PD: Relationship with mood and neuropsychological changes
P. Charpentier, P. Lecouffe, C. Dujardin, M. Steinling, S. Blond, A. Destee

P577 Acute neuro-psychiatric symptoms following subthalamic electrodes implantation in Parkinson's Disease
C. Wider, J. Ghika, J.G. Villemure, A. Perrin, J. Bogousslavsky, F. Ringeroths

P578 Adductor Laryngeal Breathing Dystonia after sub-thalamic stimulation in a Parkinson's Disease patient
G. Salazar, P. Salazar, J.A. Finocchio, J.C.J. Jimenez, E. Tolosa, S. Starosta

P579 Adverse effects of subthalamic nucleus deep brain stimulation (SIN DBS) in multiple system atrophy
D. Apetauenerova, P. Ryan, T. Norregaard, D. Tarsy

P580 Age depending anatomical variations of the subthalamic nucleus: a postmortem study
W.F. den Dunnen, J.M. Staal

P581 Alleviating drug-induced psychosis and mood swings in a Parkinson's Disease (PD) patient by Subthalamic Nucleus (SN) stimulation: a case report

P582 An unusual phenomenon from SIN deep brain stimulation: suppression of paresisethesia from traumatic cervical subluxation
V.L. Wheelock, C.T. Pappas, S. Nielsen, C.K. Na-Lee, K.A. Sgvarzd

P583 Anatomical localization of contacts producing hypomanic personality changes with deep brain stimulation of the subthalamic nucleus
R. Fysinger, J. Bronstein, A. De Salles, Z. Vanek, I. Subramanian, E. Behnke

P584 Anatomical, electrophysiological and clinical correlations in subthalamic nucleus stimulation
T. Wijjas, J.-P. Azulay, T. Ochial, J.C. Peragut, J. Regis

P585 Behavioural effects of neurosurgery to the substantia nigra pars reticulata in Parkinsonian monkeys
J.M. Henderson, D.J. Finkelstein, D. Stanic, D. Tomas, J. Patch, D. Bourke

P586 Bilateral pallidal stimulation in primary generalized dystonia: preliminary results of the SPIDY French Multi-centric study
M. Vidalilhet, L. Veccuill, J. L. Houeto, P. Krystkowiak, S. Tezenas Du Montcel, A.L. Benabid

P587 Bilateral pallidotomy for severe dystonia in a child with Glutaric Aciduria: a case report
G. Rakovic, K.E. Lyons, S.B. Wilkinson, J. Kieltkya, R. Pahwa

P588 Bilateral posteroventral pallidotomy in Generalized Dystonia: a preliminary report
C. Maragoto, G. Lopez, R. Macias, L. Alvarez, J. Tejeiro, E. Tolosa

P589 Bilateral stimulation of the subthalamic nucleus disturbs emotional information processing
K. Dujardin, L. Defebvre, P. Krystkowiak, S. Blairy, S. Blond, A. Destee

P590 Bilateral subthalamic stimulation in advanced Parkinson’s Disease improves OFF duration and disease-severity at three months after surgery
F. Vaiznia, C. Sturila, S.A. Nassetti, A. Tiopeani, A. Bisull, C.A. Tassinari

P591 Bilateral subthalamic stimulation using anatomic landmarks on MR Imaging for localization-a preliminary result

P592 Blood pressure and heart rate in patients with Parkinson’s Disease following deep brain stimulation of the internal globus pallidus or subthalamic nucleus
G.R. Sigurdardottir, S. Rehncrona, M. Grabowski

P593 Brain perfusion SPECT before surgery and during high frequency stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson’s Disease
A. Antonini, R. Benti, C. Mariani, A. Landi, R. DeNotaris, M. Parolin
Poster Sessions

Poster Session 4 - Tuesday, November 12 Noon - 1:30 pm

P594 Burr hole ring and cap fixation in SIN-DBS: Technical note
J.C. Jimenez, P.M. Salazar, J.A. Finocchio, M.M. Rojas

P595 Cardiac pacemakers and deep brain stimulation in patients with movement disorders
H.H. Capelle, R. Simpson, M. Kronenbuerger, V. Tonnier, J. Michaelisen, J.K. Krauss

P596 Chronic bilateral medial thalamic (MT) stimulation for the treatment of diseases in 3 adult patients with Gilles de la Tourette's Syndrome (GTS)
C. van der Linden, H. Colle, V. Vandewalle, G. Alessi, D. Rijckaert, L. De Waele

P597 Chronic intraputaminal infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's Disease: an in-vivo dopa PET study
G.R. Hutton, S.S. Gill, N.K. Patel, P. Heywood, C.N. Svendsen, D.J. Brooks

P598 Chronic zona incerta stimulation improved Holmes' Tremor: a case report

P599 Clinical and acoustic study of the effect of bilateral subthalamic nucleus stimulation on Parkinson's disease
T. Ronzere, P. Auzou, C. Ozsancak, I. Rivier, Y. Lajat, M. Verin

P600 Chronic clinical outcome of bilateral subthalamic nucleus stimulation in patients with Parkinson's Disease and previous pallidotomy

P601 Community referral patterns of candidates for surgical treatment of movement disorders: the UCLA experience
I. Subramanian, A. DeSalles, J. Bronstein

P602 Comparison of outcomes of unilateral pallidotomy with unilateral subthalamic nucleus deep brain stimulation for Parkinson's Disease

P603 Computerized Posturography balance assessments of patients with bilateral VIM deep brain stimulation
W.G. Ondo, H. Cohen, J. Jankovic

P604 Contemporary bilateral targeting of GPi and SIN for DBS in Parkinson's Disease
P. Mazzone, G. Altbrandi, P. Stanzone, A. Insola

P605 Contribution of non-neurosurgeons in publications on surgery for Parkinson's Disease: a survey of old and modern literature
M.I. Hariz

P606 Correlations between perihemispheric electrophysiology, localization of the electrode and clinical outcome in SIN stimulation for PD
P. Esposito, P. Krack, S. Chabardes, A. Koudse, P. Pollack, A.L. Benabid

P607 Deep brain stimulation - stereotactic target localization using Magnetic Resonance Imaging
D. Urgosik, J. Vymazal, E. Ruzcka, J. Novotny, J.R. Jech, R. Liscak

P608 Deep brain stimulation in subthalamic nucleus in Parkinson's Disease: clinical results of a simplified technique
A.P. Jeanjean, A. Collard, J.-M. Guerit, C. Raftopoulos

P609 Deep brain stimulation in the subthalamic area for severe idiopathic Parkinson's Disease: relationships between location of active contacts and improvement of Parkinsonian symptoms
J.J. Lemaitre, J.Y. Boire, D. Debilly, F. Durif

P610 Deep brain stimulation of the bilateral subthalamic nucleus reduces the cost of anti-Parkinsonian medications
P.D. Charles, P.E. Konrad, E.J. Battle, B.L. Jacobs, J.Y. Fang, T.L. Davis

P611 Deep brain stimulation of the subthalamic nucleus increased striatal dopamine release in Parkinsonian humans?
R. Hilker, J. Voges, M. Ghaemi, K. Wienhard, V. Sturm, W.D. Heiss

P612 Differential effects of thalamic stimulation parameters on tremor and paraesthesias in Essential Tremor
S. Cooper, R. Baker, A. Kuncel, J. Henderson, W. Grill, E. Montgomery

P613 Differential response of PD symptoms to active electrode position in the subthalamic nucleus during deep brain stimulation
J.L. Shils, M. Tagliati, J. Miravitlles, B. Sullivan, R.L. Alterman

P614 Economic impact of the reduction in medication requirements after SIN deep brain stimulation in Parkinson's Disease
J.L. Shils, J. Miravitlles, M. Tagliati, R.L. Alterman

P615 Effect of bilateral deep brain stimulation on subthalamic nucleus in Parkinson's Disease on speech
A. Perrin, A. Carruzzo, J. Ghika, J.G. Villemure, J. Bogousslavsky, F. Vingerhoets

P616 Effect of bilateral subthalamic nucleus stimulation on tremor in Parkinson's Disease-a computerized qualitative study
C. Blahak, H. Baezner, E. Grips, J.C. Woehrl, H.H. Capelle, J.K. Krauss

P617 Effects of deep brain stimulation and levodopa on a variety of postural tasks in Parkinson's patients
F.B. Horak, P. Carlson-Kuhta, M. Stephens, A. Gross, P. Hogarth, K. Burchell

P618 Effects of subthalamic nucleus stimulation on corticospinal pathway and motor cortex excitability in Parkinson's Disease
V. Fraix, L. Vercueil, F. Mauquiere, A.-L. Benabid, P. Pollak

P619 Effects of thalamic deep brain stimulation on the cerebellothalamocortical pathway
G.F. Molnar, A. Sailer, C.A. Gunraj, A.E. Lang, A.M. Lozano, R.E. Chen

P620 Efficacy of subthalamic nucleus stimulation in advanced Parkinson's Disease depends on the accuracy of the intraoperative electrophysiological targeting: Study of 24 consecutive patients
J.P. Nguyen, P. Lefaucheur, F. Von Raison, J.M. Gumuchhaga, H. Shima, S. Oshino

P621 Electrophysiological changes in balance and gait control from bilateral STN-DBS in Parkinson's Disease: an in-depth case study
G.T. Mandybur, T. Lencolle, M. Kronenbuerger, V. Tronnier, J. Bogousslavsky, F. Vingerhoets

P622 Electrophysiological recordings of subthalamic neurons in Parkinson's Disease
U.M. Fietzek, D. Weinert, W. Hamel, A. Morinowski, J. Vollmann, R. Jan

P623 Electrophysiological recordings of subthalamic neurons in Parkinson's Disease
U.M. Fietzek, D. Weinert, W. Hamel, A. Morinowski, J. Vollmann, R. Jan

P624 Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's Disease (PD)
R. Mintner, M. Almaguer, M. Sanghera, R. Simpson, W.G. Ondo, J. Jankovic
Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

P657 Outcome of the SIN-DBS in patients that are not ideal candidates
G. A. Tagaris, A. Koulosakis, P. Ziros, C. E. Karageorgiou

P658 Pallidal deep brain stimulation for medically refractory dystonias

P659 Pallidal deep brain stimulation for PD: correlation of long term clinical outcome and active lead location

P660 Parkinson’s Disease (PD) patients with bilateral subthalamic deep brain stimulation (SIN-DBS) weight gain
F. Macla, F. Tison, I. Coman, C. Perlemoine, H. Gin, V. Rigalleau

P661 Pitfalls in microelectrode-guided stereotactic surgery for movement disorders: problems encountered and how to avoid them

P662 Possible role of GABA in the therapeutic efficacy of high frequency stimulation of the subthalamic nucleus
Parkinson’s Disease: a microwavable study in rats
F. Windels, N. Bruet, A. Poupard, C. Feuerstein, A. Bertrand, M. Savasta

P663 Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson’s Disease
R. Tintner, M. Almaguer, K.D. Vuong, W.G. Ondo, J.J. Jankovic, M. Sanghera

P664 Pre-operative assessment for DBS: are multiple core evaluations necessary?

P665 Relationship between vegetative and motor response in subthalamic area in a Parkinsonian patient with a previous contralateral pallidotomy
M. Mata, J.J. Lopez-Lozano, R. Martinez, J. Burzaco

P666 Results and adverse events in 50 consecutive PD patients
F. J. Vingerhoets, H. Russman, C. Pollo, J.G. Villemure, P.R. Burkhard, J. Ghika

P667 Safety and efficacy of microelectrode-guided thalamotomy for tremor
V.L. Wheelock, C.I. Higgin, C.T. Pappas, C.K. Na-Le, N. Khamphay, K.A. Sigvardt

P668 Severe dystonic-dyskinesia after electrical stimulation of the subthalamic area in a Parkinsonian patient with a previous contralateral pallidotomy
M. Mata, J.J. Lopez-Lozano, R. Martinez, J. Burzaco

P669 Sleep effects of bilateral subthalamic stimulation in Parkinson’s Disease

P670 Staged lesions through implanted deep brain stimulating electrodes: a new surgical procedure for treating tremor or dyskinesia
S. Raoul, M. Verin, M. Faighe, I. Rivrier, Y. Lajat, P. Damier

P671 StarFixÔ: a novel approach to frameless stereotactic neurosurgery utilizing a miniaturized customized pretargeted cranial platform fixture-technical description, unique features, and case reports
J. L. Franck, P.E. Konrad, R. Franklin, F. Haer

P672 STN DBS in Parkinson’s Disease patients above 70 years old
H. Russman, J. Ghika, J.G. Villemure, P.R. Burkhard, J. Bogousslavsky, J. Vingerhoets

P673 STN DBS complicated with cyanoacrylate granulomas and secondary staphylococcal infection
J.C. Jimenez, P.M. Salazar, J.A. Finocchio, G. Salazar, S. Starosta, R. Weiser

P674 Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)-induced dystonia and management with botulinum toxin (Botox) injections
R. Kumar

P675 Subthalamic stimulation does not improve autonomic dysfunction in Parkinson’s Disease

P676 Subthalamic stimulation in Parkinson’s Disease. The Gothenburg experience 1993-2000
B. Johnels, E. Augustinsson, O. Corneliusson, B. Holmberg, J. Ahlberg, J. Stammark

P677 Surgical treatment of essential tremor
I. Valask, J. J. Jow

P678 Surgical treatment of patients with movement disorders at Johns Hopkins Hospital: a 12-year experience
I.M. Garmunik, M. Barnes, L.H. Rowland, S.E. Hua, F.A. Lenz, S. Ohara

P679 The accuracy of pretargeting the subthalamic nucleus
S. Breit, J.F. LeBas, A. Koudsie, A. Benazzouz, J.B. Schulz, P. Pollak, A.L. Benabid

P680 The CM-PF complex- a target for the treatment of movement disorders? Review of previous experience and current pathophysiological concepts
R. Weigel, J.K. Krauss

P681 The effects of pallidotomy on articulatory function and perceptual measures of speech function in Parkinson Disease (PD)
A.M. Farrell, D.G. Theodoros, E. C. Ward, P. Slumb, B. Hall

P682 The kinetic of the effects of high frequency subthalamic stimulation on Parkinsonian rigidity and akinesia
M. Faighe, S. Raoul, Y. Lajat, P. Damier

P683 The timing of Antiparkinsonian treatment reduction after subthalamic nucleus stimulation
S. Thobois, S. Corravais, P. Mertens, G. Chazot, M. Sindou, E. Broussolle

P684 The use of bilateral deep brain stimulation of the subthalamic nucleus in advanced Parkinsons Disease patients previously reliant on apomorphine
T.R.K. Varma, S. Fox, P. Eldridge, P. Littlechild, P. Byrne, A. Forster

P685 Time requirements for assessment and programming of patients undergoing insertion of deep brain stimulators for movement disorders
K. Hunka, S. Wood, L. Derwent, Z. Kiss, O. Suchowersky

P686 Unilateral deep-brain stimulation (DBS) of the subthalamic nucleus (STN) in the treatment of advanced Parkinson’s Disease (PD)
N. Van Blercom, A. Lasa, E. Ramos, C. Magarinos, G. Linaresoro
Poster Sessions

Poster Session 4 - Tuesday, November 12, Noon - 1:30 pm

P687 Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson's Disease: a randomized, observer-blind, multi-center trial

P688 Use of unconscious sedation with propofol during implantation of deep brain stimulator (DBS) electrodes

P689 Behavioral correction of Parkinsonian rats by transplantation of immortalized fibroblasts genetically modified by TH gene and GCH gene

P690 Human neural stem cell transplantation in the MPTP-lesioned mouse

P691 In vivo neuronal differentiation of primate parthenogenetic ES cells (Cyno-1) after transplantation into the rat striatum
R. Sanchez-Pernaute, L. Studer, L. Bjorklund, O. Cooper, O. Isacson

P692 Stable outcome five years after embryonic dopamine cell transplantation for Parkinson's Disease is compatible with ongoing transplant development or lack of disease progression
C.R. Freed, K.B. Bjugstad, R.E. Breeze, P. Green, D. Edelberg, S. Fahn

P693 Survival and migration of transplanted neural stem cell-derived dopamine cells in the brain of Parkinsonian rat

P694 Transplantation of differentiated human embryonic germ cells rescues apomorphine-induced rotation in a mouse model of Parkinson's Disease

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

Poster numbers 695-850
Non-motor aspects of movement disorders, clinical, parkinsonism

P695 An abnormal sleep pattern and excessive movements can characterize patients with Huntington's Disease
M.H. Anca, N. Weizmann, A. Blonder, E. Davidov, N. Giladi, A.D. Korczyn

P696 Anxietas tibiarum. Depression and anxiety disorders in patients with Restless Legs Syndrome
J. Winkelmann, R. Lieb, H.U. Wittchen, M. Prager, C. Trenkwalder, A. Strohle

P697 Arginine-stimulated growth hormone (GH) secretion in patients with idiopathic Parkinson's Disease under chronic dopaminergic therapy
T. Vogt, S. Schäfer, P. Kann

P698 Bladder dysfunction in young patients with Parkinson's Disease
K. Winge, L.M. Werdelin, K. Krøyer, H. Stimpel

P699 Botulinum toxin type B (Myobloc) for drooling
J. Y. Fang, T. L. Davis

P700 Burden and distress in the caregivers of patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)
R.G. Brown, J. Hodges, B. Dubois, I. Utter, L. Lacomblez, Neuropsychology Working Group and NNIPPS Consortium

P701 Caregiver burden in corticobasal degeneration
S.L. Lewis, I. Litvan, A. E. Lang, M. Phipps

P702 Chronic unilateral thalamic stimulation for tremor: the effect of stimulation per se on neurobehavioral functioning

P703 Cognitive and motor deficits in patients with cerebellar degeneration
E. Stefanova, I. Ribnic, N. Dragasevic, M. Mijajlovic, M. Svetel, V. Kostic

P704 Cognitive challenge increases gait variability in patients with Parkinson's Disease
J. M. Hausdorff, J. Balash, N. Giladi

P705 Cognitive function in Essential Tremor: a comparison to Parkinson's Disease
C. I. Higginson, D. S. King, D. Levine, V. W. Wheelock, N. O. Khamphay, K. A. Sgvardt

P706 Cognitive function in patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)

P707 Cognitive Linguistic Quick Test (CLQT) and MMSE in Parkinson's Disease
M. L. Johnson, C. L. Wiens, S. A. Parashos, M. J. Fuhrman

P708 Cognitive, psychiatric and MRI findings in Wilson's Disease
E. Stefanova, S. Pejovic, I. Ribnic, M. Mijajlovic, M. Svetel, V. Kostic

P709 Correlates of generalized anxiety and panic attacks in dystonia and Parkinson's Disease
E. C. Lauterbach, K. D. Sethi
Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

P710 Deep brain stimulation of the subthalar nucleus versus dopaminergic agents and decision making in Parkinson's Disease

P711 Depression in Parkinson's Disease (PD): study of 60 cases
R.C. Prado, E.R. Barbosa

P712 Differential correlates of mood and cognition in dystonia and Parkinson's Disease
E.C. Lauterbach, K.D. Sethi

P713 Differential DIS-ascertained DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson Disease
E.C. Lauterbach, K.D. Sethi

P714 Effect of NT-3 on bowel function in Parkinson's Disease
R.F. Pfeiffer, K. Markopoulou, E.M. Quigley, N. Stambler, J.M. Cederaub

P715 Effect of apronine on depression and anhedonia in Parkinson's Disease patients
M.R. Lemke, M. Brecht, J. Koester, P.H. Kraus, H. Reichmann

P716 Evaluation of nocturnal pain symptoms in Parkinson's Disease using the Parkinson's Disease Sleep Scale. A case control study
A.N. Di Marco, S. Pal, C. Whately-Smith, K. Bridgman, C. Myint

P717 Health related quality of life and sleep disorders in Parkinson's Disease
T. Scaravilli, E. Gasparoli, G. Polesello, F. Rinaldi, F. Bracco

P718 Is Parkinsonian phenotype predictive of dementia? A cross-sectional study
D.J. Burn, E.N. Rowan, I.G. McKeith, J.T. O'Brien, T. Minett, P. Myint

P719 Long-term outcome of clozapine use for psychosis among Parkinsonian patients
H.H. Fernandez, E.M. Donnelly, J.H. Friedman

P720 Neurodegenerative illness and the evolution of art: the effects of corticobasal degeneration in a professional artist
G. Kleiner-Fisman, S.E. Black, A.E. Lang

P721 Neuropsychiatric and neuropsychological symptoms in patients with Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA)

P722 Orofacial praxis assessment in Parkinsonism
C. Oszancak, P. Auzou, K. Dujardin, A. Destee

P723 Platelets serotonin vesicular membrane transporters (VMAT2) in Parkinsonian patients with/without depression and controls
J.M. Rabey, M. Zucher, C. Klein, Y. Gordon, M. Rehavi

P724 Predictors of cognitive impairment in advanced Parkinson's Disease
G. Vingerhoets, S. Verleden, P. Santens, M. Miatton, J. De Reuck

P725 Predictors of time-use in patients with Parkinson's Disease
R.G. Brown, E. Worthington

P726 Psychiatric co-morbidities associated with psychosis in patients with Parkinson's Disease
L. Marsh, M.M. Rocco, J.R. Williams, C. Munro, S. Grill, TM. Dawson

P727 Psychometric characteristics of the Hospital Anxiety and Depression Scale in patients with Parkinson’s Disease

P728 Radiotherapy as treatment of hypersalivation in Parkinson’s Disease is effective and safe
T. Van Laar, M.A. Heesters

P729 Sensory symptoms and radiculopathies in Parkinson’s Disease

P730 A case of post-stroke rhythmic akathisia

P731 A case with Episodic Ataxia and Multiple Paroxysmal Dyskinesias
M. Demirkiran, D. Yerdelen, H. Uysal, Y. Sarica

P732 A clinical observational study of Restless Legs Syndrome in Parkinson’s Disease
S. Mandal, L.S. Appiah-Kubi, M.-C. Porter, K.R. Chaudhuri

P733 Alcohol induced movement disorders
S.A. Groppa, M.T. Ganea, L.E. Ziporjan, L.D. Iuimovschi, E.E. Zita

P734 Assessing characteristics of patients diagnosed with Restless Legs Syndrome using a primary care database
H. Petri, D. van de Vijver, T. Sampson

P735 Botulinum toxin treatment for drooling in children with neurological disorders
S. Hassan-Baer, E. Scheuer, A.S. Buchman, I. Jacobson, B. Ben-Zerev

P736 Brain MR imaging in patients with Wilson’s Disease
D. Kozic, M. Svetel, R. Semnic, I. Petrovic, N. Dragasevic, V.S. Kosic

P737 Brainstem interneuronitis causing hyperekplexia, gaze palsy and rigidity
S. O’Riordan, C. McGuigan, A. Vincent, S. Connolly, M. Hutchinson

P738 Brainstem involvement as onset of Stiff Limb Syndrome: a case report
F. Ceriani, N. Masetto, C. Rosci, M. Pietrogrande

P739 Cabergoline in advanced RLS - a double-blind placebo-controlled multicenter trial
K. Stiasny-Kolster, M. Ueberall, W. Oertel, German Cabergoline-RLS-Study-Group

P740 Centrally acting cholinesterase inhibitors in hyperkinetic movement disorders
K.A. Chung, J.G. Nutt, S.W. Johnson

P741 Chronic neurological problems in patients with Wilson's Disease
M. Velickovic, M.L. Schilsky

P742 Complete remission of severe Restless Legs Syndrome after relief of iron deficiency: a case report
B. Frauscher, B. Hoegl, E. Brandauer, M. Saletu, A. Muigg, W. Poewe

P743 Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire
J. Marinus, H. Benes, C.R. Heinrich, B. Kurella

P744 Diagnosing large volume CSF removal in patients with suspected NPH: evaluation of hearing
O. Leheta, S. Sander, M. Huelse, K. Hoermann, J.K. Krauss

P745 Ear dyskinesias
L. Carlier, C. Schupp, G.-L. Defer
P746 Early onset dystonia/chorea ataxia secondary to GLUT-1 deficiency, responsive to ketogenic diet
J. Friedman, E.A. Thiele, D. Wang, D.C. DeVivo, P. Penny, P. Heid
P747 Effect of selegiline on autonomic functions in Parkinson’s Disease
M. Behari, R. Thomas, S. Singh, V. Goyal, T. Srivastava, K.K. Deepak
P748 Effects of Gabapentin on Restless Legs Syndrome. Results of a double-blind, crossover study with polysomnographic control on 24 patients
P749 Effects of motor, psychiatric and cognitive impairment on physical disability in Parkinson’s Disease
S.S. Bassett, L. Marsh, T.M. Dawson
P750 Facial myokymia and chin tremor in Celiac Disease
P. Vrentas, V. Panayiotopoulou, G. Tagaris, S. Sameli, V. Krikakis, C. Clarke
P751 Familial dementia masquerading as Huntington’s Disease
C.S. Ivan, M. Saint-Hilaire, J.M. Milunsky
P752 Festination as a symptom of aqueductal stenosis and its treatment by CSF diversion
O. Lehet, J. Boschert, I. Whittle, J.K. Krauss
P753 Gait and Balance Scale (GABS): validation and utilization
M. Thomas, J. Jankovic, M. Suteerawattanon, S. Wankadia, K. Caroline, E. Protas
P754 Gait variability & fractal dynamics of older adults with high level gait disturbances
T. Herman, T. Gurevich, R. Baltadjeva, N. Giladi, J.M. Hausdorff
P755 Hemifacial spasm: a clinical and epidemiological study in 52 patients
C. Colosimo, M. Chianese, S. Romano, V. Della Chiara, N. Vanacore
P756 High frequency of affected first and second degree relatives of restless legs probands
W.A. Hening, T. Washburn, R.P. Allen, C.J. Earley
P757 Iron-chelating therapy in a case of hereditary centrolamin deficiency with motor disturbances
U. Bonuccelli, C. Lucetti, L. Petrozzi, S. Bosio, M.C. Bianchi, C. Camaschella
P758 Long-term kinetics of anti-GAD65 antibody suppression by intravenous gamma globulin in a study of 15 patients with type 1 diabetes mellitus
E.B. George, M.S. Mohamed
P759 Manifestation of movement disorders after intervertebral disc surgery: causal relationship or coincidence?
P760 Mitrazapine induces confusion with hallucinations and REM sleep behaviour disorder in Parkinsonism
M. Onofrj, A.L. Luciano, D. Iacono, G. D’Andreamatteo, A. Thomas
P761 Movement disorders in Multiple Sclerosis
A.V. Sinwasan, R.R. Lakshmi Narasimhan, C.U. Velmurugendran
P762 Neuroacantocytosis clinico-pathological study of a family with different phenotypes
G.J. Amango, M. ‘Enoro, E. Marulanda, G. Toro, P. Lorenzana, W. Fernandez
P763 Neuropsychological deficits in patients with treated Wilson Disease
K. Portala, S. Levander, K. Westemark, L. Eksellus, L. von Knorring
P764 Normal pressure hydrocephalus presenting as chorea
Z. Unal, E. Gozke, E. Deniz, O. Us
P765 Painful legs and moving toes: evidence for a central origin
A. Coeytaux, Y. Blanc, H. Groetzsch, M. Chofflon, T. Landis, P.R. Burkh
P766 Periodic Limb Movement Disorder after stroke in three patients with supratentorial lesion
H.I. Ma, S.C. Jeong, K.H. Yu, B.C. Lee
P767 Paroxysmal dyskinesias and ataxias in the South of Brazil
H.G. Têve, N. Becker, M.H.B. Heroíza, L.C. Wemeck
P768 Quality of life in Parkinson’s Disease: what do we measure and how does it affect our results?
E. Moro, P. Cortelli
P769 Restless Legs Syndrome in Parkinson’s Disease: a case - controlled study
M. Behari, P.R. Krishnan, M. Bhatia
P770 Restless Legs Syndrome (RLS) is a common disorder rarely diagnosed in Europe or USA: the REST (RLS Epidemiology, Symptoms and Treatment) study in primary care
P771 Restless Legs Syndrome: absence of specific tau- and alpha-synuclein pathology
P772 Restless Legs Syndrome (RLS) is a common disorder rarely diagnosed in Europe or USA: the REST (RLS Epidemiology, Symptoms and Treatment) study in primary care
P773 Randomised, open label, crossover, comparator trial of doctor and nurse-given buterin toxin injections
P. Moore, D.J. Rog, R. Bulloch, D. Collins
P774 Resanalysed, open label, crossover, comparator trial of doctor and nurse-given buterin toxin injections
P. Moore, D.J. Rog, R. Bulloch, D. Collins
P775 Restless Legs Syndrome in Parkinson’s Disease: a case - controlled study
M. Behari, P.R. Krishnan, M. Bhatia
P776 Rotigotine CDS (Constant Delivery System) in the treatment of moderate to advanced stages of Restless Legs Syndrome - a double-blind, placebo-controlled pilot study
K. Slaisny, H. Benes, R. Bodenschatz, J.C. Moller, E. Schollmayer, W.H. Oettle, RTG Study Group
P777 Stiff-person syndrome associated with anti-amphiphysin antibodies: neuropathology and antibody-binding studies
M. Naumann, C. Sommer, C. Wessig, K. Tofla
P778 Stiff-person Syndrome presenting with asymmetric axial muscle spasms and hypotrophy
C. Chuang
P779 Successful treatment of recalcitrant Restless Legs Syndrome with butulinum toxin A
K.M. Kudelko, J.S. Rotenberg, M.P. DiFazio, E. Jabbari
P780 Suppression of syncopes after butulinum toxin treatment
E. More, P. Cortelli
Poster Sessions

Poster Session 5 - Wednesday, November 13, 7:00 am - 8:30 am

P830 Parkinsonian phenotype is associated with late onset and low abnormal range of CAG repeat in Romosa SC2A families
C.S. Lu, Y.H. Wu Chou, P.C. Kuo, H.C. Chang, T.C. Yen, Y.H. Wen

P831 Parkinsonism and dropped head (PADRH): a coincidental finding or a new presentation of mitoc hondrial disorders?
M. Merello, J.C. Legarre, A. Javelle, G. Piran Arce, M. Garcia Alvarez, A. Cammarota

P832 Parkinsonism and the response to treatment in Dementia with Lewy Bodies (DLB)

P833 Parkinsonism responsive to plasmapheresis treatment in a case of Multiple Sclerosis

P834 Parkinsonism, manganese and brain imaging in liver failure
M.A. Brodsky, M.L. Schilsky, D.J. Bronster, G. Fatterpekar, T.P. Naidich, W. Olanow

P835 Pathology of primary progressive freezing gait: a case report
S.A. Factor, J. Qian, A.J. Santiago

P836 Progressive Supranuclear Palsy and Multiple System Atrophy: difficulties of diagnostic
F. Bloch, M.L. Welter, O. Messouak, A.M. Bonnet, M. Vidailhet, the NNIPPS Study Group

P837 Protective effect of riluzole in a double lesion rat model of Multiple System Atrophy
N. Stefanova, T. Sather, W. Poewe, G.K. Wenning

P838 PSP: MRI and clinical correlates

P839 Quality of death certification in Progressive Supranuclear Palsy
M. Tuncel, E. Schmutz, R. Thomson, A. Lees, D. Burn

P840 Re-emergence of Encephalitis lethargica-like syndrome: evidence of CNS autoimmunity
R.C. Dale, A.J. Church, R.A. Surtees, A.J. Lees, B.G. Neville, G. Giovanni

P841 Service use and costs of Parkinson’s Plus Syndromes
P. McCrone, P. Aigd, G. Bensimon, N. Leigh, A. Ludolph

P842 SL V318: novel antiparkinsonian agent with antidepressant and anxiolytic-like actions
T. Tuinstra, J. van der Heyden, J. Glennon, L. Smith, P. Jenner, G. Bensimon

P843 Sputum and serum substance P in Parkinson’s Disease

P844 Subtle mirror movements in Hemiparkinsonism: a useful clinical sign (preliminary observations)
A.J. Espay, J. Li, R. Chen, A.E. Lang

P845 The accuracy of clinical diagnosis of Progressive Supranuclear Palsy
Y. Osaki, C. Colosimo, Y. Ben-Shlomo, G. Wenning, N. Quinn, A. Lees

P846 The sensitivity and specificity of weight-loaded, computer-assisted polymography in the differential diagnosis of tremor
A.J. Espay, J. Li, R. Chen, A.E. Lang

P847 Three dimensional magnetic resonance based volumetry in Multiple System Atrophy
T. Tuinstra, J. Glennon, L. Smith, P. Jenner, G. Bensimon

P848 Transcranial magnetic stimulation in corticobasal degeneration: a report of two cases
S. Thonke, H. Baas

P849 Upper body involvement in lower body Parkinsonism – a study based on three-dimensional computerized movement analysis
H. Baezner, J. Schanz, E. Gripps, J.C. Woehlke, M.G. Hennerici

P850 Use of the Thermoregulatory Sweat Test to discriminate Multiple System Atrophy from Parkinson Disease with autonomic failure and from Progressive Supranuclear Palsy
R.M. Hutchman, J.E. Ashkog, R.D. Fealey
Poster Sessions

Poster Session 6 - Wednesday, November 13
Noon - 1:30 pm

Poster numbers 851-1020
Clinical Electrophysiology, Dystonia
Poster numbers 851-1020

P851 A case of “painful shoulder, undulating deltoid” syndrome
Z. Mili, M. Hallett

P852 A study of abnormal head retraction reflex elicited by facial sensory stimulation
A. Hayashi, Y. Kohn

P853 Acoustic startle reflex, acoustic blink reflex and electro-oculography in atypical Parkinsonian Syndromes: a prospective study
A. Girone, J. Kulisevsky, C. Roig, P. Pascual-Sedano, A. Rodriguez-Fomells, P. Otermin

P854 An EMG-analysis of Parkinsonian gait

P855 Applications of transcranial magnetic stimulation in movement disorders
R. Tarletti, R. Cantello

P856 Assessment of impairment of corticale inhibitory mechanisms in blepharospasm and cervical dystonia: a study of silent period evoked by transcranial magnetic stimulation
R. Cakmur, B. Donmez, F. Uzunel, H. Aydin, S. Kesken

P857 Automatic EMG in assessment of cervical dystonia treated with botulinum toxin
S. W. Cichy, C. W. Glazowski, M. Wieclawka

P858 Bilateral pallidal deep brain stimulation and somatosensory automatic EMG in assessment of cervical dystonia treated
R. Cakmur, B. Donmez, F. Uzunel, H. Aydin, S. Kesken

P859 Cortical activation related to voluntary muscular relaxation
F. Cassim, E. Labyt, J. L. Bourniez, P. Derambure, A. Destee, J. D. Guieu

P860 Cortical silent period in Essential Tremor
M. Behari, G. Shukla, M. Bhatia, R. M. Pandey

P861 Deficient sensorimotor integration in Parkinson’s Disease
A. Sailer, G. F. Molnar, G. Paradiso, A. E. Lang, R. Chen

P862 Effect of aging on anticipatory postural adjustments: interest of vertical torque
S. Bleuse, F. Cassim, J. L. Blatt, L. Depré, A. Destee, J. D. Guieu

P863 Effect of high-frequency stimulation on the cellular activity of subthalamic nucleus in Parkinson’s Disease
A. F. Sadikot, A. P. Srafela

P864 Effects of subthalamic nucleus deep brain stimulation and muscle vibration on motor cortex excitability in advanced Parkinson’s Disease
T. Peschel, J. D. Daeuper, C. Schrader, R. Dengler, J. D. Rollnik

P865 Excitability changes of group II afferents interneuronal transmission in rigid lower limb of de novo patients with Parkinson’s Disease
M. Simonetta-Moreau, S. Meunier, M. Vidalilhet

P866 Gait disturbances induced by bilateral pallidal lesions
P. Krystkowiak, L. Depré, J. L. Blatt, J. D. Guieu, A. Destee

P867 High frequency repetitive TMS can cause lasting effects on cortico-cortical coupling of motor areas with behavioural consequences
A. Oliviero, L. H. Strens, V. Di Lazzaro, P. A. Tonali, P. Brown

P868 Illustration of a micro lesion effect by semi microrecording of the SN
H. L. Journée, L. Lamers, A. A. Postma, M. J. Staal, T. vanLaar, on Behalf of the Groningen Functional Stereotaxy Study Group

P869 Intracortical modulation of transcortical inhibition
P. A. Shanahan, G. Mazbrada, J. C. Rothwell

P870 Intraoperative recording of local field potentials for assisting localisation of the targets for deep brain stimulation
X. Liu, D. Nandi, J. F. Stein, T. Z. Azziz

P871 Neurophysiological explanation of possible role of Peripheral Facial Palsy in development of cranial dystonia
T. A. Filipova, O. R. Orlova, A. M. Vein

P872 Peripheral silent periods in Essential Tremor
M. M. Behari, G. G. Shukla, M. M. Bhatia, R. M. Pandey

P873 Premovement potentials from the subthalamic nucleus and ventrointermedius nucleus of the thalamus in humans with self-paced and externally triggered movements
G. Paradiso, D. Cunic, G. F. Molnar, A. E. Lang, A. M. Lozano, R. Chen

P874 Quantitative measurement for Parkinson’s Disease: DatacqO gloves
Y. Su, U. Brechany, D. J. Burn, D. Geng, D. Bell, C. R. Allen

P875 Relevance of multi channel micorecording electrode in deep brain stimulation of the subthalamic nucleus in Parkinson’s Disease
D. Servello, L. Geremia, V. De Smone, C. Paccchetti, S. Radice, M. Fornai

P876 Results of neurophysiological investigation in Parkinson’s Disease patients
E. I. Gusev, A. B. Guekht, G. V. Serkin, E. S. Chikina, Y. A. Merkulov

P877 Short-term effects of pallidal stimulation on motor cortex output in patients with dystonia: a TMS-study
A. A. Kuehn, A. Kupsch, T. Trottenberg, G. H. Schneider, S. A. Brandt, B. U. Meyer

P878 Single tract semi-micro electrode recording to identify the subthalamic nucleus in Parkinson’s Disease
E. C. Lamers, H. L. Journée, A. A. Postma, T. Laar van, M. J. Staal

P879 Spectral differences in local field potentials recorded from globus pallidus in treated and untreated Parkinson’s Disease (PD) and dystonia
P. Silberstein, P. Brown, A. Kuhn, A. Kupsch, V. Di Lazzaro, T. Azziz

P880 Tapping and peg insertion after apomorphine injection in Parkinsonian patients
T. Muller, S. Benz, C. Bomke, H. Przuntek

P881 Transcallosal inhibition in patients with corticobasal degeneration
C. Trompetto, A. Buccolieri, R. Marchese, L. Avanzino, G. Abruzzese

P882 Trigeminocervical reflexes: normative data and application to cervical dystonia patients

P883 Visual evoked potentials in Lewy body dementia and Alzheimer’s Disease
Z. Pirtosek

P884 12 Years follow-up and natural history of Blepharospasm and Meige-Syndrome treated with Botulinum toxin A
P. Haussemer, S. Marczach, C. Klinger, M. Landgrebe, B. Conrad, A. Ceballos-Baumann
Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

P886 12 years follow-up and natural history of Cervical Dystonia treated with Botulinum toxin A
P. Hausermann, C. Kingler, S. Marczoch, M. Landgrebe, B. Conrad, A. Ceballos-Baumann

P887 A Clinical trial with Cabergoline in patients with advanced Parkinson Disease: one or several doses. A clinical preview
M.E. Esteguy, J. F. Fusillo

P888 A novel mutation in the epsilon-sarcoglycan gene causing atypical Myoclonus-Dystonia Syndrome in a large Danish family

P889 A phenotypic study of Irish families with adult-onset focal cranio-cervical dystonia
S. O’Riordan, T. Lynch, S. Bressman, M. Hutchinson

P890 A remarkable association of generalized dystonia, Huntington’s Disease, Progressive Supranuclear Palsy and Secondary Paroxysmal Dysthesia in one family

P891 Abnormalities of somatotopy of sensorimotor interactions in patients with focal dystonia
S. Tamburin, P. Manganotti, A. Andreoli, A. Fiaschi, G. Zanette

P892 Aids-related symptomatic dystonia improvement after botulinum toxin type a: a treatment a case report
G. Lagalla, M. Milevolte, C. Gioia, M. Danni, L. Provinciali, M. Cerasolo

P893 An 11C-diprenorphine PET study investigating opioid binding

P894 Botulinum toxin type B (Myobloc) is safe and effective for treating adductor spasmodic dysphonia: a functional MRI study

P895 Botulinum toxin type B (Myobloc) at doses > 10,000 units for the treatment of cervical dystonia: two case studies
L.K. Struck

P896 Botulinum toxin type B (Myobloc) at doses > 10,000 units for the treatment of hemifacial spasm and blepharospasm
L.K. Struck

P897 Brain activation during complex finger tapping in patients with writer’s cramp: a functional MRI study
G. Iannetti, A. Curra, P. Pantano, A. Suppa, L. Bozzo, A. Berardelli

P898 Camptocormia secondary to adult-onset dopa-responsive dystonia
J.A. Van Gerpen, D.M. Maraganore

P899 Candidate gene research in focal dystonia excludes involvement of ATP7A, ATP7B, ATOX, HLA-DR and MTHFR
O. Bandmann, D. Sibbing, F. Asmus, I. Köenig, M. Grundmann, A. Ziegler

P900 Bilateral pallidal stimulation for treatment of Meige Syndrome: results in four patients after one year
K. Vermilion, J. Peterson, D. Duane

P901 Bilateral deep brain stimulation for treatment of hemifacial spasm and blepharospasm: a pilot study
M. Chiarese, M. Giovannelli, F. Contarino, A.R. Bentivoglio, C. Colosimo

P902 Botulinum neurotoxin B in blepharospasm and hemifacial spasm: a pilot study
M. Chiarese, M. Giovannelli, F. Contarino, A.R. Bentivoglio, C. Colosimo
Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

P961 Long-term safety, efficacy, and dosing of botulinum toxin type B (Myobloc) in cervical dystonia (CD) and other movement disorders
R. Kumar, L.C. Seeger, Be

P962 Mirror dystonia (mirror movements) in writer's cramps and thera
pic outcome with botulinum toxin - a prospective study
R. Borghain, M.A. Kankannan, S. Sattaluri, J. Mani, M. Surya

P963 Motor planning and interhemispheric relationship in dystonia and Parkinson's Disease

P964 Movement disorders, cervical spondylosis and myelopathy
TJ. Loher, C.B. Balofcher, J.K. Krauss

P965 Muscle relaxation is impaired in dystonia: a reaction time study
G. Abbruzzese, A. Buccolieri, R. Marchese, C. Tompetto, L. Marinelli

P966 Neuronal GP activity in patients with generalized dystonia
M. Merello, F. Micheli, D. Cerqueti, J. Antico, A. Camarota, E. Benca

P967 Novel neuropathological findings in 'Lubag' or x-linked Dystonia-Parkinsonism
V.G.H. Evidente, D. Dickson, A. Singleton, F. Natividad, J. Hardy, D. Hernandez

P968 Ontogenetic increases of striatal GABAergic interneuron density in a genetic animal model of primary paroxysmal dystonia
A. Richter, M. Hamann

P969 Pallidal DBS in seven patients with primary and secondary generalized dystonia
M. Tagliati, J.L. Shils, S. Bressman, R.L. Alterman

P970 Paroxysmal dystonia in a MS patient with cervical spinal cord lesion
L. Carluco, I. Leber, G. Defer

P971 Patients with cervical dystonia thought to be secondary non responders to botulinum toxin treatment should be given a trial of EMG guided injections
C. Cordivari, A. Vincent, V.P. Misra, S. Catania, K.P. Bhatia, A.J. Lees

P972 Postsynaptic dopaminergic function in idiopathic cervical dystonia: a PET study
H.M. Ruottilin, H. Efjanti, K. Nagren, V. Oikonen, R. Marttila

P973 Prevalence of primary dystonia in the Belgrade population. Preliminary report
T. Pekmezovic, N. Ivanovic, M. Svetel, V.S. Kostic

P974 Pseudoathetosis or sensory dystonia
N.M. Biay, B.A. Yaqub, S.M. Al Deeb

P975 Quantitative EMG and MRI volumetry of cervical muscles in Torticollis spasmodicus
P. Haussemann, C. Bischoff, N. Draheim, H. von Einsiedel, B. Conrad, A. Ceballos-Baumann

P976 Reliability and validity of the PIMSE cervical dystonia patient self assessment scale
M. Welsh, C. Kawai, G. Broutman, B. Lopez, M. Lew

P977 Retrospective evaluation of Dysport® and BOTOX® drug utilization in the management of patients with cervical dystonia or blepharospasm
R. Maga, A. Marchetti, F. Ahmed, I. Ferguson

P978 Role of the platysma muscle in Cervical Dystonia and experience with surgical denervation/resection of this muscle
C.A. Arce

P979 Safety and efficacy of Botulinum Toxin “BT” in facial hemispasm
G. Iani, G. Santamato, F. Saponieri, P. Diello, G. Megna

P980 Safety and efficacy of injection of psosas major muscle with botulinum toxin type A in early adulthood-onset idiopathic torsion dystonia
S.S. Ochudlo, G.G. Opala, J.J. Baron

P981 Screening methods for Dystonia: Beth Israel Medical Center Dystonia Telephone Screen
J. Shiberg, J. Soto, K. Habermann, D. Raymond, S. Bressman, R. Saunders-Pullman

P982 Screening of a large cohort of movement disorder patients and controls for the GAG deletion in the DYT1 gene and detection of a novel mutation
K. Kabakci, P.P. Primstaller, K. Hedrich, L.J. Ozelius, V. Kostic, C. Klein

P983 Selective peripheral denervation for the treatment of Spasmodic Torticollis technique and results
A.A. Cohen-Gadol, E.J. Ahlskog, J.Y. Matsumoto, M.A. Swenson, D.H. Davis

P984 Sensitivity and specificity of a screening method for dystonia

P985 Sensor-motor coupling is deficient in focal task dystonia
M. Simonetta-Moreau, M. Vidalhart, J. Lourenco, S. Meunier

P986 Sequence learning is impaired in clinically unaffected carriers of the DYT1 mutation
M.F. Ghilardi, M. Carbon, G. Silvestri, V. Dhanaw, M. Tagliati, S. Bressman

P987 Seven-year experience of cranio-cervical spasm disorders treatment with Botulinum-A toxin: short- and long-term effects
S.L. Timmeriaeva, E.D. Markova, I.A. Ivona-Smolenskaya, N.G. Savitskaya, O.Y. Rebrova

P988 Signs for shoulder girdle dystonia in selected patients with cervical disc prolapse

P989 Similarities and dissimilarities between patients with cervical dystonia with and without tremor and essential tremor: family history, cognition and affective state
J.D. Peterson, K.J. Verniown, D.D. Duane

P990 Somatosensory processing in cranial dystonia: neurophysiological observations and effect of botulinum toxin treatment with Botulinum-A toxin: short- and long-term effects

P991 Spasmodic torticollis and hemifacial spasm after electrically induced injury
S.M. Kuniyoshi, D.E. Riley

P992 Spinocerebellar ataxia 3 (SCA3) cousins presenting as dopa-responsive dystonia
J.H. Tan, E. Wilder-Smith

P993 Spinal volume and energy consumption in improved dystonic patients treated by high frequency GPi stimulation
S. Hemm, N. Diakonova, G. Mennessier, N. Vayssiere, L. Cif, P. Coubes

P994 Stimulation - drug interactions in chronic deep brain stimulation of the internal globus pallidus for risperidone-responsive segmental dystonia
J.C. Wohrle, R. Weigel, E. Grips, C. Blahak, H.H. Capelle, J.K. Krauss
Poster Sessions

Poster Session 6 - Wednesday, November 13, Noon - 1:30 pm

P995 Striatal extracellular monoamine levels in a genetic animal model of primary paroxysmal dystonia
M. Hamann, A. Richter

P996 Study of mutant and wild type torsinA in human SH-SY5Y cell lines

P997 Study of the electrical stimulation of the internal globus pallidus by functional Magnetic Resonance Imaging
M. Zanca, B. Bataille, G. Morrot, N. Vayssiere, S. Hemm, P. Coubes

P998 Subthalamic nucleus deep brain stimulation (SN-DBS) in a patient with X-linked Dystonia-Parkinsonism (XPD): a case report
O.V. Kopyov, R.F. Young, K. Spes, B. Copcutt, J.P. Sutton

P999 Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex in writer's cramp
N. Murase, R. Kaji, N. Murayama, T. Igasaki, J.C. Rothwell, H. Shibasaki

P1000 Sudden loss of benefit from botulinum toxin for Spasmodic Torticollis
D.E. Riley

P1001 Surround inhibition is impaired in patients with focal hand dystonia during movement preparation
F.M. Molloy, Y.H. Sohn, M. Hallett

P1002 Temporal discrimination of unimodal and cross-modal tactile and visual stimuli in primary dystonia
M. Tinazzi, M. Florio, N. Smania, S. Tamburin, A. Fiaschi, S.M. Aglioti

P1003 The auditory startle response in cervical dystonia
J. Mueller, M. Koffer, W. Poewe

P1004 The differences between dystonic movement in primary and secondary dystonia
J.S. Dedic, N.S. Ivanovic, M.V. Svetel, S.N. Dedic, V.S. Kostic

P1005 The disorder of cortical excitability and cortical inhibition in focal dystonia is lateralized: an evidence from somatosensory evoked potentials and transcranial magnetic stimulation recordings
P. Kanovsky, M. Bares, H. Streitova, H. Klajblova, P. Daniel, I. Rektor

P1006 The effects of clozapine on treatment of genaralized and focal dystonia
M. Kapiszzi, J. Kruja

P1007 The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia; results of the first US study
D.D. Truong, D.D. Duane, J. Jankovic, C. Singer, C.L. Comella, the US Dysport Dystonia Study Group

P1008 The efficiency of continuous intrathecal baclofen for the treatment of generalized dystonia. Our experience in four cases
J. Chacon, R. Vahi, M.A. Grande, E. Duran, M.D. Paramo, M. Alvarez

P1009 The MIND Patient Registry: capturing the clinical uses of MyoblocÔ
M. Royal, C. Towey, D. Bevers, C. O Briien

P1010 The natural history of posttraumatic torticollis
K.P. Frei, M. Pathak, S.W. Jenkins, D.D. Truong

P1011 The yips: an electrophysiologic evaluation
C.H. Adler, J.N. Caviness, D. Crews

P1012 Transient blepharospasm secondary to striatal infarction
L. Lopez, S. Garcia, F. Diaz, A. Gil, A. Traba, F. Grandas

P1013 Treatment of adductor laryngeal breathing dystonia with tetrabenzine
M.G. Jabre, W.W. Bejjani, B.P.W. Bejjani

P1014 Treatment of dystonia due to Pantothenate Kinase Associated Neurodegeneration (PKAN) by GPI stimulation (DBS)
A. Gannau, P.A. Castelnau, L. Clf, S. Hemm, P. Evrard, P. Coubes

P1015 Treatment of hemi facial spasm with Botulinum toxin-B (Myobloc)
A. Ahmed, A. Kanwaliit, T. Subramanian, J.S. Perumal

P1016 Treatment of limb dystonia with botulinum toxin - type B
M.A. Stacy

P1017 Two cases of task-specific movement disorders
J.S. Baik, J.H. Park, Y. Kim, Y. Min

P1018 Unusual phenotypes in DYT1 dystonia - a report of 5 cases and a review of the literature

P1019 What are the predictive factors of good outcome in writer’s cramps treated with Botulinum toxin injections?

P1020 Writer's cramp treated with hand immobilization
S. Badarny, J. Meer, T. Drori, S. Zivziner, S. Honigman
**Poster Sessions**

**Poster Session 7 - Thursday, November 14**
7:00 am - 8:30 am

**Poster numbers 1021-1182**

Ataxia, Chorea, Drug-induced Movement Disorders, Myoclonus, Spasticity, Stereotypies, Tics, Tremor

---

**P1021** Abnormal striatal dopaminergic function in SCA2 revealed by beta-CIT and IB2M SPECT
S.M. Boesch, M. Schocke, K. Seppi, P. Hollosi, W. Poewe, G.K. Wenning

**P1022** Antioxidant treatment of patients with Friedreich's Ataxia: 3 year follow up
P.E. Hart, R. Lodi, B. Rajagopalan, J.L. Bradley, D.J. Taylor, J.M. Cooper

**P1023** Ataxia: a common movement disorder in central nervous system Whipple's disease
L.K. Jones, K. Joseph, D.A. Saad, A. Aksamit, J.E. Ahlskog

**P1024** Cerebellar degenerative ataxias - terminology, classification and diagnostic criteria
N.P. Nikoelvić

**P1025** Clinical and electrophysiological peculiarities of ataxia of different origin
M. Ganea, S. Groppa, E. Zota, L. Lüthimovschi

**P1026** Concordance between two methods for measurement of dystonia

**P1028** Early-onset ataxia associated with oculomotor apraxia and hypoalbuminemia (EAOH), a variant form of Friedreich's ataxia - Clinical and genetic analyses
O. Onodera, H. Date, A. Yokoseki, S. Igarashi, H. Tanaka, S. Tsuji

**P1029** Gluten sensitivity in Huntington's Disease
K.O. Bushara, C.M. Gomez, M. Nance

**P1030** High-dose Pracetam is effective on cerebellar ataxia in a patient with cerebellar cortical atrophy
M. Vural, S. Ozekmekci, H. Apaydin, A. Altinel

**P1031** Idiopathic late onset cerebellar ataxia: a follow-up study of 12 years
H.G. Teve, W.O. Amuda, L.C. Wemeck

**P1032** Movement disorders in a series of 83 spinocerebellar ataxia families
H.G. Teve, W.O. Amuda, L.C. Wemeck

**P1033** Open-label trial of gluten-free diet in sporadic and hereditary cerebellar ataxia with gluten sensitivity
K.O. Bushara, H.S. Shill, M. Hallitt

**P1034** Progressive cerebellar syndrome as the first manifestation of HIV infection
I. Puertas, F.J. Jiménez-Jiménez, C. Gómez-Escalonilla, Y. Sayed, F. Cabrera-Valdivia, R. Rojas

**P1035** relentlessly progressive myoclonic ataxia in gluten sensitivity: a case presentation
M. Eccher, M.A. Wein, D.E. Riley

**P1036** SCA10 description of 2 families with different phenotype
H.G. Teve, T. Ashizawa, S. Raskin, W.O. Amuda, B. Roa, L.C. Wemeck

**P1037** SCA2 and Multiple Sclerosis: a case report
P. Hollosi, M. Schocke, S.M. Boesch

---

**P1038** Validation and use of assessment protocols to determine clinical progression in Friedreich's Ataxia
J.L. Bradley, P.E. Hart, M. Al Khayatt, A.H. Schapira, J. Cooper

**P1039** A case of abetalipoproteinemia with a choreic-ataxic syndrome and none of the known mutations
S. Konitsiotis, C. Mokou, S. Kalantaridou, M. Symrou, M. Kavarioti, A. Tatsoulis

**P1040** A case of hemichorea with an ipsilateral thalamic infarction
J.S. Baik, J.H. Park, J.Y. Kim, Y.K. Minn

**P1041** Assessment of Huntington's Disease - correlation between motor and cognitive deficits
R. Reilmann, F. Kirsten, L. Quinn, H. Henningens, K. Marder, A.M. Gordon

**P1042** Benign Hereditary Chorea: neuropathological findings
G. Klein, M. Kilman, W. Halliday, A.E. Lang

**P1043** Chorea and contraceptives: A case report with PET study
L. Vela, C. Sänger, G.N. Stakianakis, D. Herro, W.C. Koller

**P1044** Chorea and orobuccal dyskinesia due to Hansen's Disease
L.S. Boylan

**P1045** Chorea in a 21-year-old female associated with multiple risk factors
M. Zeák, S.M. Vergenz

**P1046** Clinical and genetic heterogeneity in Benign Hereditary Chorea

**P1047** Clinical care for HD-patients: five years of experience in Germany
J. Andrich, C. Saft, I. Wilhelms, P.H. Kraus, H. Pzuntnek

**P1048** Clinical characteristics of Huntington's Disease in Albania
M. Kapisyzi, A. Kujo, G. Nurja, G. Vito, J. Kuja

**P1049** Clinical improvement after neuronal graft in Huntington Disease (HD) is related to striatal and cortical metabolic changes
V. Gaura, A.C. Bachoud-Lévi, J.P. Nguyen, P. Hantraye, M. Peschanski, P. Remy

**P1050** Cortical dopamine D2 receptor dysfunction in Huntington's Disease
N. Pavese, A.E. Rosser, D.J. Brooks, R.A. Barker, S.B. Dunnett, P. Piccini

**P1051** Creatine therapy for Huntington's Disease (HD): clinical and 
phosphorous magnetic resonance spectroscopy (31P MRS) findings in a one year pilot study
S.J. Tabrizi, B. Rajagopalan, P. Styles, D. Manners, A.H. Schapira, T.T. Warner

**P1052** Disease modifying therapy with metabotropic Glutamate receptor (mGluR) specific drugs in a mouse model for Huntington's Disease
J. Schiefer, C. Puls, A. Spuenken, E. Milkerit, A. Milkerit, C.M. Kosinski

**P1053** European-Huntington's Disease-Initiative (EHDI)-Trial: objectives, design and description of the study population at the end of inclusion
Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

P1055 Highly disabling, cerebellar, juvenile-onset Huntington Disease
F. Squitieri, G. Pustorino, M. Cannella, A. Toscano, L. Mongante, G. Tortorella

P1056 Identification of spine morphometry in spectroscopic profiles of the putamen in presymptomatic Huntington’s Disease with Magnetic Resonance Imaging at 0.5 Tesla
N.C. Reynolds, R.W. Prost, L.P. Mark

P1057 In vitro cell models of Huntington’s Disease using N-terminal and full length Huntington: the relationship between excitotoxicity, mitochondrial dysfunction, and free radicals
C. Turner, L. Jones, L. Elliston, J. M. Cooper, A.H.V. Schapira

P1058 Long term progression of vascular hemiballism

P1059 Mitochondrial impairment in Huntington’s Disease: a magnetic resonance spectroscopy study

P1060 Mutations in TRP-1 are associated with Benign Hereditary Chorea
G. J. Breedveld, J. van Dongen, H. van der Linde, M. Joosse, B.A. Oost, P. Heutink

P1061 Novel features in a patient with hyperglycaemic hemichorea
J.H. Tan, B.P.L. Chan, E. Wilder-Smith, E. Lim

P1062 Objective assessment of motor slowness in Huntington’s Disease: two years follow-up
J.P.P. van Vugt, K.E. Piet, S. Siesling, A.H. Zwinderman, H.A.M. Middelkoop, R.A.C. Roos

P1063 Oral-buccal-lingual dyskinesia caused by nonketotic hyperglycemia: a case report
S.H. Park, Y.H. Hong, J.M. Kim, J.Y. Kim

P1064 Paraneoplastic chorea-dystonia in a patient with non-Hodgkin lymphoma and CRMP-5 autobody
A. Samii, D.D. Dahlen, A.M. Spence, N.C. Maronian, E.E. Kraus, V.A. Lennon

P1065 Quantitative kinematic analysis of chorea
J.W. Mink

P1066 Reversal of synaptic plasticity impairment in motor cortex in a conditional model of Huntington’s Disease
F. Battaglia, E. Tinchese, A. Yamamoto, A. Quartaone, R. Hen, O. Arancio

P1067 Reversible chorea associated with novel antidepressants
S. Pappa, C. Mantas, V. Mavreas, S. Kontsotsos

P1068 Safety and tolerability of lamotrigine in Huntington Disease
D.S. Higgins, K. Ilouz, P. Subramanian

P1069 Short-term motor effects of riluzole in Huntington’s Disease: an open label study
R. Granata, K. Seppi, J. Mueller, W. Poewe, G. Wenning

P1070 Tetrabenazine in the treatment of symptomatic pediatric chorea
A. Chatterjee, S.J. Fucht

P1071 The caudate nucleus atrophy in Huntington Disease and its relation to clinical and genetic parameters
J. Roth, J. Klemper, R. Jech, J. Zdivoska, T. Uhrova, P. Doubek

P1072 The characterisation of Huntington’s Disease (HD) skeletal muscle: mitochondrial respiratory chain, ultrastructural and light microscopic study
C. Turner, L. Jones, J.M. Cooper, A.H.V. Schapira

P1073 Topiramate in vascular hemichorea
F.E. Michel, E.M. Gatto, M.F. Gorga, M.C. Uribe Roca, S. Folgar

P1074 Treatment of Sydenham Chorea (SC) with corticosteroids
F. Cardoso, D.P. Maia, M.C.Q. Cunningham, M.E. Silva, G. Valenca

P1075 A comparison of olanzapine to typical neuroleptics for the treatment of stereotyped movement disorder: acute and long-term effects
K.M. Newell, J.W. Bodfish, S.L. Mahoney, G.R. Breese

P1076 A novel case of buropinion induced palatal and limb myoclonus: hypothesis on the mechanism of action
A.D. Hohler, J. E. Hartmann

P1077 A prospective, 6-month multicenter, open label dose-rising study of the effect of Sarizotan on dyskinesia in Parkinson’s Disease
C.W. Olanow, C. Goetz, T. Mueller, J. Nutt, O. Rascol, H. Russ

P1078 Attenuation of haloperidol-induced orofacial dyskinesia by cyclooxygenase inhibitors
S.K. Kulkami, P.S. Naidu

P1079 Automatic assessment of dyskinesia in daily life
N. Keijser, M. Honstrik, S. Giielen

P1080 Complete cessation of orofacial dyskinesias with bilateral internal pallidum stimulation in a 39 year old woman with tardive dyskinesia
C. van der Linden, H. Coll, E. Foncke, G. Alesi, D. Rijckaert, L. De Waele

P1081 Do Serotonin Reuptake Inhibitors aggravate extrapyramidal symptoms in Parkinson’s Disease? A pharmacoepidemiological study in the French Pharmacovigilance Database

P1082 Dopamine agonist induced punding
A.H. Evans, R. Katzenschlage, J. O’Sullivan, P.R. Vaughan, L.J. Andrew

P1083 Drug-induced orthostatic tremor

P1084 Increased rates of antipsychotic-induced EPS in mood disorders: myth or reality?

P1085 Movement disorders induced by cinnarizine and flunarizine
V. Kiriakakis, P. Vrentas, N. Tsiftsis

P1086 Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study
I.N. Petrovic, V.S. Kostic

P1087 Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine - a cross-sectional study
G. Fabiani, P.C. Pastro, C. Chouza

P1088 Quetiapine reversal of haloperidol-induced orofacial dyskinesia: possible antioxidant mechanism
P.S. Naidu, S.K. Kulkami

P1089 Remote methamphetamine abuse as a potential cause of tardive dyskinesia: a report of five cases
P. Hogarth

P1090 Reversible Extrapontine Myelolysis with Parkinsonism in a 25-year-old female
V. Ries, K. Shiratori, S. Bien, W.H. Oertel

P1091 ‘Familial Cortical Tremor with Epilepsy’ in a Dutch pedigree
F. van Rootselaer, P. M. Callenbach, H.H. Koelman, R.R. Frants, O.F. Brouwer, M.A. Tijssen
Poster Sessions

P1092 A unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin
A.J. Espay, P. Ashby, H. Ritsuko, M.S. Jorg, A.E. Lang

P1093 Alterations in opioid binding in Restless Legs Syndrome (RLS) patients: an in vivo diprenorphine PET study
S. von Spiczak, A.L. Whone, A. Hammers, W. Paulus, C. Tenkwalder, D.J. Brooks

P1094 Analysis of the e-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity

P1095 Long-term efficacy of levetiracetam in cortic myoclonus
M. Kofler, R. Schauer, L. Saltuari

P1096 Multifocal myoclonus caused by hepatic encephalopathy
C. Saft, J. Andrich, I. Wilhelms, P.H. Kraus, H. Przuntek

P1097 Myoclonus in Dementia with Lewy bodies
J.N. Caviness, C.H. Adler, C.J. Richard, H.L. Jose

P1098 Myoclonus in epilepsy partialis continua: successful treatment with botulinum toxin
D. Ranoux, C. Soufflet, B. Gueguen, J.-L. Mas

P1099 Myoclonus of peripheral origin
F. Cassim, P. Kystikowiak, J.-F. Hurtevent, P. Derambure, A. Destee

P1100 Neurostimulation as a treatment for Myoclonic Dystonia: a case report
H.L. Tyne, H. Cameron, P. Littlechild, T.R. Varna, M.J. Steiger

P1101 Open label comparative study on the efficacy of Pramipexole (PMX) vs. Ropinirole (RPN) for the treatment of Restless Legs Syndrome (RLS)

P1102 Patient’s perspective of hemifacial spasm - the Singapore experience
W.L. Au, L.C. Tan, A.K. Tan

P1103 Propriospinal myoclonus after electrical injury
F. Cassim, C. Boisselier, C. Monaca, O. Dereeper, J.-D. Guieu

P1104 Pseudo-sporadic myoclonus-dystonia due to a mutation in the epsilon-sarcoglycan gene

P1105 Restless Legs Syndrome in patients treated with low-density lipoprotein apheresis
T. Tings, V. Schettler, M. Canelo, W. Paulus, C. Tenkwalder

P1106 The treatment of Unverricht-Lundborg Disease with N-Acetylcysteine

P1107 Uncounted reduction of myoclonus with levetiracetam
F. Bourdain, J.-S. Vidal, E. Aparis, M. Vidalinet

P1108 Botulinum toxin A in a treatment of spasticity caused by infantile Cerebral Palsy
R. Mego, M. Brozmanova

P1109 Different types of increased resistance of a knee joint in CP children
M.K. Lebiedowska, J.R. Fisk

P1110 Flexor reflex recording: comparison between spastic patients before and after intrathecal baclofen therapy
S. Romito, V. Rigo, E. Costantini, N. Rizzuto, L. Bertolasi

P1111 Management of tolerance with intrathecal Baclofen therapy
A. Kouloussakis, D. Lenart, M. Weber, G. Koutsoumbelis

P1112 Methylphenidate does not improve spasticity in patients with hereditary spastic paraplegia (HSP). Results of an open controlled trial
S. Klebe, H. Stolze, J. Volkmann, F. Kopper, R. Wenzelburger, G. Deuschl

P1113 Modulation of the transmission in group II heteronymous pathways by Tizanidine in spastic hemiplegic patients
M. Simonetta-Moreau, E. Maupas, P. Marque

P1114 Reciprocal Ia inhibition in patients with asymmetric spinal spasticity
Y. Okuma, Y. Mizuno, R.G. Lee

P1115 Role of gait analysis in decision making in long-term spasticity treatment by Baclofen Pump in deambulatory patients
U. Dimanico, M. Coletti Moja, M. Knaflitz, V. Cavaciocchi, L. Tallone, E. Grasso

P1116 Safety and efficacy of botulinum toxin “BT” in Cerebral Palsy: four-year study
G. Iani, A. Santamato, F. Saponieri, P. Di Cillo, G. Megna

P1117 Cautionous use of intrathecal baclofen in severely spastic walking patients
T. Dones, M. Marchetti, M. Sinisi, G. Broggi

P1118 Stereotypic gait as the presenting feature of normal pressure hydrocephalus
K.A. Kijaawa, D.M. Dijak

P1119 A case of adultonset tic disorder following carbon monoxide intoxication
S.B. Ko, T.B. Ahn, B.S. Jeon

P1120 A voxel-based morphometry study of tic disorders
A.M. Goldfine, T. Hanakawa, G. Garraux, A. Mason, M. Hallett

P1121 Cognitive deficits in patients with Tourette’s Syndrome of different ages
G.M. Moscovtseva, O.S. Levin, G.M. Glozman

P1122 Explosive outbursts in children with Tourette Syndrome: relationship to comorbid symptoms in parents
N. Djemou, P. Lesperance, S. Chouinard, G. Rouleau, F. Richer

P1123 Gilles de la Tourette Syndrome: a refractory case treated with bilateral cingulotomy and clozapine
H.F. Chien, E.R. Barbosa, D.P. Basit

P1124 Metabolic brain networks in Tourette Syndrome
A. Feigin, C. Budman, E. Zgaljardic, V. Dhawan, D. Eidelberg

P1125 Olanzapine treatment in Tourette Syndrome: an open label trial
J.-J. Lin, D.-C. Chang

P1126 Prenotory sensations in tics
C.H. Kwaak, J.J. Jankovic

P1127 Safety and efficacy of primidone in Tourette Syndrome
J.L. Juncos, S.A. Shea, N. Stover, M.S. Okun

P1128 Sleep structure in Tourette Syndrome: polysomnographic data from a pediatric sample
M. Desjardins, P. Lesperance, S. Chouinard, M. Robert

P1129 Status ticcosus in Gilles de la Tourette Syndrome: identification of clinical condition and therapeutic approach
E. Dell’Anna, M. Porta, M. Camerlingo, A. Perretti, G. Magioni

P1130 Successful treatment of tics with bilateral internal pallidum (GPi) stimulation in a 27 year old male patient with Gilles de la Tourette’s Syndrome (GTS)
C. van der Linden, H. Colle, V. Vandelwelle, G. Alessi, D. Rijckaert, L. De Waele
Poster Session 7 - Thursday, November 14, 7:00 am - 8:30 am

P1170 Prevalence of self-reported physician-diagnosed Essential Tremor in the elderly: the Cardiovascular Health Study

P1171 Primary orthostatic tremor is an exaggeration of a physiological response to instability
A.D. Sharott, J.F. Marsden, P. Brown

P1172 Resetting of Orthostatic Tremor by transcranial magnetic stimulation

P1173 Routine tremor analysis as a diagnostic tool. Application of a standardized tremor analysis procedure in two different specialty centers for movement disorders
J. Raethjen, F. Pawlas, M. Lauk, B. Koester, J. Timmer, G. Deuschl

P1174 Surgical alleviation of Complex Action Tremor - role of zona incerta and field potentials

P1175 The quality of life in patients with Essential Tremor
P.V. Makedonsky, O.S. Levin, T.V. Naimushina

P1176 The syndrome of progressive ataxia and palatal tremor (PAPi)
M. Samuel, T.J. Paul, N. Turon, A.E. Lang

P1177 The syndromic associations of Orthostatic Tremor: a review of 41 patients
W. Gerschlager, A. Munchau, R. Katzenschlager, P. Brown, J.C. Rothwell, N. Quinn

P1178 Tremor and deep white matter changes in a-methylacyl-CoA racemase deficiency: extending the clinical phenotype
C.E. Clarke, S. Alger, M.A. Preece, S. Dennis, S. Ferdinandusse, R.J. Wanders

P1179 Tremor Disability Scale (TREDS): reliability and relationship to bedside clinical ratings of tremor severity
D.A. Lundervold, R. Pahwa, P.A. Ament, D.E. Corbin

P1180 Tremor in Multiple Sclerosis: a population based study in Olmsted County, Minnesota
S.J. Pittock, W.T. Mayr, M. Rodriguez, J.Y. Matsumoto

P1181 VIM thalamic DBS suppressed action tremor associated with IgM monoclonal gammopathy
E. Ruzicka, D. Urgosik, K. Zarubova, R. Jech, J. Roth, O. Vesela

P1182 Zonisamide (ZNS) for Essential Tremor (ET) and Cerebellar Outflow Tremor (COT)
N. Galvez Jimenez, M. Hargrave

P1183 New recessive ataxias
M. Koenig, M.C. Moreira, P. Bomont, S. Klur, M. Gibba, C. Lagier-Tourenne, M. Schmidt, and numerous collaborators
**COMTan® ... at the first sign of symptom reemergence**

**COMTan Significantly Improves**

Mean percentage improvements from baseline in UPDRS scores at 24 weeks\(^1\)\(^7\)

![Mean % Improvement From Baseline](chart)

- Significant increases in “on” time, the primary study end point, were evident within 2 weeks and persisted through 24 weeks in patients treated with COMTan (P<0.008 vs placebo)\(^1\)

- Significant improvements in ADLs, a secondary study end point, were observed in patients who had COMTan added to their levodopa treatment regimen\(^1\)

Used only in conjunction with carbidopa/levodopa, COMTan 200 mg tablets are indicated for patients with idiopathic Parkinson’s disease experiencing the signs and symptoms of end-of-dose “wearing off.” The most commonly reported COMTan side effects were dopaminergic in nature, such as dyskinesias, and were generally managed by lowering the carbidopa/levodopa dose. In rare cases, COMTan may be associated with orthostatic hypotension and severe diarrhea. COMTan should not be taken with nonselective monoamine oxidase (MAO) inhibitors. COMTan should be used with caution in patients with liver problems.

**References:**

Please see adjacent brief summary of prescribing information.
Patient Performance

More than 90% of patients maintained or improved daily “off” time after 3 years vs baseline\textsuperscript{6}

- 9 out of 10 patients treated with COMTAN demonstrated continued benefits in daily “off” time as measured by the UPDRS vs baseline in a 3-year, open-label extension trial (N=132)\textsuperscript{6}

Reduced mean daily levodopa dose after 3 years*\textsuperscript{6}

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>3 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>737 mg</td>
<td>696 mg</td>
</tr>
</tbody>
</table>

\[^{P<0.01}\]

\[^{*}\text{Levodopa dose reductions are typically required to alleviate dopaminergic side effects when COMTAN is added.}\]

- Patients were maintained on lower mean daily levodopa intake vs baseline\textsuperscript{6}

COMTan\textsuperscript{®} (entacapone) tablets

Helps patients stay active...longer
comtan is a dopamine prodrug that may be useful in the treatment of Parkinson's disease. However, before using comtan, it is important to consider potential side effects and interactions. Comtan should be used with caution in patients with certain conditions, including hepatic impairment or pregnancy. The recommended dosage is 200 mg per day, but the dose may be increased if tolerated. Comtan is available as tablets and capsules.

**Indications**

Comtan is indicated for the treatment of Parkinson's disease. It is used to help manage motor symptoms such as tremors, stiffness, and shaking. It is usually prescribed along with levodopa to increase the effectiveness of levodopa in the treatment of Parkinson's disease.

**Dosage and Administration**

The recommended dosage of comtan is 200 mg per day, usually taken once daily. The dose may be increased if tolerated. The dosage should be adjusted based on the patient's response and tolerance to the medication. Comtan should be taken with food to reduce the risk of GI side effects. The dose should be taken at the same time each day to maintain consistent plasma levels of entacapone.

**Contraindications**

Comtan is contraindicated in patients who have shown hypersensitivity to the drug or its components. It is also contraindicated in patients with hepatic impairment.

**Side Effects**

The most common side effects of comtan include nausea, vomiting, and diarrhea. Other side effects that have been reported include blurred vision, dizziness, and orthostatic hypotension.

**Interactions**

Comtan is metabolized by COMT, so it may interact with other drugs that are also metabolized by COMT. It may also interact with drugs that are metabolized by CYP2D6.

**References**

- The American Association for the Study of Liver Diseases. Comtan. Available at: https://www.aasl.org/health/comtan
- The American Academy of Neurology. Comtan. Available at: https://www.aan.com/clinical-guidelines/comtan

**Conclusion**

Comtan is a promising treatment option for Parkinson's disease, but its benefits and risks should be carefully considered. Patients should discuss their treatment options with their healthcare provider to determine the best course of treatment for them.